Georgia Public Broadcasting and the Atlanta History Center Partner on “37 WEEKS: Sherman on the March”

April 2014 marks the 150th anniversary of Union General William Tecumseh Sherman's 1864 march into Georgia.  Georgia Public Broadcasting and the Atlanta History Center are commemorating this extraordinary event with the launch of a new original series, “37 Weeks: Sherman on the March.” The series will bring Sherman’s devastating 37-week journey across Georgia to life and highlight key turning points in the history-making trek.  The 90-second segments will premiere Monday, April 14 during the 7 p.m. telecast of GPB’s nightly program “On the Story.” “37 Weeks” is produced by award-winning filmmaker Bruce Burkhardt, in collaboration with Atlanta History Center Civil War historian Gordon Jones. Burkhardt also wrote and produced GPB’s highly successful documentary “Augusta’s Master Plan-From Sherman’s March to Arnie’s Army.” Jones is sharing his expertise and the vast Civil War collection of photos, maps, documents, diaries and newspaper accounts curated by the Atlanta History Center. In April of 1864, the American Civil War was raging on, and more than half a million soldiers were dead. President Abraham Lincoln was facing a tough election as his political opponents were calling for a negotiated peace with the Confederacy. Lincoln, however, was determined to restore the Union at any cost, and Georgia paid the price. Without Gen. Sherman's march to the sea, the Civil War may have ended very differently and the Union dissolved.  "GPB is honored to partner with the Atlanta History Center on this project,” said Teya Ryan, president and CEO of GPB. “We are very fortunate to have access to its rich resources and knowledgeable staff.  By taking audiences on this week-by-week journey of Sherman’s March, we give our audience the opportunity to relive the dramatic history of the Civil War in Georgia." Each of the 90-second  “37 Weeks” segments will air multiple times on GPB’s television and radio platforms during the week paralleling the same week in Shermanʼs campaign and tell a story that brings an understanding to the human dimension of war. What did it feel like when Shermanʼs army - 100 thousand strong - was bearing down on your city? What was motivating Shermanʼs fateful decisions? What was it like for the foot solider on either side of the battlefield? What were some of those twists of fate or ironic moments that war inevitably produces? These are among the stories “37 Weeks” will explore. “GPB and the Atlanta History Center wished to find a way to make the history of the war relevant to a new generation of Atlantans. It is no longer enough to just know what, where, and when something occurred, making it increasingly important to engage audiences beyond traditional Civil War monuments, plaques, and memorials.” said Sheffield Hale, president and CEO of Atlanta History Center. “The concept to highlight Georgia’s Civil War history by focusing on one event, and one story, per episode allowed the opportunity to use images, documents, diaries, and objects from the History Center’s collection, coupled with GPB’s production expertise, in a way that brings the past to life through storytelling while providing personal connections to our collective – and shared history.” The series is hosted and narrated by Masud Olufani, who has worked with the Atlanta History Center for the last four years as part of their "Meet the Past Museum Theatre" program.  Most recently he played the role of African American journalist J. Max Barber in the award-winning production of the History Center's "Four Days of Fury: The Atlanta 1906 Race Riot." ABOUT GPB: As one of the largest PBS stations in the nation, Georgia Public Broadcasting (GPB Media), has been creating content worth sharing for over 50 years. With nine television stations, 17 radio stations and a multi-faceted web presence, GPB strives to educate, entertain and enrich the lives of our viewers and listeners with programming that includes statewide radio news, current affairs, high school sports, educational resources for teachers and students and enlightening programs about our state like Georgia Outdoors, Georgia Traveler and On the Story. ABOUT THE ATLANTA HISTORY CENTER:  Founded in 1926, the Atlanta History Center is an all-inclusive, thirty-three-acre destination featuring the Atlanta History Museum, one of the nation’s largest history museums; two historic houses, the 1928 Swan House and the 1860 Smith Family Farm; the Centennial Olympic Games Museum; the Kenan Research Center; the Grand Overlook event space; a museum shop, and twenty-two acres of Historic Gardens with paths and the kid-friendly Connor Brown Discovery Trail. In addition, the History Center operates the Margaret Mitchell House located in Midtown Atlanta. For information, call 404.814.4000 or visit AtlantaHistoryCenter.com.

REST WHERE GIRAFFES MIGHT “NEST”

Imagine waking up in your very own tree house in the middle of the African bush … where the only alarm clock is birdsong and the warmth of the rising sun on the horizon on your face as the bush slowly wakens and comes to life... This is the Giraffe’s Nest experience … promising an unforgettable night of adventure at Motswari Private Game Reserve in South Africa’s Timbavati, which adjoins (there are no fences) the Kruger National Park. The adventure starts as guests are dropped off at the scenic Xanatsi Dam shortly before sunset, complete with their personal belongings, a selection of drinks and a mouth-watering picnic dinner to enjoy on the viewing deck. Then it is up the ladder to an elevated wooden platform three metres above the ground – armed with a trusty hand-held radio to keep in touch with Motswari’s main lodge (just in case nerves get the better of them in the middle of the night!) and a torch to keep an eye on the exciting happenings below from the comfort of your bed! Nothing can beat the sense of being “at one with Mother Nature” as you watch the sun set from your canopy among the trees and hear the frogs and insects serenade you in your very own slice of Africa! Rest assured this is no ordinary tree house! Not only does Giraffe’s Nest have an innovative retractable roof so that guests can choose between sleeping under a canopy of stars or closing it should it rain, but the Nest boasts two wrought iron three-quarter beds, sumptuous crisp linen and mohair blankets – all surrounded by a large mosquito nets. There is even an eco-bathroom upstairs so there is no need to leave your platform, and miss a single moment in this once-in-a-lifetime experience (or for the less brave … to face the adrenaline rush of climbing down from your haven in the dark of night! ) After a night like no other, in the morning the game drive will collect you in time for a scrumptious breakfast back at Motswari Lodge. Perhaps not for the faint hearted – but an exhilarating experience for those with a sense of adventure! For more information visit www.newmarkhotels.com  and follow us on twitter on @newmarkhotels BOOK IT: Imagine Africa ( 020 7622 5114 | www.ImagineAfrica.co.uk ) offers the following package for guests wanting the full Motswari /Giraffe’s Nest safari experience in 2014, from £946pp not including flights, spending 5 nights at Motswari with one night sleeping out under the stars at Giraffe’s Nest, including road transfers. Prices are based on low season. Flights cost from £900 per person. Motswari is a traditional 4 star vintage bush lodge that has been owned by the Geiger family for over 30 years, offering luxurious accommodation, personalised service and some of the most skilful rangers you will find anywhere. The focus is not just on ticking off the “Big 5” game including their famous white lions, but on the appreciation of Nature, the beauty of its indigenous bush and the animals that thrive there.   Giraffe’s Nest is the newly launched “sleep out” experience at Motswari. A tree house 3 metres above the bush with a retractable roof - overlooking a popular dam. With two ¾ beds with crisp linen and netting, a dining area with picnic dinner and drinks and eco-loo this is unlike any tree house you have ever seen!

NOTICE OF ANNUAL GENERAL MEETING

Right to attend and notice of attendance Shareholders who wish to attend the AGM must be recorded in the share register maintained by Euroclear Sweden AB on Tuesday May 6, 2014 and notify the company of their intention to attend by no later than Tuesday May 6, 2014, preferably before 3.00 p.m. CET. Notice of attendance is made in writing to Aerocrine AB, P.O. Box 1024, 171 21 Solna, Sweden, or by phone +46-8-629 07 80, or by e-mail info@aerocrine.com. The notice of attendance shall include name, personal or corporate ID number, address and phone number. The same dates, addresses, etc. apply for notifying the company of any accompanying advisors. Powers of attorneys, certificates of incorporation and other documents of authorization must be presented at the AGM, but can preferably be sent to the company in connection with the notice of attendance. Power of attorneys must be presented in original and shall not be older than one year, provided that the power of attorney does not state a longer period of validity (maximum 5 years). A proxy form is available on the company’s website, www.aerocrine.se, and may also be ordered from the company at the above address. Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to attend the AGM, request that the nominee re-register their shares in the name of the shareholder, so that the shareholder is recorded in the share register on Tuesday May 6, 2014. Such registration may be temporary. Proposed agenda 1.Opening of the Meeting 2.Election of the Chairman of the Meeting 3.Preparation and approval of the voting list 4.Approval of the agenda 5.Election of one or two persons approving the minutes 6.Determination of whether the Meeting has been duly convened 7.Presentation of the annual report and the auditors’ report, the consolidated accounts and the auditors’ report on the consolidated accounts as well as the auditors’ statement on whether the guidelines for remuneration to senior management, effective from the most recent AGM, has been complied with 8.Presentations by the Chairman of the Board and the CEO 9.Resolutions with respect to 1.adoption of the income statement and the balance sheet, the consolidated income statement and the consolidated balance sheet 2.appropriation of the company’s profit or loss in accordance with the approved balance sheet 3.discharge from liability towards the company for the Board members and the CEO 1.Resolution on the number of Board members 2.Resolution on fees payable to the Board 3.The Nomination Committee’s proposal for resolution on: (a)   the adoption of a Board member share plan (b)   the issuance and approval of transfer of warrants 4.Election of Board members and the Chairman of the Board 5.Resolution on instructions for the Nomination Committee 6.Resolution on guidelines for determination of salary and other remuneration to senior management 7.Resolution on authorization for the Board of Directors to resolve on new share issues and to issue convertible bonds and warrants 8.Closing of the Meeting The Board of Directors’ resolution proposals Appropriation of the company’s profit or loss in accordance with the approved balance sheet (item 9 b) The Board of Directors and the CEO propose that no dividend is paid and that the year’s loss be carried forward. Guidelines for determination of salary and other remuneration to senior management (item 19) The Board of Directors proposes that the AGM resolves on guidelines for determination of salary and other remuneration to the CEO and other members of the senior management, principally entailing the following. Remuneration to the senior management shall consist of fixed salary, variable salary, other benefits and pension benefits. The aggregate remuneration shall be in line with market conditions and be competitive as well as related to position, performance, responsibility and authority. The variable salary shall consist of bonus and be based on predetermined and well defined objectives. The variable salary shall have a cap and never exceed the fixed salary, nor shall it entitle to pension benefits. In case cash variable salary has been paid on the basis of information which later proves to be manifestly misstated, Aerocrine should be assured possibility to reclaim such remuneration. Dismissal and severance pay shall in aggregate not exceed twelve months for the executives. Employment agreements should not include provisions on severance pay. Pension benefits shall either be benefit- or contribution-defined, or a combination thereof. In addition, share-based or share price-based incentive programs may be resolved upon from time to time. Consultant fees in line with prevailing market conditions may be payable insofar as any Board member performs work on behalf of the company, in addition to the Board work. The Board of Directors shall be entitled to deviate from the guidelines, provided that there are particular reasons for such deviation in an individual case. Authorization for the Board of Directors to resolve on new share issues and to issue convertible bonds and warrants (item 16) The Board of Directors proposes that the AGM authorizes the Board to resolve – at one or several occasions and for the time period until the next AGM – to increase the company’s share capital by new share issues and to issue warrants and convertible bonds, to the extent that it corresponds to a dilution of not more than 10 percent of the number of shares outstanding at the time of this notice, after full exercise of the hereby proposed authorization. New share issues, as well as issues of warrants and convertible bonds, may be made with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. Pursuant to Chapter 16 of the Swedish Companies Act, the Board of Directors may not by virtue of this authorization resolve on issues to Board members in group companies, employees, etc. The purpose of the authorization is to increase the financial flexibility of the company and the acting scope of the Board. Should the Board of Directors resolve on an issue with deviation from the shareholder’s preferential rights, the reason shall be to enable external raising of capital (through new owners of strategic importance for the company or otherwise) for the financing of the company’s business, commercialization and development of the company’s products and intellectual property rights and/or acquisitions of other companies or businesses. Upon such deviation from the shareholders’ preferential rights, the basis for the issue price shall be market conditions. Majority requirements A valid resolution on authorization requires that the proposal be approved by shareholders representing at least two-thirds of both the votes cast as well as the shares represented at the AGM. The Nomination Committee’s proposals The Nomination Committee in respect of the 2014 AGM consists of its chairman Ulrik Spork (Novo A/S), Staffan Josephsson (Investor), Björn Odlander (HealthCap), Ulrica Slåne (Tredje AP-fonden) and Rolf Classon (Chairman of the Board). Rolf Classon has not participated in the preparation of the proposals under item 12. The Nomination Committee proposes the following. Chairman of the Meeting (item 2): Chairman of the board of directors, Rolf Classon. Number of Board members (item 10): Seven Board members, with no deputy members. Fees payable to Board members elected by the Meeting (item 11): To the Chairman of the Board: SEK 250,000; to each of the other Board members: SEK 75,000. To members of committees: The chairman of the Audit Committee: SEK 25,000; to each of the other members of the Audit Committee: SEK 12,500; to the chairman of the Remuneration Committee: SEK 25,000; to each of the other members of the Remuneration Committee: SEK 12,500. In addition and part of the Board remuneration, the Nomination Committee proposes that the AGM resolves to adopt a Board member share plan under which each Board member who is independent in relation to Aerocrine and its executive management as well as the company’s major shareholders also (i) shall receive additional remuneration corresponding to SEK 250,000 to the Chairman and SEK 75,000 to other Board members in the form of so-called Board shares, and (ii) may elect to receive up to SEK 75,000 of the above-mentioned cash Board fee in the form of additional Board shares. See separate proposal under item 12. Resolution on (A) the adoption of a Board member share plan, and (B) the issuance and approval of transfer of warrants (item 12) Background and reasons The Nomination Committee proposes that the AGM as part of the Board remuneration resolves to adopt a Board member share plan (“SAP 2014”) for Board members elected by the General Meeting who are independent in relation to Aerocrine and its executive management as well as the company’s major shareholders. SAP 2014 includes Board shares (options to acquire shares in Aerocrine) (“Board Shares”) and hedging measures created through the issuance and approval of transfer of warrants. The purpose of the proposed plan is to enable Aerocrine to attract, motivate and retain Board members, to increase the Board members’ interest in Aerocrine and its financial development and to offer them a financial interest in Aerocrine comparable to the one of shareholders. The proposed terms and conditions correspond to those applicable to the Board member share plan that was approved by the 2013 AGM. (A) Adoption of Board member share plan 2014 In addition to the cash Board fee that the 2014 AGM resolves upon, each Board member who participates in SAP 2014 shall receive remuneration through the grant of a number of Board Shares that in value correspond to SEK 250,000 to the Chairman and SEK 75,000 to each other participant. In addition, each participant may elect to receive up to SEK 75,000 of the cash Board fee that the 2014 AGM resolves upon in the form of a number of additional Board Shares that in value correspond to the amount thus selected by the participant. The number of Board Shares granted to participants shall be based on the volume-weighted average price paid (VWAP) for the Aerocrine share on NASDAQ OMX Stockholm during the five (5) trading days immediately following the AGM on May 12, 2014, less the quota value of the share (SEK 0.50). The grant of Board Shares shall, however, be made with a maximum number that is based on the VWAP on May 12, 2014. Vesting of Board Shares will take place over a period of 12 months, with one-fourth at a time. Each vested Board Share shall entitle to the acquisition of one (1) share in Aerocrine at an exercise price corresponding to the quota value of the share from time to time. Board members that, due to tax or other reasons, cannot receive shares upon exercise may be offered cash settlement. Exercise of Board Shares shall be allowed in connection with Aerocrine’s publication of year-end reports and ordinary interim reports over a period starting on the day when the Board Shares have vested and ending on May 31, 2024. Exercise of Board Shares shall require that the participant is still a Board member. Upon the termination of the Board assignment, specific rules on exercise shall apply. Board Shares shall not be considered as securities and shall not be transferable. For United States tax purposes, Board Shares shall be treated as restricted stock. (B) Issuance and approval of transfer of warrants Issuance of warrants of series 2014/2024 In order to enable the delivery of shares and otherwise safeguard the fulfillment of Aerocrine’s obligations under SAP 2014, the Nomination Committee proposes that the AGM resolves to issue warrants on the following terms and conditions. Not more than 150,000 warrants shall be issued, whereby Aerocrine’s share capital may increase by not more than SEK 75,000. The warrants shall, with deviation from the shareholders’ preferential rights, be subscribed for by the wholly-owned subsidiary Aerocrine ESOP AB. Subscription for warrants shall be made not later than September 30, 2014. The warrants shall be issued free of charge. Each warrant shall entitle the holder to subscribe for one new share in Aerocrine at a subscription price corresponding to the quota value of the share from time to time (currently SEK 0.50). The warrants may be exercised from the time of registration with the Swedish Companies Registration Office until June 30, 2024. Shares issued upon exercise of warrants shall entitle to any dividend the first time on the record date for dividend occurring next after the registration of the shares with the Swedish Companies Registration Office. The warrants shall be subject to customary re-calculation provisions. The reason for the deviation from the shareholders’ preferential rights is that the issuance constitutes a part of the implementation of SAP 2014. Approval of transfer of warrants The Nomination Committee proposes that the AGM resolves to approve that Aerocrine ESOP AB may transfer the warrants of series 2014/2024 to Board members under SAP 2014, and otherwise may dispose of the warrants to safeguard the fulfillment of Aerocrine’s obligations under SAP 2014. Estimated costs, dilution and majority requirements The maximum cost over the income statement for the proposed plan has been calculated at approximately SEK 831,000, excluding social security costs. SAP 2014 is expected to incur social security costs on Aerocrine for the participants in the plan. SAP 2014 includes the issuance of not more than 150,000 warrants. If the warrants are exercised in full, the number of shares will increase with 150,000, corresponding to a dilution of approximately 0.097% of the number of shares and votes in Aerocrine. SAP 2014, together with previously issued warrants, may result in a dilution of in total not more than approximately 6.92% of the number of shares and votes in Aerocrine. The Nomination Committee’s proposals under Sections (A) and (B) above constitute a package since they are interdependent. It is therefore proposed that the AGM resolves on the proposals under Sections (A) and (B) through one single resolution, subject to majority requirements in Chapter 16, section 8 of the Swedish Companies Act. This means that the resolution must be supported by shareholders representing at least nine-tenths of both the votes cast and the shares represented at the AGM. Board members and Chairman of the Board (item 13): Re-election of Rolf Classon, Thomas Eklund, Lars Gustafsson, Dennis Kane and Staffan Lindstrand. Election of Michael Shalmi and Maria Strømme. Chairman of the Board: Re-election of Rolf Classon. Scott Beardsley and Anders Williamsson have declined re-election. Michael Shalmi (born 1965, MD from University of Copenhagen, Executive MBA from Scandinavian International Management Institute) is Senior Partner at Novo Growth Equity (Novo A/S) since 2009. Other assignments include Board member of Orexo AB. Michael Shalmi has before his current position as Senior Partner inter alia 14 years of experience from various leading positions within Novo Nordisk. Maria Strømme (born 1970) is Professor in Nanotechnology and Functional Materials at Ångströmlaboratoriet. Maria Strømme has inter alia been part of the Research Committee (Sw. Forskningsberedningen) as an advisor to the Ministry of Research and Education (Sw. Forsknings och Utbildningsdepartementet). She is the founder of several start-up companies based on own inventions and has had Board assignments in inter alia Svenska Rymdaktiebolaget and Miljöstrategiska Forskningsstiftelsen. Other assignments include Board member in Biolin Scientific Holding, Swednanotech, Uppsala University (konsistoriet) and in her own companies Disruptive Materials and BactInact. Maria Strømme is member of The Royal Swedish Academy of Engineering Sciences (IVA) and the Royal Swedish Academy of Sciences (KVA).   Instructions for the Nomination Committee (item 14): The Nomination Committee shall consist of representatives from the four largest shareholders by voting powers (grouped by owner) and the Chairman of the Board, whom shall also convene the Nomination Committee for its first meeting. The Nomination Committee will thereafter elect its chairman, whom may not be the Chairman of the Board. Should a member resign from the Nomination Committee before its work is finalized, an alternate member may, if the Nomination Committee finds it suitable, represent the same shareholder or, if such shareholder is no longer one of the larger shareholders, the next following qualified shareholder. Should the ownership otherwise materially change before the work of the Nomination Committee is finalized, alterations may, if the Nomination Committee so decides, be made in the composition of the Nomination Committee in a way deemed appropriate by the Nomination Committee. The composition of the Nomination Committee in respect of the 2015 AGM shall be based on the share register maintained by Euroclear Sweden AB as per August 31, 2014. Information on the Nomination Committee’s composition shall be published on the company’s web page immediately following the appointment of the Nomination Committee, however by no later than six months prior to the AGM. The members of the Nomination Committee shall not be remunerated. Any expenses in conjunction with the Nomination Committee’s work shall be borne by the company. The mandate of the Nomination Committee shall last until the next Nomination Committee’s composition is made public. Documents etc. Financial reports, audit reports and auditor statement as well as the Board of Directors’ complete proposals in accordance with the above, and the Nomination Committee’s complete proposal under item 12 above, will be available at the company and on the company’s website, www.aerocrine.se, by no later than April 17, 2014, and will also be sent upon request to shareholders who provide their postal address. The documents will also be available at the AGM. Upon request by a shareholder and where the Board of Directors believes that it can be done without significant harm to the company, the Board and the CEO shall at the AGM provide information on circumstances which may affect the assessment of a matter on the agenda, circumstances which may affect the assessment of the company’s or a subsidiary’s financial situation and the company’s relation to other group companies. There are 155,059,538 shares and votes in the company as at the issuance of this notice. Solna in April 2014 Aerocrine AB (publ)The Board of Directors

Approval of annual accounts and Board of Director's report for 2013

Oslo, April 11, 2014. The Board of Directors of Opera Software ASA has approved the consolidated financial statements, the parent company's financial statements and the Board of Directors' report for 2013. No substantive changes have been made to the accounts compared with those presented in the 4Q 2013 report published on February 11, 2014.  The Board will propose to the Annual General Meeting to be held on June 3, 2014 that a dividend for 2013 of NOK 0.24 per share is paid out, representing an aggregate dividend payment of approximately USD 5.2 million (based on the applicable FX rate as at December 31, 2013). If approved, the shares will be trading ex dividend rights as from June 4, 2014. A complete Annual Report for 2013 will be published on the company's web site www.opera.com by April 30, 2014. Petter Lade, Investor Relations Tel: +47 2369 2400 Opera products enable more than 350 million Internet consumers worldwide to discover and connect with the content and services that matter most to them, no matter what device, network or location. In turn, we help advertisers reach the audiences that build value for their businesses. Opera also delivers products and services to more than 130 mobile operators around the world, enabling them to provide a faster, more economical and better network experience to their subscribers. From family photos and funny videos to business ideas that change the world economy, the internet has always been about discovery. Whether you are a consumer getting online for the first time, or a multinational corporation trying to reach the right audience, Opera can help you discover more online. Opera Software ASA is listed on the Oslo Stock Exchange under the ticker symbol OPERA. 'Opera', 'Opera Software', 'Opera Mini' and the 'O' logo are trademarks of Opera Software ASA. All other trademarks are the property of their respective owners. Learn more about Opera at www.opera.com.

Hoist Finance strengthens its presence in the Netherlands

Hoist Finance builds upon its recent landmark acquisition in the Netherlands by acquiring additional portfolio and entering a forward-flow agreement with Credit Agricole Consumer Finance Nederland B.V. This transaction represents a continuation to the deal completed in autumn 2013, whereby Hoist Finance acquired the Special Collection department of Credit Agricole Consumer Finance in Amsterdam. Transaction details are not disclosed. "With this transaction we further strengthen our presence in Benelux and build on our European expansion strategy. This is another proof-point to our ambition to be a trusted partner to global banks and financial institutions,” says Jörgen Olsson, CEO of Hoist Finance. "By closing yet another landmark transaction of unsecured consumer receivables we have successfully built another core market within our group. This transaction can be considered a confirmation of trust and a logical continuation of our strategic partnership with one of the leading banks in consumer finance in The Netherlands” continues Charles de Munter, Regional Manager of Hoist Finance Benelux, France, Italy and Poland. For further information, please contact:  Jörgen Olsson, CEO Hoist Finance  Jane Niedra, IR Hoist Finance  Contact details:  Phone +46 (0)8 55 51 77 90  Email: jane.niedra@hoistfinance.com The information above has been published pursuant to the Swedish Securities Markets Act (Sw. lag om värdepappersmarknaden).  This information was released for publication at 8.00 on 11 April 2014.

Report from Björn Borg’s Annual General Meeting 2014

The Annual General Meeting of Björn Borg AB was held at 5 pm on 10 April, 2014 at the company’s offices in Stockholm. The Annual General Meeting adopted the income statement and balance sheet, the consolidated income statement and the consolidated balance sheet for the year 2013. The Annual General Meeting resolved that no dividend be paid to the shareholders for the year 2013. Instead of a dividend, the Annual General Meeting resolved on a share redemption program as set out below. DirectorsThe Annual General Meeting resolved to re-elect the Directors Kerstin Hessius, Fredrik Lövstedt, Mats H Nilsson and Isabelle Ducellier and to elect Martin Bjäringer, Nathalie Schuterman and Anders Slettengren as new Directors, meaning also that the total number of Directors increased from six to seven. Vilhelm Schottenius and Michael Storåkers declined re-election. The Meeting resolved to re-elect Fredrik Lövstedt as Chairman of the Board of Directors. Further the Meeting resolved that the remuneration to the Board shall be slightly increased, which means that the Chairman of the Board receives SEK 350,000 (previously 325,000) and other Directors SEK 140,000 (previously 125,000) each. The Meeting also resolved that remuneration to be paid to the Directors for work on board committees would remain unchanged, at SEK 15,000 to each of the members of the remuneration committee and SEK 25,000 to the Chairman of the remuneration committee, and SEK 50 000 to each of the members of the audit committee and SEK 75,000 to the Chairman of the audit committee. AuditorsThe Annual General Meeting resolved to re-elect Deloitte AB for the period until the end of the next Annual General Meeting. The Meeting also decided that fair remuneration to the auditors shall be paid on approved accounts. Automatic share redemption procedureThe Annual General Meeting resolved on an automatic share redemption procedure, including a share split 2:1, in accordance with proposal by the Board of Directors. The proposal involves a distribution to the shareholders of SEK 1.50 per existing share. The Annual General Meeting authorized the Board of Directors to set the record date for the share split, which is estimated to occur 24 April 2014. Payment of the redemption amount is estimated to take place by 20 May 2014, through Euroclear. ISIN code for redemption share is SE0003857457 and for original share SE0005849437. Authorization to resolve on new issues of shares, warrants and/or convertiblesIn accordance with the proposal by the Board of Directors, the Annual General Meeting authorized the Board of Directors, until the next Annual General Meeting, to resolve on new issues of shares, warrants or convertibles on one or several occasions, with or without deviation from the shareholders' preferential rights. The reasons for deviating from the shareholders' preferential rights shall be to enable directed share issues for the purpose of acquisitions companies or businesses, in whole or in part, alternatively for raising capital to be used for such acquisitions. Guidelines for remuneration to the executive managementThe Meeting adopted the Board of Directors' proposal regarding guidelines for remuneration to the executive management, comprising the managing director and the other individuals in the executive management. Nomination committeeThe Annual General Meeting approved the nomination committee’s proposal regarding the nomination committee. OtherThe CEO gave a presentation and answered questions. The new CEO was also introduced to the shareholders. For further information, please contact:Fredrik Lövstedt, Chairman of the Board, telephone: +46 708 59 54 80, e-mail fredrik.lovstedt@bjornborg.com   Björn Borg is required to make public the information in this press release in accordance with the Securities Market Act. The information was released for publication on 11 April, 2014 at 8.00 a.m. (CET).   About Björn BorgThe Group owns the Björn Borg trademark and its core business is underwear. It also offers sportswear and fragrances as well as footwear, luggage & bags and eyewear through licensees. Björn Borg products are sold in around thirty markets, of which Sweden and the Netherlands are the largest. The Björn Borg Group has operations at every level from branding to consumer sales in its own Björn Borg stores. In total, there are 38 Björn Borg stores, of which 17 are operated in the Group. Total sales of Björn Borg products in 2013 amounted to around SEK 1.5 billion at the consumer level. Group net sales amounted to SEK 499 million in 2013, with 159 employees. The Björn Borg share has been listed on NASDAQ OMX Nordic in Stockholm since 2007.

Proposals to the Annual General Meeting 2014 on a Board member share plan

The purpose of the proposed plan is to enable Aerocrine to attract, motivate and retain Board members, to increase the Board members’ interest in Aerocrine and its financial development and to offer them a financial interest in Aerocrine comparable to such of shareholders. In brief, the Nomination Committee’s proposal means that, in addition to the cash Board fee that the 2014 AGM resolves upon, Board members who participates in SAP 2014 shall receive remuneration through the grant of a number of Board Shares that in value correspond to SEK 250,000 to the Chairman and SEK 75,000 to other Board members. In addition, each participant may elect to receive up to SEK 75,000 of the cash Board fee that the 2014 AGM resolves upon in the form of a number additional Board Shares that in value correspond to the amount thus selected by the participant. In order to enable the delivery of shares and otherwise safeguard the fulfillment of Aerocrine’s obligations under SAP 2014, the Nomination Committee proposes that the AGM resolves to issue not more than 150,000 warrants to the wholly-owned subsidiary Aerocrine ESOP AB and approves that the warrants may be disposed of to safeguard the fulfillment of Aerocrine’s obligations under SAP 2014. A more detailed description of the Nomination Committee’s proposal together with other information is included in the notice of the AGM. For more information, contact: Ulrik Spork, Chairman of the Nomination Committee in Aerocrine AB, telephone +45 3067 4794 Rolf Classon, Chairman of the Board of Aerocrine AB, telephone +1 914 320 11 88 Michael Colérus, CFO Aerocrine AB, telephone +46 70 341 34 72 About Aerocrine: Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU). Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 AM on 11 March 2014.

Unibet Group plc - NOTICE TO ANNUAL GENERAL MEETING

Notice to holders of Swedish Depository Receipts (“SDR’s”) Holders of SDR’s who wish to attend and/or vote at the AGM must: (i) be registered in the register kept by Euroclear Sweden AB by 17.00 CEST Friday 9 May 2014; (ii) notify Skandinaviska Enskilda Banken AB (publ) (SEB) of their intention to attend the AGM no later than 11.00 CEST on Thursday 15 May 2014; and (iii) send an original signed proxy form to the Company no later than 17.00 BST on Thursday 15 May, 2014 (unless the holder will attend the AGM in person). Requirement (i): Holders of SDR’s whose holding is registered in the name of a nominee must, to be able to exercise their voting rights at the AGM (by proxy or in person), temporarily register their SDR’s in their own name in the register kept by Euroclear Sweden AB by 17.00 CEST on Friday 9 May 2014. Such holders must well before that day contact their custodian bank or brokerage to request that their holding be temporarily registered in their own name with Euroclear Sweden AB before Friday 9 May 2014. Requirement (ii): Holders of SDR’s must, to be able to exercise their voting rights at the AGM (by proxy or in person), give notice to SEB of their intention to attend no later than 11.00 CEST on Thursday 15 May 2014. This must be done by completing the enrolment form provided on www.unibetgroupplc.com/AGM, "Notification to holders of Swedish Depository Receipts in Unibet Group plc". The form must be completed in full and delivered electronically. Requirement (iii): Holders of SDR’s who will not attend the AGM in person must send their original signed proxy forms by post or courier so as to arrive at Unibet Group plc, c/o Unibet (London) Ltd, Wimbledon Bridge House, 1 Hartfield Road, London SW19 3RU, United Kingdom no later than 17.00 BST on Thursday 15 May, 2014. Proxy forms are available on www.unibetgroupplc.com. Please note that conversions to and from SDR’s and ordinary shares will not be permitted between 9 May and 20 May 2014. Proposed Agenda It is proposed that the AGM conducts the following business: 1. Opening of the Meeting. 2. Election of Chairman of the Meeting. 3. Drawing up and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two person(s) to approve the minutes. 6. Determination that the Meeting has been duly convened. 7. The CEO’s presentation. Ordinary Business Dividend 8. Declaration of Dividend in cash. 9..Declaration of Dividend in kind by distribution of shares in Kambi Group Limited to be renamed Kambi Group plc. 10. To receive and consider the Report of the Directors and the Consolidated Financial Statements (Annual Report) prepared in accordance with International Financial Reporting Standards for the year ended 31 December 2013, together with the Report of the Auditors. 11. To approve the remuneration report set out on pages 40 and 41 of the Company’s Annual Report and Financial Statements for the year ended 31 December 2013 12. To   determine the number of Board members. 13. To   determine the Board members’ fees. 14. To   re-elect Kristofer Arwin as a   director of the Company. 15. To   re-elect Peter Boggs as a director   of the Company. 16. To   re-elect Nigel Cooper as director   of the Company.     17. To   re-elect Stefan Lundborg as   director of the Company.            18. To   re-elect Anders Ström as a   director of the Company. 19. To   elect Sophia Bendz as new director of the company. 20. To   elect Peter Friis as new director of the company. 21. To   appoint the Chairman of the Board. 22. Resolution  on guidelines for how the Nomination Committee shall be appointed. 23. To reappoint PricewaterhouseCoopers as auditors of the   Company and to authorise the directors to determine their remuneration. 24. To   resolve on guidelines for remuneration and other terms of employment for senior management.  As Special   Business, to consider the following resolutions which will be proposed as   Extraordinary   Resolutions:25. The   meeting will be requested to consider and if thought fit, approve, by   extraordinary resolution, the following further resolution: it   being noted that (i)   at a Board of Directors´ meeting held on 10 April 2014, the directors   resolved to obtain authority to buy back GBP 0.005 Ordinary Shares/SDR´s in   the Company (the purpose of buyback being to achieve added value for the   Company’s shareholders); and(ii)   pursuant to article 106(1) (b) of the Companies Act (Cap.386 of the Laws of   Malta) a company may acquire any of its own shares otherwise than by   subscription, provided inter alia authorisation is given by an extraordinary   resolution, which resolution will need to determine the terms and conditions   of such acquisitions and in particular the maximum number of shares/SDR’s to   be acquired, the duration of the period for which the authorisation is given   and the maximum and minimum consideration, given   this it is proposed thatthe   Company be generally authorised to make purchases of ordinary shares/SDR’s of   GBP 0.005 each in its capital, subject to the following: (a)   the maximum number of shares/SDR’s that may be so acquired is 2,828,585; (b)   the minimum price that may be paid for the shares/SDR’s is 1 SEK per   share/SDR’s exclusive of tax;(c)   the maximum price that may be paid for the shares/SDR’s is 500 SEK per share/SDR’s exclusive of tax;   and(d)   the authority conferred by this resolution shall expire on the date of the   2015 Annual General Meeting but not so as to prejudice the completion of a   purchase contracted before that date. 26. The meeting will be requested to consider   and if thought fit, approve, by extraordinary resolution, the following   further resolution:That the directors be and are hereby duly   authorised and empowered in accordance with articles 85(2) and 88(7) in the   Companies Act, on one or several occasions prior to the date of the next Annual   General Meeting of the Company, to issue and allot up to a maximum of 2.8   million ordinary shares in the Company of a nominal value of GBP 0.005 each   (corresponding to a dilution of about 10 per cent) for payment in kind or   through a directed set -off in connection with an acquisition without first   offering the said shares to existing shareholders. This resolution is being   taken in terms and for the purposes of the approvals necessary in terms of   the Companies Act and the Articles of Association of the Company. 27.        Closing of the meeting. Information about proposals related to Agenda items Agenda item 2 The Nomination Committee proposes that Gunnar Johansson be elected Chairman of the Meeting. Agenda item 8The Board of Directors proposes that a dividend of GBP 1.100 (equivalent to SEK 12.04 on 10 April 2014 exchange rates and payable in SEK) per share/SDR be declared and paid to owners of shares/SDR´s as at 23 May 2014. The ex-dividend date is proposed to be the 21 May 2014. A Euroclear Sweden AB record date of 23 May 2014 is proposed. If the AGM approves, the dividend is expected to be distributed by Euroclear Sweden AB on 28 May 2014. For accounting purposes the rate of exchange to be used shall be the SEK-GBP rate prevalent on the record date of 23 May 2014. Agenda item 9 The Board of Directors proposes a distribution in kind of Kambi Group Limited (to be renamed Kambi Group plc) (“Kambi”) shares in terms of article 105 of the Articles of Association of the Company. This dividend distribution is conditional on and subject to the approval by NASDAQ OMX of the listing of the shares in Kambi on NASDAQ OMX First North in Stockholm. Unless such approval is received by the 30 September 2014, the Company shall not be under any obligation to pay and distribute as a dividend the shares it holds in Kambi Group Limited (to be renamed Kambi Group plc). Kambi Group Limited will apply for its shares to be listed on the First North exchange in Stockholm with the intention of having 100 per cent of Kambi’s shares in free float on the market. If the distribution takes place, for each share/SDR in Unibet the holder will receive one share in Kambi Group plc. The transfer of value to the shareholders is equivalent to GBP 2.00255 per share/SDR based on an independent valuation of Kambi performed by KPMG in connection with a recapitalisation of Kambi prior to the distribution to shareholders. Kambi Group Limited (to be renamed Kambi Group plc) is 95 per cent owned by Unibet Group plc, with the remaining 5 per cent owned by certain Kambi management employees. The shares that will, subject to listing and approval by the AGM, be distributed to Unibet shareholders, therefore represent 95 per cent of the equity in Kambi. Unibet will distribute all of its shareholding with the result that Unibet will not have any shareholding in Kambi after the separation. The ex-dividend date is proposed to 21 May 2014. A Euroclear Sweden AB record date of 23 May 2014 is proposed. If the AGM approves, the shares in Kambi are expected to be distributed by Euroclear Sweden AB on 28 May 2014. More information about Kambi and the distribution process is to be found in the Kambi Company Description which will be available on www.unibetgroupplc.com/AGM on 29 April 2014. Agenda item 10 The 2013 Annual Report was finalised and signed on 14 March 2014 and reflects events up to that date. On 10 April 2014, the Board resolved to propose an additional final dividend for 2013 of GBP 2.00255 per share in respect of the proposed dividend in specie of Kambi Group Limited. This additional dividend, which is not reflected in the 2013 Annual Report is expected to utilise approximately GBP 56 million of distributable reserves. Agenda item 11The Board of Directors proposes that the AGM approves the remuneration report on pages 40 and 41 of the Company’s Annual Report and Financial Statements for the year ended 31 December 2013.Agenda item 12The Nomination Committee proposes that the Board of Directors should consist of seven Directors.Agenda item 13The Nomination Committee proposes that a total fee of GBP 494,000 (the “Total Fee”) be paid to Directors elected at the AGM, who are not employees of the Company. It is proposed that the Board of Directors will apportion the fee within the Board so that the Chairman will receive a fee of GBP 125,000, the Deputy Chairman will receive a fee of GBP 70,000 and a fee of GBP 45,000 be paid to each other Director, and an additional GBP 22,000 be paid for Audit Committee work, GBP 12,000 for Remuneration Committee work and an additional GBP 3,000 be paid to the Chairman of the Audit Committee, and the Chairman of the Remuneration Committee. The Nomination Committee also proposes that a fee pool of up to a maximum of GBP 150,000 is available to the Board for project work outside of normal Board work, and which is assigned by the Board.         The Nomination Committee also proposes that a fee pool of up to a maximum of GBP 100,000 is available to the Board for project work that has been assigned by the Board to the Chairman, and which is outside of his ordinary duties as Chairman of the Board. Agenda item 14-18CVs for Directors are to be found on page 33 in the Unibet Group plc Annual Report for 2013 and on the Company’s website. Agenda item 19 Sophia Bendz is 34 year old and a Swedish citizen with a Master in Economics from Stockholm University. Sophia is Global Director of Brand at Spotify and have been part of the core team since 2007. Agenda item 20 Peter Friis is 41 years old and a Danish citizen with a BA in Communications from Roskilde University. Peter has been a key player in building up Google’s Nordic market and his present role is Nordic Director for Google. Agenda item 21The Nomination Committee proposes that Anders Ström is appointed the Chairman of the Board. Agenda item 22The Nomination Committee proposes that the Annual General Meeting resolves that, until the general meeting of the shareholders decides otherwise, the Nomination Committee shall consist of not less than four and not more than five members, of which one shall be the Chairman of the Board of Directors. The members of the Nomination Committee shall represent all shareholders and be appointed by the four largest shareholders at the end of August 2014 having expressed their willingness to participate in the Nomination Committee. Should one of these shareholders appoint the Chairman of the Board of Directors as its representative, the Nomination Committee shall consist of four members. The other three members shall be appointed by each of the other three of the four largest shareholders expressing their willingness to participate in the Nomination Committee within one week from that they are asked. The appointment of a member of the Nomination Committee shall state which shareholder has appointed that member. Should one of the four largest shareholders waive its right to appoint a member of the Nomination Committee, the opportunity to appoint a member shall be offered to the largest shareholder not represented in the Nomination Committee. The opportunity to appoint a member of the Nomination Committee shall thereafter be passed on in order of the largest shareholding. The members of the Nomination Committee shall appoint the committee chair among themselves. The names of the members of the Nomination Committee shall be announced not later than the date of the publication of the Company's interim report for the third quarter of 2014. Should the ownership in the Company change, after the announcement of the Nomination Committee but before the end of the fourth quarter of 2014, to such extent that the members of the Nomination Committee no longer represent the shareholding as stipulated above, then the member of the Nomination Committee representing the shareholder with the lesser number of shares in the Company shall resign from the committee and the shareholder who has become the larger shareholder in the Company shall, in the order corresponding to its shareholding in the Company, be offered to appoint a new member of the Nomination Committee. Minor changes in the shareholding of the Company shall not be taken into account. Shareholders who have appointed a representative in the Nomination Committee have the right to dismiss that representative and appoint a new representative. Should a member of the Nomination Committee leave his/her assignment prematurely and if the Nomination Committee deems it appropriate, a new member shall be appointed by the shareholder who appointed the resigning member or that other shareholder who at that point of time has the larger shareholding in the Company. All changes of the Nomination Committee will be announced. No remuneration will be paid to the members of the Nomination Committee. Agenda item 23 The Nomination Committee proposes that PricewaterhouseCoopers are re-appointed as auditors for the Company. Agenda item 24The Board of Directors proposes that the AGM resolves upon guidelines for remuneration to management.  The policy of the Board is to attract, retain and motivate the best managers by rewarding them with competitive salary and benefit packages linked to achieving the Company’s financial objectives. Senior Managers receive base salaries based on position, responsibilities, performance and skills. The base salary is a fixed amount, payable monthly, which is reviewed annually in March . Benefits are based on the requirements of the country where the manager is employed. The performance-related salary is designed to support key business strategies and financial objectives and create a strong, performance-orientated environment. The performance targets are reviewed annually and are based on both quantitative and qualitative goals. The payout is conditional upon the Company achieving set financial targets. Thereafter, individual targets are mainly linked to financial objectives such as gross winnings revenue and EBITDA. There is also a part which is based on delivery of specific projects and business critical processes. Achievement of targets is assessed on an annual basis. The amount of potential variable pay compared to basic salary varies depending on position and situation, but is in general less than half the amount of the basic salary. All variable elements have a limit, which means that they cannot exceed a predetermined amount. Under the standard annual cycle of bonuses for the CEO and executive management, formal approval and payment of bonuses is typically completed after the publication of the Annual Report. Participation in long-term incentive schemes is based on position in the Company, performance and country of residence. Equity awards are made through option schemes (up to 2012) and the Performance Share Plan from 2013. They are granted under the terms of the Unibet Performance Share Plan, and Equity awards are linked to the performance of the Group to further align senior management’s interests with those of the shareholders. All the 700,314 share options and the 31,100 PSP shares outstanding at 31 December 2013 may generally only be exercised if the holder is employed by the Unibet Group at the date of exercise. Exceptions are made in special circumstances. The PSP performance measures are non-market based conditions providing participants with a high degree of alignment to company performance. PSP awards will depend on Unibet achieving financial performance targets over three financial years establishing a clearer link between how Unibet performs and the value that the PSP can deliver. These targets are Gross Contribution (Gross Winnings Revenue Less Cost of Sales less Marketing Costs), Free Cash Flow per Share and EBITDA and will be measured on an aggregate basis between the full year 2013 and the full year 2015 so that performance in each financial year will be important. Aggregated performance against the targets and the resulting allocation of PSP awards will be disclosed after the full year 2015. Agenda item 25 The Board of Directors proposes that the acquisition of shares/SDR´s shall take place on the NASDAQ OMX Stockholm or via an offer to acquire the shares/SDR´s to all shareholders. Repurchases may take place on multiple occasions and will be based on market terms, prevailing regulations and the capital situation at any given time. Notification of any purchase will be made to NASDAQ OMX Stockholm and details will appear in the Company’s annual report and accounts.The objective of the buyback is to achieve added value for the Company’s shareholders and to give the Board increased flexibility with the Company’s capital structure.Following repurchase the intention of the Board would be to either cancel, use as consideration for an acquisition or issue to employees under a Share Option programme or Share Performance Scheme. Once repurchased under the Maltese Companies Act further shareholder approval will be required before those shares could be cancelled only. If used as consideration for an acquisition the intention would be that they would be issued as shares/SDR´s and not sold first. Agenda item 26 The objectives of the authorisation are to increase the financial flexibility of the Company and to enable the Company to use its own financial instruments for payment in kind or through a directed set-off to a selling partner in connection with any business acquisitions the Company may undertake or to settle any deferred payments in connection with business acquisitions. The market value of the shares on each issue date that will be used in determining the price at which shares will be issued, should be the same as the market value of the shares/SDR’s listed on the NASDAQ OMX Stockholm. Shareholders/SDR holders representing approximately  28.4 per cent of the voting rights of all shares in the Company have stated that they intend to vote in favour of the proposals of the Nomination Committee. The Annual Report in English together with other documents regarding the AGM are available on the Company’s website www.unibetgroupplc.com.By order of the BoardUnibet Group plcMalta, April 2014NOTE1. A member entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote on his or her behalf. A proxy need not also be a member.

New study shows that probiotics from Probi can reduce the risk for osteoporosis

Osteoporosis constitutes a major health concern that places a huge economic burden on the health care system and entails a lot of suffering for the patients. The increasing number of fractures associated with the increasing age of the population makes it of vast importance to develop alternatives for both prevention and treatment of the disease. A recently published study in mice shows that intake of Lactobacillus paracasei DSM13434, Lactobacillus plantarum DSM 15312 and Lactobacillus plantarum DSM 15313 (Probi) reduces the risk for bone loss which could in turn reduce the risk for osteoporosis and bone fractures. BackgroundIn Sweden there are 70 000 new cases of bone fractures reported every year linked to osteoporosis. Approximately 25% of women above the age of 65 have already experienced a fracture once. As a consequence, these women have an increased risk of experiencing more fractures later in life. Studies have shown that age related bone loss is primarily linked to environmental factors such as diet, physical activity and inflammation. It is also known that intestinal inflammatory diseases are associated with a lower bone mass which further highlights the link between the gut system and the skeleton. The studyThe present study was recently published in PLOS ONE (DOI: 10.1371/journal.pone.0092368) and was conducted under the supervision of the Ass. Prof. Klara Sjögren and Prof. Claes Ohlsson. The purpose of the study was to examine the preventive effect of probiotics on induced bone loss in a mouse model applied when studying conditions linked to menopause. Mice were treated with either Lactobacillus paracasei DSM13434 or a mixture of three bacterial strains, Lactobacillus paracasei DSM13434, Lactobacillus plantarum DSM 15312 and Lactobacillus plantarum DSM 15313 (Probi). The controls used in the study were mice with induced bone loss that did not receive any probiotics and a group of sham mice without any treatment. The mice were given the probiotics in the drinking water for a total period of 6 weeks, starting two weeks before the treatment that induced bone loss. ResultsThe study shows that probiotic treatment significantly protects mice from induced bone loss as compared to the controls. Moreover, probiotic treatment results in a reduced urinary excretion of calcium and a reduced expression of markers of inflammation. To summarize, the results in the present study show that probiotics can reduce the risk for bone loss by affecting the immune system and reducing inflammation. Probiotics protect mice from ovariectomy-induced cortical bone loss. Ohlsson C (http://www.ncbi.nlm.nih.gov/pubmed?term=Ohlsson%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Engdahl C (http://www.ncbi.nlm.nih.gov/pubmed?term=Engdahl%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Fåk F (http://www.ncbi.nlm.nih.gov/pubmed?term=F%C3%A5k%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Andersson A (http://www.ncbi.nlm.nih.gov/pubmed?term=Andersson%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Windahl SH (http://www.ncbi.nlm.nih.gov/pubmed?term=Windahl%20SH%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Farman HH (http://www.ncbi.nlm.nih.gov/pubmed?term=Farman%20HH%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Movérare-Skrtic S (http://www.ncbi.nlm.nih.gov/pubmed?term=Mov%C3%A9rare-Skrtic%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Islander U (http://www.ncbi.nlm.nih.gov/pubmed?term=Islander%20U%5BAuthor%5D&cauthor=true&cauthor_uid=24637895), Sjögren K (http://www.ncbi.nlm.nih.gov/pubmed?term=Sj%C3%B6gren%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24637895). PLoS One. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Probiotics+protects+mice+2014+Sjogren) 2014 Mar 17;9(3):e92368. doi: 10.1371/journal.pone.0092368. http://dx.plos.org/10.1371/journal.pone.0092368.   FOR FURTHER INFORMATION, CONTACT:Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.seGun-Britt Fransson, Vice President Research & Development, Probi, tel +46 46 286 89 74 or mobile +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se ABOUT PROBIProbi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 30 countries worldwide.  The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm, Small-cap. Probi has approximately 3,500 shareholders. Read more on www.probi.se.

Scania Interim Report, January–March 2014

Summary of the first three months of 2014 · Operating income rose to SEK 2,257 m. (1,933), and earnings per share rose to SEK 1.95 (1.75) · Net sales rose by 9 percent to SEK 21,126 m. (19,341) · Cash flow amounted to SEK 730 m. (-88) in Vehicles and Services Comments by Martin Lundstedt, President and CEO: “Scania’s earnings for the first quarter amounted to SEK 2,257 m. Both vehicle and service volume increased, which was partly offset by weaker emerging markets currencies. Total order bookings for trucks during the first quarter were higher than the beginning of last year. The negative effect on demand in Europe after pre-buys of Euro 5 vehicles was less than expected and order bookings increased. The improved economic situation in Europe together with the replacement need means that the underlying trend in demand is positive. Scania has strengthened its position in the European market through increased market share and a leading Euro 6 range, which is confirmed by Euro 6 tests in the trade press. Order bookings in Latin America remained in line with the previous two quarters. In Asia, order bookings improved and in Russia, order bookings increased significantly. Order bookings for buses and coaches rose in Europe, while they fell in Latin America and Eurasia. In Engines, order bookings were somewhat better than in the same period of 2013 and Scania has initiated collaboration on engine deliveries with another major OEM. Scania is continuing its long-term efforts to boost market share in Services and revenue increased by 7 percent in local currencies during the first quarter. Financial Services showed a strong performance and customer payment capacity is good. The trend in demand in early 2014 indicates a continued high level of vehicle and service volume. There are also good growth opportunities in the longer term and the expansion of annual technical production capacity towards 120,000 vehicles is continuing. To strengthen competitiveness, the level of activity related to development projects remains high, at the same time as Scania is expanding its sales and service capacity in emerging markets.” For more information please see the attached pdf. Contact personsPer HillströmInvestor RelationsTel. +46 8 553 502 26Mobile tel. +46 70 648 30 52 Erik LjungbergCorporate RelationsTel. +46 8 553 835 57Mobile tel. +46 73 988 35 57

Axis AB: Invitation to Axis' interim report conference call for the first quarter 2014

Time: Thursday, April 24, at 10 a.m. CET.To join the conference: + 46 (0)8-519 993 57 The presentation will be webcasted live at: http://financialhearings.nu/140424/axis/ Axis AB participants:Ray Mauritsson, CEO and Fredrik Sjöstrand, CFO. Axis AB's interim report will be issued around 08.00 a.m. CET on Thursday, April 24.The slide presentation and the report will be available at: http://www.axis.com/corporate/investor/index.htm The report and presentation will be available on Axis’ investor pages after publication. For more information, please contact:Johan Lundin, Manager, Investor RelationsTelephone: +46 (0) 46 272 18 00, E-mail: IR@axis.com.   About Axis CommunicationsAxis offers intelligent security solutions that enable a smarter, safer world. As the global market leader in network video, Axis is driving the industry by continually launching innovative network products based on an open platform - delivering high value to customers through a global partner network. Axis has long-term relationships with partners and provides them with knowledge and ground-breaking network products in existing and new markets. Axis has more than 1,600 dedicated employees in more than 40 countries around the world, supported by a network of over 65,000 partners across 179 countries. Founded in 1984, Axis is a Sweden-based company listed on NASDAQ OMX Stockholm under the ticker AXIS. For more information about Axis, please visit our website www.axis.com

Invitation to presentation of interim report for the first quarter

Nobia will publish its interim report for the first quarter 2014 on 28 April at 8.00 CET. A webcasted telephone conference will be held the same day at 9.00 CET.Nobia’s President and CEO Morten Falkenberg and CFO Mikael Norman will present the results and answer questions. The telephone conference will be held in English and will be webcasted live on Nobia’s website: www.nobia.com (http://file://nobianet.global/hq/groups/Common/Gemensam/COMMUNICATIONS/Pressmeddelanden/Engelska/2014/www.nobia.com), or via the following link:  (http://www.media-server.com/m/s/b9gfpqmq/lan/en)http://www.media-server.com/m/s/b9gfpqmq/lan/enTo participate in the telephone conference, and thereby be able to ask questions, please call one of the following numbers:Sweden: +46 (0)8 505 564 74UK: +44 (0)203 364 5374USA: +1 855 753 22 30The presentation material will be available at www.nobia.com before the conference starts.For further informationLena Schattauer, Head of Investor Relations+46 (0)8 440 16 07 or +46 (0)705 95 51 00lena.schattauer@nobia.comNobia develops and sells kitchens through some twenty strong brands in Europe, including Magnet in the UK; Hygena in France; HTH, Norema, Sigdal, Invita and Marbodal in Scandinavia; Petra, Parma and A la Carte in Finland; ewe, FM and Intuo in Austria, as well as Poggenpohl globally. Nobia generates profitability by combining economies of scale with attractive kitchen offerings. The Group has approximately 6,500 employees and net sales of about SEK 12 billion in 2013. The Nobia share is listed on the NASDAQ OMX Stockholm under the ticker NOBI. Website: www.nobia.com.

New rankings in the Life Science Investment Hotlist for the Stockholm-Uppsala region

The list has been updated with the top ten companies that are seeing the greatest demand from investors right now. “A whole lot is happening now in the field of life science in the Stockholm-Uppsala region, and that is why we updated the list,” observes Ylva Hultman Erlandsson, Business Development Manager at Stockholm Business Region Development. One company within the digital health field is DDinnovation AB. They have developed an app that will help patients in rural areas to more quickly obtain a diagnosis and information on whether they need to go to the hospital. There are also more companies in the Stockholm-Uppsala region doing research on stem cells. Two companies that can be mentioned in this regard is IsletOne Therapeutics and Biolamina AB. “The interest in stem cells research is substantial in the region, and we are internationally successful. Kenneth Chien is one example of this. Kenneth left Harvard to conduct research at the Karolinska Institute in Stockholm,” notes Ylva Hultman Erlandsson. The Life Science Investment Hotlist functions as a tool for investors, and by creating awareness of companies, joint projects and other collaborations are fostered. To qualify for the list, the company must offer a product or service with a global potential. See the Investment Hotlist in its entirety:www.investstockholm.com/en/Life-Science-Hotlist For more informationSabina von Greyerz, Public Relations Manager, Stockholm Business RegionPhone: 070-472 80 69e-mail: sabina.von.greyerz@stockholm.se Stockholm Business Region has the mission, together with its subsidiaries Stockholm Business Region Development and the Stockholm Visitors Board, to develop and market Stockholm as a place to establish one’s business enterprise and as a tourist destination. Stockholm Business

Christian Luiga appointed Chief Financial Officer

“I am very pleased to announce that Christian Luiga has accepted the position of Chief Financial Officer at TeliaSonera. Christian has been acting CFO for the past four months and has done an excellent job. Christian is very familiar with our operations and well equipped to be part of shaping TeliaSonera into the future. He is also known in our investor community in his capacity as acting CFO”, says Johan Dennelind, President and CEO of TeliaSonera. Christian Luiga joined TeliaSonera in 2009 and has been acting CFO since November 2013. Previously, he was CFO at the listed companies Teleca AB and Framfab AB.   TeliaSonera AB discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instrument Trading Act. The information was submitted for publication at 11.20 a.m. CET on April 11, 2014. For more information, please contact the TeliaSonera press office +46 771 77 58 30, press@teliasonera.com, visit our Newsroom (http://www.teliasonera.com/en/newsroom/) or follow us on Twitter @TLSN_Media (https://twitter.com/TLSN_Media). Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of TeliaSonera. TeliaSonera provides network access and telecommunication services in the Nordic and Baltic countries, the emerging markets of Eurasia, including Russia and Turkey, and in Spain. TeliaSonera helps people and companies communicate in an easy, efficient and environmentally friendly way. Our ambition is to be number one or two in all our markets, providing the best customer experience, high quality networks and cost efficient operations. TeliaSonera is also a leading wholesale provider who owns and operate one of the world’s most extensive fiber backbones. In 2013, net sales amounted to SEK 101.7 billion, EBITDA to SEK 35.6 billion and earnings per share to SEK 3.46. The TeliaSonera share is listed on NASDAQ OMX Stockholm and NASDAQ OMX Helsinki. Read more at www.teliasonera.com.

Burton Constable Hall needs YOU to share your war time stories

Burton Constable Hall is seeking the help of local people to share their stories from times of war (World War 1 and 2). Burton Constable wants to preserve stories and memories of how the war impacted on the Hall, the estate and its workers as part of an exhibition to be held in June 2014 in the newly restored stable block. Burton Constable is currently undergoing a £417,800 Heritage Lottery Funded development to repair and restore the derelict stable block and bring the space back to life with new interpretation and a series of fascinating exhibitions for the community and visitors. The learning and public access programming for the stable block project is being led by local creative learning specialists Heritage Learning. Sarah Howard, Project Manager at Heritage Learning, said “We are looking for people who had any sort of connection with the Hall during times of war to share their stories, photographs and memories with us. The theme of the exhibition is “Burton Constable at War: Home and Away so alongside stories based here in East Yorkshire, we would also like to hear stories of former estate workers who served in either world war. Did you or a family member work on the estate? Were you evacuated to the Holderness area or remember those who were? Do you have your own “Warhorse” story in your family? This is a really exciting opportunity for members of the community to have their stories preserved in an exhibition. So if you have a story to tell please get in touch. We need to collect your stories and photos by Friday 2ndMay”. If you have a story to share or would simply like to find out more you can get in touch with Sarah Howard at Heritage Learning on 01482 318734 or via email: sarah.howard@hullcc.gov.uk. ENDS Notes to editors The Burton Constable Foundation is a charity established in 1992 by the National Heritage Memorial Fund with the purpose of preserving Burton Constable Hall, its collections and parkland for public benefit. Supported by The National Lottery through the Heritage Lottery Fund.  Organised in collaboration with Heritage Learning. An award-winning service with the mission to bring human stories to life through diverse art and heritage collections. Heritage Learning is recognised nationally and internationally as delivering examples of best practice across cultural and creative learning – delivering high-quality learning opportunities for children, young people and communities. Contact For further information on learning and public access programming for the stable block project please contact Sarah Howard at: Heritage Learning 35 High Street Hull HU1 1NQ T: 01482 318736 For all other enquiries relating to the Burton Constable Foundation, please contact: Burton Constable Foundation Burton Constable, Skirlaugh EastYorkshire,HU11 4LN Tel: 01964 562400 Fax:01964 563229 Links www.heritage-learning.com http://www.burtonconstable.com

Focus on children's rights when world leaders gather at the Global Child Forum

Press release Stockholm, April 11, 2014 Four hundred chosen leaders from the United Nations, child welfare organizations, multi-national corporations , financial institutions and academia are now targeting their focus on children's rights at the Global Child Forum. In its fourth year, the Global Child Forum will again be held at the Royal Palace in the presence of the King and Queen . Also the World Trade Organization's General Secretary, Roberto Azevedo, will present the effect of international trade on issues regarding children’s rights: - The crisis in recent years has hit many western economies hard – and one of the most worrying effects has been very high levels of youth unemployment. Trade can be part of the solution, because one of the key differences that trade makes is through job creation, stated Roberto Azevedo, Director - General, the World Trade Organization. - Today, 25 years after the UN Convention on the Rights of the Child was adopted by almost all nations in the world, it is obvious that many parts of the global society has not yet accepted the message. At the Global Child Forum, our objective is to spread the message and aid every level of society in respecting and supporting children's rights - helping to create a more sustainable world, according to Ulf Karlberg, President, Global Child Forum . The Global Child Forum and The Boston Consulting Group have jointly analyzed how over 1000 publicly traded companies in eight industries from the Forbes Global 2000 list, are addressing issues on children’s rights in the study "Children's rights and corporate sector – setting a benchmark ". This was also presented at the Forum. - It was revealed that 13 percent of companies consider that the Board has a responsibility for children's rights, according to the study. We must work for the rights of children to be placed high on their agendas. Consumers are becoming more aware and increasingly demanding that companies take a stand and demonstrate how they are working on issues of children’s rights. How will consumers otherwise know with certainty that companies act based on the children 's best interest, questions Magdalena Kettis, Research Director, Global Child Forum. “Children's Rights and the corporate sector – setting a benchmark” is taking a step towards developing a correlation between companies in the area. Publicly available information has been analyzed using nine indicators of how companies work with children´s rights. The main objective is to repeat the survey annually to track developments in a range of sectors and geographic locations over time. About Global Child Forum Global Child Forum is an independent, global multi-stakeholder platform for informed dialogue and thought leadership on how to advance children’s rights in support of the UN Convention on the Rights of the Child. The Global Child Forum aims at gathering leaders from business, governments, academia and civil society in a joint effort to implement children’s rights. This multi-stakeholder approach should be supported by effective information sharing, exposing leading case studies and learning from best practice from all parts of the world.

Invitation to presentation of Swedbank’s interim report January-March 2014

Swedbank’s interim report January – March 2014 will be published at 07:00 CET on Monday 28 April 2014. You are invited to participate in the following presentations:Analyst conference call and audio cast (in English) on 28 April at 09:00 CETMichael Wolf, President and CEO, Göran Bronner, CFO, and Anders Karlsson, CRO, will present the results. To listen to the live audio cast, please visit www.swedbank.com/ir, where a recording of the conference call also will be available. To attend the conference call, please dial +44 203 364 5374 or + 46 8 505 564 74, five minutes prior to the start of the call. Press conference (in Swedish) on 28 April at 10:30 CET at Swedbank’s head office, Brunkebergstorg 8, Stockholm. Michael Wolf, President and CEO, and Göran Bronner, CFO, will present and comment on the results. To view the live webcast please visit www.swedbank.com/ir where a recording of the press conference also will be available.Analyst lunch in London on Tuesday 29 April at 12:00 BTGöran Bronner, CFO, and Gregori Karamouzis, Head of Investor Relations, will present and comment on the results at an analyst meeting held at the offices of Deutsche Bank, Garden House Dining Rooms, 23 Great Winchester Street, London EC2N 2DB. The meeting is expected to end by 13:15 BT.To attend in London please RSVP to ir@swedbank.com (ir@swedbank.se) For further information, please contact:Gregori Karamouzis, Head of Investor Relations, Swedbank, tel: +46 72 740 63 38, gregori.karamouzis@swedbank.com

Supplement to the offer document made public regarding Blue Canyon Holdings’ cash offer to the shareholders of Cision

Blue Canyon Holdings AB (“Blue Canyon Holdings”), controlled by GTCR Investment X AIV Ltd., announced a recommended cash offer on 14 February 2014 (the “Offer”) to the shareholders of Cision AB (publ) (“Cision”). The Offer was declared unconditional by way of a press release announced on 18 March 2014. In a press release announced on 20 March 2014, Blue Canyon Holdings increased the offer price from SEK 52.00 to SEK 55.10 in cash per share and extended the acceptance period to 4 April 2014. On 7 April 2014, Blue Canyon Holdings announced a press release regarding its decision to further increase the offer price to SEK 61 per share[1] and to extend the acceptance period to 22 April 2014. In light thereof, Blue Canyon Holdings has prepared and today made public a supplement to the offer document regarding the Offer. The Swedish version of the supplement has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The supplement together with the offer document and the acceptance form are available at Blue Canyon Holdings’ website (www.bluecanyon.se) and SEB Emissioner’s website (www.sebgroup.com/prospectuses). Settlement to shareholders who have accepted the Offer up until 27 March 2014 occurred on 4 April 2014. The increase of the price in accordance with press release on 7 April 2014 to such shareholders is expected to be settled around 14 April 2014. Settlement to shareholders who have accepted the Offer after 27 March 2014 and up until 4 April 2014 is expected to begin around 14 April 2014. Settlement to shareholders who have accepted the Offer after 4 April 2014 and up until 22 April 2014, is expected to begin around 30 April 2014. As the Offer is unconditional, shareholders do not have the right to withdraw given acceptances. Fairford Holdings Finance AB, Cyril Acquisition AB, Lannebo Fonder and Accendo Capital SICAV-SIF, representing in aggregate 43.3 per cent of the shares and votes in Cision, have accepted the Offer in accordance with their undertakings. Together with the Cision shares controlled by Blue Canyon Holdings as announced in a press release on 3 April 2014, these shares represent in aggregate 63.4 per cent of the shares and votes in Cision. Information about the OfferFor information about the Offer, please see www.bluecanyon.se.           Further informationFor media questions, please contact:Eileen RochfordPhone: +1 312.953.3305E-mail: eileenr@theharbingergroup.com This press release was submitted for publication on 11 April 2014 at 12:20 (CET). Important noticeThis is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail. Offer restrictionsThe Offer is not being made to persons whose participation in the Offer requires that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law. This press release and any documentation relating to the Offer are not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Any such action will not be permitted or sanctioned by Blue Canyon Holdings. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Blue Canyon Holdings will not deliver any consideration under the Offer into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Blue Canyon Holdings and Cision. Any such forward-looking statements speak only as of the date on which they are made and Blue Canyon Holdings has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United StatesThe Offer described in this announcement is subject to the laws of Sweden. It is important for US securities holders to be aware that this document is subject to disclosure and takeover laws and regulations in Sweden that are different from those in the United States. As applicable, Blue Canyon Holdings will comply with Regulation 14E under the US Securities Exchange Act of 1934, as amended (“Exchange Act”) in connection with the Offer. The Offer is being treated in the United States as one to which the “Tier II” exemption mentioned in Rule 14d-1(d) under the Exchange Act is applicable. Pursuant to an exemption from Rule 14e-5 under the Exchange Act, Blue Canyon Holdings and certain of its Representatives may, from time to time, purchase or make arrangements to purchase shares outside the Offer from the time the Offer was announced until the expiration of the acceptance period of the Offer, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, in each case, outside of the United States and to the extent permitted under the applicable Swedish laws and regulations. Any such purchases will not be made at prices higher than the price of the Offer provided in this announcement unless the price of the Offer is increased accordingly. Any future purchases will be made in accordance with applicable laws, rules and regulations. Any such purchases of shares will be disclosed to the extent required by Swedish law or rules or regulations and, if so disclosed, will also be disclosed in the US. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THIS OFFER, PASSED UPON THE FAIRNESS OR MERITS OF THIS ANNOUNCEMENT OR DETERMINED WHETHER THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE IN THE UNITED STATES. ---------------------------------------------------------------------- [1] Based on 14,909,583 outstanding shares. In the event that Cision should pay any dividend or make any other value transfer prior to the settlement of the Offer, the price per share in the Offer will be reduced correspondingly.

YORKSHIRE AMBULANCE SERVICE REDUCES TYRE COSTS WITH ATS EUROMASTER

ATS Euromaster has helped to reduce the Yorkshire Ambulance Service NHS Trust’s (YAS) tyre spend by approximately 20 per cent – just eight months after being appointed to service the Trust’s fleet. The three year deal, which was secured via the Government Procurement Service (GPS) tyre framework agreement (now part of the Crown Commercial Service), sees ATS Euromaster’s experienced technicians fitting Michelin tyres to the Trust’s vehicles, which include more than 280 emergency ambulances, 200 rapid response vehicles and 460 patient transport service vehicles. ATS Euromaster has been working closely with YAS to replace its existing tyres as wear dictates. The replacement Michelin fitments, backed up by ATS Euromaster’s expert tyre management, is helping to extract the maximum mileage out of every tyre, significantly reducing the fleet’s tyre bills. Gary Walden, Accident Reduction Manager at YAS, says: “Our fleet covers a vast area of almost 6,000 square miles from busy urban areas through to isolated moors and dales. Our vehicles cover thousands of miles every week, often making swift progress to patients under blue lights and sirens. As such our tyres are worked very hard and optimising our fitment and service strategy is key. By working in partnership with ATS Euromaster we’ve made great in-roads and the impact on our running costs is evident.” The Trust handles an average of 2,180 emergency calls a day and operates from 62 ambulance stations located across the county. As part of the new deal it has been trialling Michelin cold weather tyres on a number of its vehicles to prepare for the harsh Yorkshire winters. Walden says: “So far the tyres have performed well, but we’re looking to see how they cope in even colder conditions and how they fare as it warms up. If we see the safety benefits we expect to and no impact on handling when the weather turns, we’ll consider rolling them out across the fleet.” The contract also gives YAS access to ATS Euromaster’s 24/7 roadside rapid response service, which is key to getting emergency vehicles back on the road as quickly as possible. Walden added: “ATS Euromaster understands that unplanned fleet downtime is simply not an option for an emergency service and has made the transition to a new service provider as smooth as possible. They are providing us with a great service and have been easy to do business with.” ends About ATS EuromasterBirmingham-based ATS Euromaster Ltd (http://www.atseuromaster.co.uk/), part of the Euromaster Group (http://www.euromaster.com/), was established in 1965 and operates approximately 345 centres, more than 820 service vans and employs nearly 2,600 people, providing coverage across Great Britain. It is the country’s largest comprehensive tyre distributor, supplying tyres for cars, vans, trucks, buses/coaches, materials handling equipment, agricultural machinery and construction plant. The company’s expertise also extends to car and van service, maintenance and repair (SMR), including: menu-driven servicing, Class IV & Class VII MoT tests, brakes, batteries, shock absorbers, oil, exhausts, fault diagnostics and air-conditioning servicing. ATS Euromaster is accredited by both safecontractor (http://www.safecontractor.com/) and the Contractors Health and Safety Scheme (http://www.chas.co.uk/) (CHAS) and has been granted a Royal Warrant (http://www.royalwarrant.org/) as tyre specialists to Her Majesty The Queen. It is also an official ‘industry partner’ to the Freight Transport Association’s Van Excellence (http://www.vanexcellence.co.uk/) programme. For further information visit: http://www.atseuromaster.co.uk/business Note to editor: For press information visit ATS Euromaster’s online newsroom (http://news.cision.com/ats-euromaster) or contact Faye McBride or James Keeler on 020 8647 4467, or by email to faye.mcbride@garnettkeeler.com / james.keeler@garnettkeeler.com. ATS/500/14

Report from ICA Gruppen’s 2014 Annual General Meeting

ICA Gruppen’s Annual General Meeting approved the proposed dividend of SEK 8.00 per ordinary share for the 2013 financial year. 16 April 2014 was set as the record date for receiving a dividend. Dividends are expected to be paid by Euroclear Sweden AB on Wednesday, 23 April 2014. The Annual General Meeting resolved on re-election of Board members Peter Berlin, Göran Blomberg, Cecilia Daun Wennborg, Andrea Gisle Joosen, Fredrik Hägglund, Bengt Kjell, Magnus Moberg, Jan Olofsson, Claes-Göran Sylvén and Margot Wallström for the period until the next Annual General Meeting has been held, which meant that all ten members of the Board were re-elected. Claes-Göran Sylvén was re-elected as the Chairman of the Board. The Meeting resolved that total fees to the Board amount to SEK 3,780,000, with SEK 900,000 to be paid to the Chairman of the Board and SEK 320,000 to each of the other members elected by the Meeting. It was further resolved that SEK 900,000 be allocated for committee work. Fees to auditors to be paid in accordance with approved invoices. Registered accounting firm Ernst & Young AB was re-elected as auditor with Tomas Forslund as Senior Auditor. The Annual General Meeting resolved to accept the income statement and balance sheet for the parent company and for the Group and granted discharge from liability for ICA Gruppen’s Board members and the CEO for the 2013 financial year. The Annual General Meeting resolved on principles for remuneration and other employment terms for senior executives, which essentially correspond to the principles adopted at the 2013 Annual General Meeting. Remuneration shall comprise basic salary, pension and two variable remuneration schemes in the form of a cash bonus, one of which runs for one year and the other for three years. Senior executives are expected to invest annually in shares in ICA Gruppen corresponding to 5-10%of their gross salary. After 12 months senior executives are entitled under certain conditions to receive a net amount corresponding to half of the amount invested. A recorded version of CEO Per Strömberg’s address to the Annual General Meeting is available at www.icagruppen.se/arsstamma-2014. ICA Gruppen AB discloses the information provided herein pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 13.00 CET on Friday, 11 April 2014. For more information ICA Gruppen press service, telephone: +46 702 53 66 60

Britain’s Katy Dunne in the semi-finals of Aegon GB Pro-Series Gloucester

Quarter-finals day at Oxstalls Sports Park saw 19 year old Katy Dunne’s winning form continue as she booked her place in Friday’s semi-final. Facing Nora Niedmers of Germany, a lucky loser from qualifying, Dunne started well breaking serve in the first game. The 19 year old German fought back and the pair exchanged a couple of breaks with both playing high quality tennis. The young Brit served for the first set at 5-4 but soon found herself at 5-6 serving to stay in the first set. A love service game took the set to a tie break, and with the momentum swinging the way of Dunne, she took a 4-0 lead. Niedmers saved one set point on her serve, however, Dunne did not miss the next opportunity on her own serve and claimed the first set 76(3) in 57 minutes. The second set remained a close fight, and with one break apiece the set was level at 3-3. Dunne played a solid service game in the seventh game and found a way to break the German in the following game to lead 5-3. With a steely focus the Brit sealed the match with a love service game, reaching her second semi-final of 2014. After the match Dunne commented “I played a really tough match, mentally I stayed strong and I didn’t drop my level much. [In the tie break] I made her play every point, but I stayed aggressive. “Playing in the top junior events is good preparation, the level is similar to $10k events, and so I think it has helped me.” With relatives from Gloucestershire, Dunne has ties to the area. Talking of the support from spectators when competing on home soil Dunne said “it is always good to play in front of a crowd as it creates a good atmosphere and that always helps.” Dunne’s opponent in the semi-finals is Belgium’s Klaartje Liebens, after the seventh seed came through a tough encounter with fourth seed Anna-Giulia Remondina from Italy. Liebens, leading by one set, had a match point in the second set tie break but was forced into a third set by the gutsy Italian. Despite losing the tie break the 19 year old Belgian regained the momentum racing to a 3-0 lead for the loss of just two points. The third set was wrapped up quickly in just 25 minutes with Liebens winning 63 67(7) 60. The top seed, Hiroko Kuwata from Japan, eased into the semi-finals with a straight sets victory over sixth seed Belarussian, Sviatlana Pirazhenka, 75 62. Her opponent on Friday is third seed Bernada Pera from USA, who ended the run of the un-seeded German, Justine Ozga, for the loss of three games, 62 61. In the doubles the top seeded Anglo-Swedish pairing of Lucy Brown and Hilda Melander secured their place in Friday’s doubles final with a win over third seeds Harriet Dart (GBR) & Sviatlana Pirazhenka (BLR). They will take on British fourth seeds Beth Askew and Katy Dunne, who defeated Rona Berisha & Louise Ronaldson (GBR). The semi-finals kick off at 10.30am on Friday with Katy Dunne on first, followed by the second semi-final before Dunne returns for the doubles final. Entry is free to spectators. The final is being held on Saturday 12th April starting at 11.00am

Clarification on suspicion of insider crime

Following the media coverage relating to the suspicion of insider crime by an employee at Getinge AB, Getinge would like to make the following clarification. Getinge confirms that an employee who works in the IT organization at Getinge AB’s headquarters is under investigation by the Swedish Economic Crime Authority for insider crime. The employee’s current position involves responsibility for developing and managing the IT systems used by Getinge AB's head office. Since 2007, the person has had no managerial position but works as a specialist within IT. "This is highly regrettable and we take this incident very seriously. From the outset, we have cooperated with the Swedish Economic Crime Authority in its investigation," says Kornelia Rasmussen, Getinge Group Communications Director. "Parallel to the investigation by the Economic Crime Authority, we have initiated an internal investigation." The employee concerned has been suspended pending the internal investigation. At present, no other employee at Getinge AB is suspected of crimes. For further information, please contact:Kornelia RasmussenGetinge Group Communications DirectorPhone: +46 10 335 5810E-mail: kornelia.rasmussen@getinge.com GETINGE GROUP is a leading global medical technology company with operations in the areas of surgery, intensive care, infection control, care ergonomics and wound care. The Group is organized into three business areas: Extended Care, Infection Control and Medical Systems, and operates under the ArjoHuntleigh, GETINGE and MAQUET brands.

ATLANTA HISTORY CENTER ANNOUNCES SPRING/SUMMER 2014 AUTHOR PROGRAMS

The Atlanta History Center offers lectures on a wide variety of topics, from presidential history and gardens to social history and non-fiction adventures. Each lecture program is designed to join authors and audiences in an intimate setting complete with author presentation, audience discussions, and book signings. Past lecturers have included such world-renowned authors as Walter Isaacson, James McPherson, Kelly Corrigan, and Alice Hoffman. The Atlanta History Center’s spring/summer lecture line-up continues to offer audiences a wide variety of subject matter with current and award-winning authors.   The series kicks off with beloved travel author Frances Mayes, discussing her new book Under Magnolia, and continues on through July featuring authors such as bestselling chef personalities Gina and Pat Neely, award-winning journalist Jennifer Senior, beloved author and radio personality Garrison Keilor, and New York Times bestselling author Peter Heller. Lectures are held at either the Atlanta History Center in Buckhead or at the Margaret Mitchell House in Midtown. At each lecture, guests receive a 25% discount on the featured author’s book. Admission to all lectures is $5 for members, $10 for nonmembers, and free to AHC Insiders unless noted otherwise. Reservations are required; please call 404.814.4150 or purchase advance tickets online at AtlantaHistoryCenter.com/Lectures.  (http://www.atlantahistorycenter.com/Lectures)  April 2014                                                                                                                                                         Frances Mayes, Under Magnolia: A Southern Memoir Tuesday, April 15, 2014 7:00 pm Location: Margaret Mitchell House The author of three beloved books about her life in Italy, Frances Mayes revisits the turning points that defined her early years in Fitzgerald, Georgia. With her signature style and grace, Mayes explores the power of landscape, the idea of home, and the lasting force of a chaotic and loving family. From her years as a spirited, secretive child, through her university studies—a period of exquisite freedom that imbued her with a profound appreciation of friendship and a love of travel—to her escape to a new life in California, Mayes exuberantly recreates the intense relationships of her past, recounting the bitter and sweet stories of her complicated family: her beautiful yet fragile mother, Frankye; her unpredictable father, Garbert; Daddy Jack, whose life Garbert saved; grandmother Mother Mayes; and the family maid, Frances’s confidant Willie Bell.Under Magnolia is a searingly honest, humorous, and moving ode to family and place, and a thoughtful meditation on the ways they define us, or cause us to define ourselves. With acute sensory language, Mayes relishes the sweetness of the South, the smells and tastes at her family table, the fragrance of her hometown trees, and writes an unforgettable story of a girl whose perspicacity and dawning self-knowledge lead her out of the South and into the rest of the world, and then to a profound return home. An Evening with Gina and Pat Neely, Back Home with the Neely’s Wednesday, April 16, 2014 7:00 pm Location: Atlanta History Center Pat and Gina Neely are known for a few things, among them: food and family. In their third cookbook, the best-selling Neely couple returns to their down home roots with classic Southern recipes passed down through generations. Through recipes framed by childhood memories, we're drawn into the kitchens of their mothers and grandmothers and back to a time when produce came from the backyard garden and catfish was caught on afternoon fishing trips with Grandpa. In their signature style, Pat and Gina have taken the recipes they were raised on and updated them to make them more approachable for today's readers. Arrive early for samples of recipes featured in Back Home with the Neely’s and prepared by Viking Store & Cooking School chefs. An Evening with Jennifer Senior, All Joy and No Fun Wednesday April 23, 2014 8:00 pm Location: Atlanta History Center Thousands of books have examined the effects of parents on their children. In All Joy and No Fun award-winning journalist Jennifer Senior now asks: what are the effects of children on their parents? Senior tackles this question, isolating and analyzing the many ways in which children reshape their parents' lives, whether it's their marriages, their jobs, their habits, their hobbies, their friendships, or their internal senses of self. She argues that changes in the last half century have radically altered the roles of today's mothers and fathers, making their mandates at once more complex and far less clear. Recruiting from a wide variety of sources—in history, sociology, economics, psychology, philosophy, and anthropology—she dissects both the timeless strains of parenting and the ones that are brand new, and then brings her research to life in the homes of ordinary parents around the country. The result is an unforgettable series of family portraits, starting with parents of young children and progressing to parents of teens. Through lively and accessible storytelling, Senior follows these mothers and fathers as they wrestle with some of parenthood's deepest vexations—and luxuriate in some of its finest rewards. Jennifer Senior is a contributing editor at New York Magazine, where she writes profiles and cover stories about politics and social science. She has been a frequent guest on NPR and numerous television programs, including Charlie Rose, The Chris Matthews Show, Hardball, Morning Joe, Washington Journal with Brian Lamb, CNN/American Morning, and NBC/Today. She is a regular contributor to the New York Times Book Review. She lives in New York with her husband and young son. Support: This is the eighteenth annual Sidney Isenberg Lecture. The Sidney Isenberg Lectures have been established by his friends, colleagues, and family as an expression of love and appreciation for his values and commitment to the healing process and to the advancement of learning and growth – affirming his conviction that the human relationship is the agency through which change comes about. Civil War to Civil Rights Lecture Series: Todd Purdum, An Idea Whose Time Has Come: Two Presidents, Two Parties and the Battle for the Civil Rights Act of 1964 Thursday, April 24, 2014 8:00 pm Location: Atlanta History Center In a powerful narrative layered with revealing detail, Todd S. Purdum tells the story of the Civil Rights Act of 1964, recreating the legislative maneuvering and the larger-than-life characters who made its passage possible. From the Kennedy brothers to Lyndon Johnson, from Martin Luther King Jr. to Hubert Humphrey and Everett Dirksen, Purdum shows how these all-too-human figures managed, in just over a year, to create a bill that prompted the longest filibuster in the history of the U.S. Senate yet was ultimately adopted with overwhelming bipartisan support. He evokes the high purpose and low dealings that marked the creation of this monumental law, drawing on extensive archival research and dozens of new interviews that bring to life this signal achievement in American history. Todd Purdum is a contributing editor at Vanity Fair and Politico. He lives in D.C. with his wife, Dee Dee Myers. Support:Civil Rights 50 lectures are presented through the generous support of Vicki and Howard Palefsky. Cherokee Garden Library Lecture: Kathryn Holland Braund, William Bartram’s Surprising Travels Sunday, April 27, 2014 3:00 pm Location: Atlanta History Center Kathryn Braund, Hollifield Professor of Southern History, Auburn University, is an expert in the ethnohistory of Creek and Seminole Indians in the eighteenth and early nineteenth centuries. Among her many publications, she is the co-author with Gregory A. Waselkov of William Bartram on the Southeastern Indians (1995) and co-editor with Charlotte M. Porter of Fields of Vision: Essays on the Travels of William Bartram (2010). Lecture followed by a special exploration of Bartrams’ flora in the Mary Howard Gilbert Memorial Quarry Garden led by Sarah Roberts, Atlanta History Center Director of Historic Gardens and Living Collections. Lecture and garden tour followed by a light reception. May 2014 Victoria Wilcox, Gone West Saturday, May 10, 2014 2:00 pm Location: Margaret Mitchell House  The name Doc Holliday conjures images of the Wild West and the shootout at the OK Corral, but before he was a Western legend he was a Southern son, born in the last days of the Old South with family links to the author of Gone With the Wind.  Now the amazing story introduced in Inheritance, the first book in the trilogy of Southern Son: The Saga of Doc Holliday, continues in Gone West. The American Wild West, 1873:  Jesse James and his gang are robbing trains, the Sioux Indians are on the warpath, and John Henry Holliday arrives in Texas as a young man with a troubled past hoping to regain his place as a Southern gentleman.  Starting over in Texas, he attempts to remake his career and win back the respect of his family and the love of the girl he left behind. But his life in the West doesn’t turn out the way he has planned, and soon he’s in trouble with the law again and facing a terrifying truth. Gone West is the story of how a gentleman becomes an outlaw, how an outlaw becomes a lawman, and how a Southern son named John Henry becomes a legend called Doc Holliday. An Evening with Garrison Keillor, The Keillor Reader Thursday, May 15, 2014 8:00 pm Location: Atlanta History Center Join the Atlanta History Center for an evening you won’t soon forget, as Garrison Keillor takes to the stage to share stories, poems and essays from The Keillor Reader.  When, at thirteen, he caught on as a sportswriter for the Anoka Herald, Garrison Keillor set out to become a professional writer, and so he has done. The Keillor Reader brings together the full range of his work, including monologues from A Prairie Home Companion, stories from The New Yorker and The Atlantic, excerpts from novels, newspaper columns, and pieces never before published, including the essays “Cheerfulness” and “What We Have Learned So Far.”                                                                                                                     In a vibrant blend of nonfiction, fiction, and straight-up parody, Keillor once again draws on his lifetime of experience among the hardworking, God-fearing people of the Midwest and pays homage to their stories as a lens on our national zeitgeist. The collection features familiar characters such as Guy Noir, cowboys Dusty and Lefty, and many more favorites from Lake Wobegon, the town dubbed the “Gateway to Central Minnesota.” Garrison Keillor is the founder and host of A Prairie Home Companion, celebrating its 40th anniversary in 2014. He is the author of nineteen books of fiction and humor, the editor of the Good Poems collections, and a member of the American Academy of Arts and Letters. A Minnesota native, he lives in St. Paul and New York City. Ellen Gilchrist, Acts of God Wednesday, May 21, 2014 7:00 pm Location: Margaret Mitchell House Ellen Gilchrist returns after eight years with a new short story collection, Acts of God, which follows ten scenarios thematically linked about people dealing with forces beyond their control who somehow manage to survive, persevere, and even triumph. Readers are given a glimpse into the vitality, fear, the joy and redemption of those who remain on this earth. Hailed as a national cultural treasure by The Washington Post, Ellen Gilchrist is the distinguished author of more than twenty works, including Victory Over Japan, which won the National Book Award. She lives in Fayetteville, Arkansas. Civil War 150 Program: A Changing Wind: Commerce and Conflict in Civil War Atlanta, Wendy Hamand Venet Thursday, May 22, 2014 8:00 pm Location: Atlanta History Center In the Civil War, Atlanta was a thriving Confederate city, second only to Richmond in importance. A Changing Wind explores the experiences of Atlanta’s civilians during the city’s rapid growth, Civil War siege and devastation, Reconstruction, and emergence as a New South city. A rich account of residents’ changing loyalties to the Union and the Confederacy, the book highlights the economic and social impacts of the war and Atlanta’s stunning postwar rebirth. The final chapter focuses on Atlanta’s historical memory of the Civil War and how racial divisions led to separate commemorations of the war’s meaning. Wendy Hamand Venet is a professor in the Department of History at Georgia State University. She is editor of Sam Richards’s Civil War Diary and lives in Decatur, Georgia. Support: Civil War 150 lectures are presented through the generous support of Vicki and Howard Palefsky. This program is presented in partnership with Buckhead Heritage Society. June 2014 Civil War to Civil Rights Lecture Series: Jeff Shaara, Smoke at Dawn Tuesday, June 3, 2014 8:00 pm Location: Atlanta History Center New York Times bestselling author Jeff Shaara returns to the Civil War terrain he knows so well, with the latest novel in the series that started with A Blaze of Glory and A Chain of Thunder. In The Smoke at Dawn, the last great push of the Army of the Cumberland sets the stage for a decisive confrontation at Chattanooga that could determine the outcome of the war.   Blending evocative historical detail with searing depictions of battle, Jeff Shaara immerses readers in the world of commanders and common soldiers, civilians and statesmen. From the Union side come the voices of Generals Grant, William Tecumseh Sherman, and George Thomas—the vaunted “Rock of Chickamauga”—as well as the young private Fritz “Dutchie” Bauer. From the Rebel ranks come Generals Bragg, Patrick Cleburne, and James Longstreet, as well as the legendary cavalry commander, Nathan Bedford Forrest. A tale of history played out on a human scale in the grand Shaara tradition, The Smoke at Dawn vividly recreates the climactic months of the war in the West, when the fate of a divided nation truly hangs in the balance. Support:Civil War 150 lectures are presented through the generous support of Vicki and Howard Palefsky. Cherokee Garden Library Lecture: Philip Juras, Searching for the Southern Frontier: Landscapes Inspired by Bartram’s Travels Wednesday, June 4, 2014 7:00 pm Location: Atlanta History Center Juras is an artist and author focused on natural landscapes that offer a glimpse of the Southeast before European settlement. In conjunction with an exhibition of his paintings, the book Philip Juras: The Southern Frontier: Landscapes Inspired by Bartram’s Travels was published by Telfair Museums and is distributed by the University of Georgia Press. In 2012 The Southern Frontier earned Juras the Georgia Author of the Year Award in the Specialty Book category from the Georgia Writers Association. His lecture is followed by a book signing, an exploration of Following in the Bartrams’ Footsteps, and refreshments.       Bernard Kinsey, What You Didn’t Learn in High School History Friday, June 6, 2014 Reception 6:00 pm, Lecture 7:30 pm Experience a dynamic evening of enlightenment and inspiration as historian and renowned art collector Bernard Kinsey takes you on a journey of discovery through many untold stories of African American history, accomplishments, and contributions. Kinsey debunks the more than 400-year-old “myth of absence” in American history, drawing from the extensive collection of artistic and historical treasures amassed in The Kinsey Collection. He reveals long ignored stories of the roles African Americans played in the making of America. Book signing follows the lecture. Copies of The Kinsey collection book are available before and after the program. Evening program also includes a viewing of Wells Fargo’s nationally traveling exhibition The Kinsey Collection: Shared Treasures of Bernard and Shirley Kinsey, Where Art and History Intersect. The Kinsey Collection exhibition is on display at the Atlanta History Center through July 13, 2014. Peter Heller, The Painter Monday, June 9, 2014 7:00 pm Location: Margaret Mitchell House Peter Heller, the celebrated author of the breakout best seller The Dog Stars, returns with an achingly beautiful, wildly suspenseful second novel about an artist trying to outrun his past.  Jim Stegner has seen his share of violence and loss. Years ago he shot a man in a bar. His marriage disintegrated. He grieved the one thing he loved. In the wake of tragedy, Jim, a well-known expressionist painter, abandoned the art scene of Santa Fe to start fresh in the valleys of rural Colorado. Now he spends his days painting and fly-fishing, trying to find a way to live with the dark impulses that sometimes overtake him. He works with a lovely model. His paintings fetch excellent prices. But one afternoon, on a dirt road, Jim comes across a man beating a small horse, and a brutal encounter rips his quiet life wide open. Peter Heller is the best-selling author of The Dog Stars. He holds an MFA from the Iowa Writers' Workshop in both fiction and poetry. An award-winning adventure writer and a longtime contributor to NPR, Heller is a contributing editor at Outside magazine, Men's Journal, and National Geographic Adventure, and a regular contributor to Bloomberg BusinessWeek. He is also the author of several nonfiction books, including Kook, The Whale Warriors, and Hell or High Water: Surviving Tibet's Tsangpo River. He lives in Denver, Colorado. Graeme Simsion, The Rosie Project Friday, June 20, 2014 7:00PM Location: Margaret Mitchell House The art of love is never a science: Meet Don Tillman, a brilliant yet socially inept professor of genetics, who’s decided it’s time he found a wife. In the orderly, evidence-based manner with which Don approaches all things, he designs The Wife Project to find his perfect partner: a sixteen-page, scientifically valid survey to filter out the drinkers, the smokers, the late arrivers.Rosie Jarman possesses all these qualities. Don easily disqualifies her as a candidate for The Wife Project (even if she is “quite intelligent for a barmaid”). But Don is intrigued by Rosie’s own quest to identify her biological father. When an unlikely relationship develops as they collaborate on The Father Project, Don is forced to confront the spontaneous whirlwind that is Rosie―and the realization that, despite your best scientific efforts, you don’t find love, it finds you. Graeme Simsion is a former IT consultant and the author of two nonfiction books on database design who decided at the age of fifty to turn his hand to fiction. The Rosie Project is his first novel, and was featured on several Best of 2013 lists. The screen adaption has been optioned by Sony Pictures. Graeme lives in Australia with his wife, Anne, and their two children, and is currently working on a sequel to The Rosie Project. Mary Alice Monroe and Patti Callahan Henry, The Summer Wind and The Stories We Tell Wednesday, June 25, 2014 7:00 pm Location: Margaret Mitchell House Join the Margaret Mitchell House for an evening with two beloved Southern authors as we celebrate the release of their addictive summer reads. The Summer Wind is the much anticipated follow-up to Mary Alice Monroe’s New York Times bestseller The Summer Girls. Monroe draws readers back to the unspoiled beauty of Sullivan’s Island, South Carolina for the second installment in an emotional trilogy about sisterhood, second chances, and lifelong bonds. Mary Alice Monroe is the author of over a dozen award winning and critically acclaimed novels, several non-fiction titles, and children's books. Her body of work reflects her commitment to the natural world through literature. In The Stories We Tell, Patti Callahan Henry returns with a tense family drama about secrets and lies, and the cost of finally telling the truth. Patti Callahan Henry is a full-time writer, wife, and mother, and the New York Times bestselling author of eight novels, including Between the Tides, And Then I Found You, and The Perfect Love Song: A Holiday Story. Patti lives with her husband and three children in Mountain Brook, Alabama, where she is working on her next novel. Elson Lecture: Daniel Vermilya, The Battle of Kennesaw Mountain Thursday, June 26, 2014 8:00 pm Location: Atlanta History Center In the summer of 1864, Georgia was the scene of one of the most important campaigns of the Civil War. William Tecumseh Sherman’s push southward toward Atlanta threatened the heart of the Confederacy, and Joseph E. Johnston and the Army of Tennessee were the Confederacy’s best hope to defend it. In June, Johnston managed to grind Sherman’s advance to a halt northwest of Atlanta at Kennesaw Mountain. After weeks of maneuvering, on June 27, Sherman launched a bold attack on Johnston’s lines. The Confederate victory was one of the bloodiest days of the entire campaign. And while Sherman’s assaults had a frightful cost, Union forces learned important lessons at Kennesaw Mountain that enabled the fall of Atlanta several months later. Daniel Vermilya is a Civil War historian who works as a park ranger at Antietam National Battlefield and Gettysburg National Military Park. In 2012, he was the first recipient of the Save Historic Antietam Foundation’s Joseph L. Harsh Memorial Scholar Award. Daniel received his bachelor’s degree from Hillsdale College, where he studied both history and politics. He also holds a master’s degree in history from John Carroll University. July 2014 Jo Baker, Longbourn Thursday, July 17, 2014  7:00 pm Location: Margaret Mitchell House The servants take center stage in this irresistibly imagined belowstairs answer to Pride and Prejudice. While Elizabeth Bennet and her sisters fuss over balls and husbands, Sarah, their orphaned housemaid, is beginning to chafe against the boundaries of her class. When a new footman arrives at Longbourn under mysterious circumstances, the carefully choreographed world she has known all her life threatens to be completely, perhaps irrevocably, upended. Mentioned only fleetingly in Jane Austen’s classic, here Jo Baker dares to take us beyond the drawing rooms of Regency England and, in doing so, uncovers the real world of the novel that has captivated readers’ hearts around the world for generations. Jo Baker was born in Lancashire, England, and educated at Oxford University and Queen’s University Belfast. She is the author of the novels The Under­tow, Offcomer, The Mermaid’s Child, and The Telling. She lives in Lancaster.

OpenSSL Heartbleed: Expert On Criminal and Government Theories

News of the OpenSSL Heartbleed bug, which has emerged over the last 48 hours, is arguably one of the most significant developments in the history of the website security industry. The likes of Target, Sony and TK Maxx have all made waves over the past few years, but whereas these were all incidents of a single company being breached, OpenSSL Heartbleed has potentially affected millions of websites. OpenSSL is the technology behind the TLS/SSL protocol (or padlock icon) that many of us take as a sign of trustworthiness and reputability when browsing the internet. The OpenSSL Heartbleed bug allows unauthorised users to extract data from the server’s memory, 64,000 characters of it to be precise. This could contain usernames, passwords, encryption keys or even credit card information. What is perhaps most shocking about this development is the fact there has been a flaw for at least two years and the flaw has only been found “recently”. If the TLS/SSL protocol were to hinder or prevent government surveillance, then this seemingly accidental loophole could have provided a very useful workaround. Which poses the question, could government agencies like the NSA have known about OpenSSL Heartbleed for the past two years? Government involvementAs the name suggests, OpenSSL is an open source technology. This means that the source code is freely available to download and modify, with no permission required. Open source software is generally considered to be more private, since it is usually developed for non-profit reasons without any government licensing (which has backdoor theories). It is alleged that RSA was bribed by the NSA to reduce their encryption strength, details of which can be read at http://www.techweekeurope.co.uk/news/rsa-nsa-bribe-cryptography-backdoor-134610. There have also been rumours of similar attempted persuasion at an American giant and a small English outfit, although neither story has hit the press. But regardless, is it possible that a government agency could have encouraged the implementation of the bug – either financially or otherwise? Black market tradesThe dark web is a non-indexed section of the internet, only available through certain secure browsers and home to many criminals. Fraudsters, hackers, drug dealers and even hit men will advertise their services for a hefty fee. Exploit kits and other viruses are available to purchase for the right price, somewhat ironically with free technical support. Zero day exploits, which are unknown flaws, are available – but only to the highest bidder. Is it possible that an organised criminal gang or a government agency purchased this bug to exploit a specific target or the wider world? Did the government know about this?News of the OpenSSL Heartbleed bug spread like wildfire on April 7th. This means that hundreds of people have most likely tried to exploit the flaw already. But again, we must ask, who knew about the bug before? Both Google and Finnish security outfit Codenomicon are taking credit for discovering the bug, but were they the first? Our world is home to many security research groups, both ethical and black hat, not to mention well-funded government research labs. With the news of Edward Snowden fresh in our minds, the question remains – if the NSA or GCHQ knew about the OpenSSL Heartbleed bug, would they have actually told us?

WORLD CHALLENGE OFFERS COMMUNITY SUPPORT

The global schools expeditions company, which has its head office in High Wycombe and works with schools in over 25 countries, paid a visit to Thames Valley Adventure Playground (TVAP) in Taplow, near Maidenhead on Friday (April 11) to help staff and other volunteers rebuild its Sensory Garden, situated in the middle of the 2.5 acre site. TVAP, a registered charity, has been operating since 1982 and provides a chance for children and adults with all types of special needs to enjoy the fun, freedom and friendship afforded by the opportunity to play and share experiences in a safe and stimulating environment, with users travelling from Berkshire, Buckinghamshire, Oxfordshire, London and beyond. World Challenge, part of TUI Travel Group PLC – the world’s largest leisure travel company, encourages all of its employees to take advantage of the TUI Discovery (charity) Day (on company time) each year. Group MD Matt Eastlake even donned his overalls for the day and was quick to praise the on-going efforts of the TVAP team. He said: “World Challenge’s ethos is all about challenge, participation and environment and that’s why we were delighted to be able to lend our support and in the process help make a real difference to the Playground, its users and the local community. “We plan expeditions abroad for over 10,000 students every year so hopefully our experience and knowledge ensured for a successful and rewarding day for everyone concerned. There were plenty of smiling faces which is the most important thing.” TVAP needs approximately £350,000 a year to stand any chance of surviving – a point reaffirmed by Donations Manager Nicky Hutchinson. She said: “We were absolutely delighted to have World Challenge’s help with our new Sensory Garden. Such assistance plays a crucial part in the development of the Adventure Playground, enabling us to continue to offer the most stimulating environment possible to our users and their families.  “With over 13,500 visits made to the Playground each year, the support of the local community is a key factor in providing opportunities for meaningful play for children and adults with all types of special needs - opportunities which most people would take for granted, but which can be so hard to experience if you have a disability.  “From all those for whom the Playground is such a lifeline; a huge thank you to everyone from World Challenge involved in the project - we couldn’t have done it without you!” For more information on TVAP or to donate visit: http://www.tvap.co.uk

Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that positive new simeprevir data were presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) in London.The data presented included; · Final phase II data from the interferon-free COSMOS study · Phase III efficacy data in patients with genotype 4 hepatitis C · Subgroup analyses of patients from phase III studies QUEST-1, QUEST-2 and PROMISE Final phase II data from the interferon-free COSMOS study Cohort 2Final results from cohort 2 of the phase II COSMOS study demonstrated that 93 percent of prior null responder and treatment-naïve patients with genotype 1 HCV and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir and sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of ribavirin did not improve SVR rates and consistent responses for both treatment arms were seen across HCV genotype subgroups after 12 weeks. +---------------------+-------------+-----------------------+|SVR12 Among Patient ||Subgroups with ||Genotype 1 HCV and ||Advanced Liver ||Fibrosis/Cirrhosis in ||Cohort 2 of the COSMOS ||Study* |+---------------------+-------------+-----------------------+|12 Weeks of Treatment |+---------------------+-------------+-----------------------+|Regimen |Simeprevir/So|Simeprevir/Sofosbuvir +|| |fosbuvir (%) |Ribavirin (%) |+---------------------+-------------+-----------------------+|Overall |93 |93 |+---------------------+-------------+-----------------------+|Genotype 1a HCV |88 |93 ||without the Q80K | | ||polymorphism | | |+---------------------+-------------+-----------------------+|Genotype 1a HCV with |100 |88 ||the Q80K polymorphism| | |+---------------------+-------------+-----------------------+|Genotype 1b HCV |100 |100 |+---------------------+-------------+-----------------------+|METAVIR F4 |86 |91 |+---------------------+-------------+-----------------------+        *Excluding non-virologic failures. The most common adverse events reported during the study were fatigue, headache, nausea, anemia, pruritus, dizziness, rash and photosensitivity. One patient discontinued treatment due to adverse events. Cohort 1Previously presented data from cohort 1 at AASLD in November 2013, demonstrated that 96 percent and 93 percent of prior null responder patients with METAVIR F0-F2 scores treated with simeprevir and sofosbuvir without or with ribavirin, respectively, for 12 weeks achieved SVR12. +-------+-------------+---------------------------------+|SVR12 ||Among ||Patient ||Subgroups ||with ||Genotype ||1 HCV and ||METAVIR ||Scores of ||F0-F2 in ||Cohort 1 ||of the ||COSMOS ||Study* |+-------+-------------+---------------------------------+|12 Weeks ||of ||Treatment |+-------+-------------+---------------------------------+|Regimen|Simeprevir/So|Simeprevir/Sofosbuvir + Ribavirin|| |fosbuvir (%) |(%) |+-------+-------------+---------------------------------+|Overall|96 |93 |+-------+-------------+---------------------------------+|METAVIR|100 |94 ||F2 | | |+-------+-------------+---------------------------------+        *Excluding non-virologic failures. In genotype 1a patients with the Q80K polymorphism at baseline, 83 percent and 89 percent achieved SVR12 after 12 weeks of treatment without and with ribavirin, respectively. The most common adverse events reported during the study were fatigue, headache, nausea and insomnia. Two patients discontinued treatment due to adverse events. Phase III efficacy data in patients with genotype 4 hepatitis C Results from the Phase III RESTORE trial of simeprevir in combination with pegylated interferon and ribavirin in HCV genotype 4 treatment-naïve and treatment-experienced patients demonstrated that overall 65 percent of patients achieved SVR12, including 83 percent of treatment-naïve patients, 86 percent of prior relapsers, 60 percent of prior partial responders, and 40 percent of prior null responders. Among patients with more severe liver fibrosis characterized by a METAVIR score of F3 or F4, 67 percent and 47 percent achieved SVR12, respectively. Among patients with genotype 4a and 4d HCV, 69 percent and 52 percent achieved SVR12, respectively. The most frequent adverse events included influenza-like illness, asthenia (weakness) and fatigue. Genotype 4 HCV is considered particularly difficult to cure and currently only limited treatment options are available. Subgroup analyses of patients from phase III studies of Simeprevir Analyses of pooled efficacy data from the QUEST-1 and QUEST-2 studies found 87 percent of European patients treated with simeprevir in combination with pegylated interferon and ribavirin achieved SVR12, compared to 80 in the overall study population. In an analysis from the PROMISE study, 88 percent of European patients treated with simeprevir in combination with pegylated interferon and ribavirin achieved SVR12 compared to 79 percent in the overall study population. The efficacy of simeprevir in combination with pegylated interferon and ribavirin was also observed among European patients with baseline characteristics typically considered more difficult to cure. In QUEST-1 and QUEST-2, 71 percent of patients with METAVIR F4 scores, 86 percent of patients with the IL28B CT genotype, 69 percent of patients with the IL28B TT genotype and 64 percent of genotype 1a patients with the Q80K polymorphism at baseline achieved SVR12 in the simeprevir arm, compared to 25 percent, 44 percent, 31 percent and 50 percent of patients in the active placebo arm, respectively. In PROMISE, 85 percent of patients with METAVIR F4 scores, 88 percent of patients with the IL28B CT genotype, 77 percent of patients with the IL28B TT genotype and 75 percent of genotype 1a patients with the Q80K polymorphism at baseline achieved SVR12 in the simeprevir arm, compared to 30 percent, 41 percent, 18 percent and 57 percent of patients treated in the active placebo arm, respectively. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 17.15 CET on 12 April 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Importation of softwood logs to Sweden reached a 10-year high in 2013 with Norway and Latvia being the major suppliers of both pulplogs and sawlogs

Seattle, USA. Sweden is the fourth largest importer of logs in the world, despite having forests that cover almost two-thirds of the country. The import volumes have been growing steadily the past five years, with 2013 imports being almost 60 percent higher than five years ago. Softwood logs make up all of the increase in imports and Wood Resource Quarterly (WRQ) reported that 2013 had the highest softwood log import volume over the past ten years. In a contrary development, the importation of hardwood logs in 2013 declined, with import volumes being down about 16 percent from the previous year. As a matter of fact, imports last year fell to the second lowest level in 15 years, with Latvia reducing shipments the most. During the past few years, between 10-15% of the imported log volume have been sawlogs destined for sawmills in the Southern part of Sweden, of which most have been sourced in Norway.  Almost 90% of imported logs in 2013 were pulplogs, evenly split between softwood and hardwood. The two major supplying countries have been Norway (softwood) and Latvia (softwood and hardwood), with other neighboring countries including Finland, Russia and Estonia following far behind. The total softwood log shipments from Norway to Sweden, including sawlogs and pulpwood, reached just over two million m3 in 2013, up from 1.4 million m3 in 2012 and only 709,000 m3 in 2011. The major reason for this dramatic increase was that the Swedish pulp company Sodra permanently closed its pulpmill in Tofte, Norway last summer. As a consequence, private forest owners in the region have increased their log shipments to pulp mills in central Sweden. This has had an impact on log flows and prices in the local markets in Sweden and there has been no shortage of wood fiber in this part of the country, according to the WRQ (www.woodprices.com). Imported wood-raw material for the Swedish forest industry is not just a marginal business but quite important for many manufacturers of lumber and pulp. The past two years, imported logs have accounted for about ten percent of the total log consumption in the country, this was up from 7.5 percent in 2009.   Global pulpwood and timber market reporting is included in the 52-page quarterly publication Wood Resource Quarterly (WRQ). The report, established in 1988 and with subscribers in over 30 countries, tracks sawlog, pulpwood, lumber and pellet prices, trade and market developments in most key regions around the world. To subscribe to the WRQ, please go to www.woodprices.com

H&M teams up with Alexander Wang for their next design collaboration

The New York based Fashion Designer’s eponymous brand has firmly established itself by perpetually evolving and re-contextualizing the urban uniform, since it was launched on the runway in 2007. Alexander Wang’s core sensibility is a reflection on contrasts, blending seamlessly between the refined and the imperfect. His collections have an unprecious outlook on fashion, and always reflect a sense of ease. The Alexander Wang x H&M collection will feature apparel and accessories for women and men. Typical for his irreverent approach, Alexander Wang will propose a new take on the lifestyle product offering that goes beyond fashion. The full collection will be available in 250 H&M stores worldwide, and online starting November 6, 2014. Alexander Wang says, “I am honored to be a part of H&M’s designer collaborations. The work with their team is an exciting, fun process. They are very open to push boundaries and to set a platform for creativity. This will be a great way for a wider audience to experience elements of the Alexander Wang brand and lifestyle.” "Alexander Wang is one of the most important voices in fashion today. He understands exactly what people want to wear and does it with an energy and passion that’s infectious. It feels incredible to be collaborating with him this year,” says Margareta van den Bosch, H&M’s creative advisor. #ALEXANDERWANGxHMwww.alexanderwang.comwww.hm.com/press

Sun shines on York Minster's Palm Sunday Procession

The sun shone this morning (13 April 2014) as the choir, clergy and congregation walked from St Helen's Square to York Minster, following Joey the Donkey. The Palm Sunday procession marks the start of York Minster's Holy Week.  The procession left St Helen’s Square at 10am, recalling the entry of Jesus into Jerusalem, days before he is arrested and crucified and one week before he rose from the dead on Easter Sunday (20 April).  Holy Week is one of the busiest times of the year for York Minster, which is the only cathedral in the country to host daily Choral Evensong from Palm Sunday every day until Easter Sunday.  Additional services take place throughout the week to reflect the solemnity of the days leading up to Christ’s crucifixion, marked on Good Friday. On the evening of Easter Saturday (19 April) preparations begin for the Easter celebrations, including the Easter Vigil.  This unique service takes place in darkness in the space beneath York Minster’s central tower, and sees cloths and remaining oil from the year’s services burnt, before a new candle is lit. Following the Service of Light and Service of Lessons (a series of readings) those present then move to the Crypt, where baptisms and confirmations take place by candlelight, in advance of the first Easter Communion. Easter Sunday traditionally hosts one of the busiest services of the year, Solemn Eucharist at 10.00am, which features the full York Minster Choir and at which the Archbishop of York will preside and preach. Throughout Holy Week, visitors to York Minster will see the Easter Garden, located beneath the Five Sisters Window in the North Transept.  A bare cross hangs beneath the central tower, which is draped with a white cloth ready for the Easter Sunday service – a procedure that will be familiar to those who watched the recent BBC1 Yorkshire series, The Minster. A host of activities for families and children are also planned for Holy Week, including Little Explorer Backpacks and trail sheets for children, and Easter trails for adult visitors.  Revealing York Minster in the Undercroft – the cathedral’s latest visitor attraction which is soon to celebrate its first full year of opening – will be open throughout the week, allowing visitors to explore 2000 years of history through interactive underground chambers. Visitors will also be able to explore The Orb in the East End of the Minster and see the latest conserved panel of medieval stained glass taken from the Great East Window, which depicts an angel pruning vines, with horses outside the raised portcullis of a walled city. For more information on services, events and activities at York Minster over the Easter period, please visit www.yorkminster.org ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Hexagon to Acquire Mintec, Software Developer and Service Provider for the Mining Industry

Hexagon AB, a leading global provider of design, measurement and visualisation technologies, has as of today entered into an agreement to acquire Mintec Inc., a resource modelling, optimisation, mine planning and scheduling software developer for the mining industry. Headquartered in Tucson, AZ, USA, Mintec has with its 232 employees grown into a global network of mining professionals providing technology, service and support in some of the most complex mining operations around the world. MineSight, the company’s modeling and mine planning brand since 1970, is well-known and respected in the industry. Mining is becoming a more precise practice, and accurate mine planning and scheduling is at the forefront of this change. Hexagon has been active primarily in the operations domain, but the integration of the planning, scheduling and daily production capabilities of Mintec will enable Hexagon to close the loop and control data flow from design and mine planning through extraction and back into life- of-mine planning, providing a comprehensive flow of data across all mining operations. “The acquisition of planning and scheduling software strengthens our mining solution strategy, providing a platform for comprehensive life-of-mine solutions,” said Hexagon President and CEO Ola Rollén. “The combination of proven technologies from Leica Geosystems, Devex, SAFEmine and now Mintec, in connection with our geospatial product suite and computer-aided dispatch solutions from Intergraph, we have the tools and technologies to leap ahead of the competition, giving Hexagon a unique position in the market.” The transaction remains subject to customary closing conditions. Closing is expected to be effected no later than June 2014.

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Attendance at the Annual General Meeting Shareholders who wish to participate in the Annual General Meeting must:-       Be recorded in the share register maintained by Euroclear Sweden AB (“Euroclear”), on Wednesday, May 7, 2014, and-   Give notice of attendance to the Company under address: Moberg Pharma AB (publ), Gustavslundsvägen 42, 5 tr, 167 51 Bromma, att. Anna Ljung or by e-mail to anna.ljung@mobergpharma.se, at the latest on Wednesday, May 7, 2014 at 4:00 p.m. When giving notice of attendance, shareholders must state their name, civil registration number or corporate registration number, address, telephone number and, where applicable, number of accompanying assistants (no more than two). Shareholders can participate and vote at the Meeting personally or by proxy. Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to participate in the Annual General Meeting, with the help of the nominee, re-register their shares in their own names in the share register maintained by Euroclear, so that they are registered on Wednesday, May 7, 2014. Shareholders represented by proxy should submit a power of attorney in original, along with other authorization documents, when giving notice of attendance to the Annual General Meeting. A power of attorney may be valid for up to five years from issuance. The Company provides forms of power of attorney on the Company´s website www.mobergpharma.se. Representatives of legal persons must present a copy of the legal person’s certificate of registration or other equivalent document demonstrating the right to act on behalf of the legal person. Number of shares and votesAs per the date of this notice, there are a total of 11,893,572 shares and votes in the Company. The Company holds no own shares. Proposed agenda 1. Opening of the Meeting 2. Election of Chairman of the Meeting 3. Preparation and approval of the voting list 4. Election of one or two persons to verify the minutes 5. Determination whether the Meeting has been duly convened 6. Approval of the agenda 7. Presentation of the annual report and the audit report as well as the consolidated accounts and the consolidated audit report 8. Speech by the Chief Executive Officer, Peter Wolpert 9. Resolutions on:a) Adoption of the income statement and the balance sheet, as well as the consolidated income statement and the consolidated balance sheetb) Allocation of the Company’s result according to the adopted balance sheetc) Discharge from liability of the Board members and the Chief Executive Officer10. Determination of the number of Board members and deputy members11. Determination of fees to the Board of Directors and Auditors12. Election of the Board of Directors and Chairman of the Board of Directors13. Proposal for resolution on principles for establishing the Nomination Committee and its work14. Proposal for resolution on principles for remuneration of senior executives15. Proposal for resolution on Employee Stock Option Plan 201416. Proposal for resolution regarding authorization for the Board of Directors to issue new shares17. Closing of the Meeting Proposals for resolution Election of Chairman of the Meeting (Item 2)The Nomination Committee of the Company, consisting of Per-Olof Edin, Chairman of the Nomination Committee, representative of Östersjöstiftelsen, and the members Henrik Blomquist, representative of Bure Equity AB (publ), Håkan Åström, representative of SIX SIS AG, and Mats Pettersson, Chairman of the Board of Directors, proposes that Mats Pettersson be elected as Chairman of the Annual General Meeting. Resolution on allocation of the Company’s result according to the adopted balance sheet (Item 9.b) The Board of Directors proposes that no dividend should be paid for the fiscal year 2013. Election of the Board of Directors and Chairman of the Board of Directors and determination of fees to the Board of Directors and Auditors (Items 10, 11 and 12)The Nomination Committee proposes that the Board of Directors shall consist of six (6) persons and no Deputies. The Nomination Committee proposes re-election of Mats Pettersson, Wenche Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh and George Aitken-Davies for a term of office extending until the end of the next Annual General Meeting, while Peter Wolpert, Gustaf Lindewald and Peter Rothschild have declined re-election and, thus, resign as board directors. In consultation with Peter Wolpert the Nomination Committee has found it principally more correct to refine his capacity at the Board Meetings, and that he will therefore only attend as CEO and not as board director. Further, the Nomination Committee has proposed to also appoint Thomas B. Thomsen as a Board Director. In addition, the Nomination Committee proposes re-election of Mats Pettersson as Chairman of the Board of Directors. Thomas B. Thomsen has a broad international experience from senior positions within the pharmacy industry with focus on OTC products, inter alia as Managing Director of marketing companies within Pfizer and Johnson & Johnson, Senior Vice President for OTC products within Reckitt Benckiser and Global Head of Category at Novartis Consumer Health. Thomas B Thomsen is a Board Director of Cederroth AB (Sweden) and Symprove PLC (England). The Nomination Committee proposes an aggregate fee to Board members of SEK 1,000,000, of which SEK 300,000 to the Chairman, SEK 250,000 to the Deputy Chairman and SEK 150,000 per member elected by the Annual General Meeting with the exception of George Aitken-Davies. It is noted that at the 2011 Annual General Meeting the auditing firm Ernst & Young AB was appointed as the Company’s Auditor. It is noted that the authorized public accountant Björn Ohlsson was appointed as Chief Auditor. The mandate runs until the end of the 2015 Annual General Meeting. The Nomination Committee proposes that fees to the Auditors, for a period until the end of the 2015 Annual General Meeting, are to be paid as per approved invoice. Proposal for resolution on principles for establishing the Nomination Committee and its work (Item 13)             The Nomination Committee proposes that the Annual General Meeting resolves on a Nomination Committee in accordance with the following principles. The Annual General Meeting assigns the Chairman of the Board of Directors to contact the three largest shareholders in term of votes or owner groups (hereby referred to both directly-registered shareholders and nominee-registered shareholders), according to a transcript of the share register maintained by Euroclear Sweden AB as per September 30, 2014, each appointing a representative to, besides the Chairman of the Board of Directors, constitute the Nomination Committee for the period until a new Nomination Committee is appointed by mandate from the next Annual General Meeting. If any of the three largest shareholders or owner groups declines to elect a representative, the fourth largest shareholder or owner group will be asked, and so on, until the Nomination Committee consists of four members. The majority of the members of the Nomination Committee are to be independent of the Company and its executive management. At least one member of the Nomination Committee is to be independent of the Company´s largest shareholder in term of votes, or any group of shareholders that act in concert in the governance of the Company. Neither the Chief Executive Officer nor other members of the executive management are to be members of the Nomination Committee. Board members may be members of the Nomination Committee but may not constitute a majority thereof. If more than one Board member is on the Nomination Committee, no more than one of these may be dependent of a major shareholder in the Company. The Nomination Committee appoints Chairman within the Committee. Neither the Chairman of the Board of Directors nor any other Board member may be Chairman of the Nomination Committee. The names of the members of the Nomination Committee shall be announced no later than six months prior to the 2015 Annual General Meeting. In the event that one of the members of the Nomination Committee resigns before the Committee´s work is completed and if the Nomination Committee is of the opinion that there is a need to replace the member, the Nomination Committee shall appoint a new member according to the principles above, but based on a transcript of the share register maintained by Euroclear Sweden AB, as soon as possible after the member has resigned. A change in the composition of the Nomination Committee shall be announced immediately. No fees shall be paid to the members of the Nomination Committee for their work in the Nomination Committee. The Nomination Committee shall submit proposals on the following issues for resolution by the 2015 Annual General Meeting: a)    Proposal for Chairman of the Meetingb)    Proposal for the Board of Directorsc)    Proposal for Chairman of the Board of Directorsd)    Proposal for fees to the Board of Directors, with distribution between the Chairman and other Board memberse)    Proposal for Auditorsf)     Proposal for fee to Company Auditorsg)    Proposal for principles for establishing the Nomination Committee for the 2016 Annual General Meeting. Proposal for resolution on principles for remuneration of senior executives (Item 14)The Board of Directors proposal for resolution on principles for remuneration of senior executives is consistent with previous years´ principles for remuneration and is mainly based on existing contracts between the Company and senior executives. The Board of Directors proposes that the Meeting resolves to adopt principles for remuneration of senior executives on the following terms: Moberg Pharma shall offer a total compensation at market rate that enables for qualified senior executives to be recruited and retained. The compensation paid to the Chief Executive Officer and other senior executives may consist of basic salary, variable compensation, other benefits and pension benefits. The total compensation is based on the basic salary and must be proportionate to the executive’s responsibilities and authority. Variable compensation is capped at 25 - 50 per cent of each executive’s basic annual salary and is based on results achieved in relation to individually defined qualitative and quantitative targets as well as the Company´s result in relation to goals set by the Board of Directors. Pensionable salary comprises only of basic salary. To the extent that Board members perform work for the Company or any other Group Company, besides work in the Board of Directors, consultancy fee at market rate may be paid. The notice period shall be at least three months if the senior executive takes the initiative and if the Company takes the initiative between three and twelve months. Severance is not paid. The Meeting shall, when applicable, decide on all share and share-price related programs. Allotment shall be made in accordance with the resolution of the Shareholders’ Meeting. With the exception of the employee stock options allotted and accrued, and what is provided for under existing employment contracts as referred to above, senior executives are not entitled to any benefits after the termination of the employment/assignment. The Board of Directors shall be entitled to deviate from the above mentioned principles for remuneration of senior executives if there are special reasons. Proposal for resolution on Employee Stock Option Plan (Item 15)The Board of Directors proposes that the Annual General Meeting (i) resolve to adopt an employee stock option plan for 2014 for employees in the Company and in the Company’s wholly-owned subsidiary Moberg Pharma North America LLC (”Moberg North America”), (ii) resolve on issue of warrants to the Company’s wholly-owned subsidiary Moberg Derma Incentives AB, reg. no. 556750-1589, (”Incentives”) for the fulfillment of the Company’s commitments under the employee stock option plan, and (iii) approve transfer of warrants or shares in the Company to employees in the Company and Moberg North America. (i) Employee Stock Option Plan 2014The Board of Directors proposes that the Annual General Meeting resolves to adopt Employee Stock Option Plan 2014 on principally the following terms: The Board of Directors and the Chief Executive Officer are entitled to, within the scope of the employee stock option plan, resolve on allotment of maximum 213, 500 employee stock options to key personnel in the Company and Moberg North America. It will be permissible to allot a maximum of 50,000 employee stock options per plan participant. The Board of Directors and the Chief Executive Officer shall decide which persons shall be encompassed by the Employee Stock Option Plan based on position, qualification and individual performance. The maximum allotment may be adjusted proportionally based on each person's time as an employee in the Company. The employee stock option plan will include the following senior executives in the Company; Anna Ljung, Kjell Rensfeldt, Martin Ingman, Peter Wolpert and Steve Cagle. The three first mentioned are proposed to be allotted 15,000 employee stock options each and the two last mentioned are proposed to be allotted 50,000 employee stock options each. Participants in the employee stock option plan shall be allotted the employee stock options free of charge. The allotment of employee stock options will take place immediately, in connection with the 2014 Annual General Meeting. Each employee stock option shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price equivalent to 110 per cent of the volume-weighted average price paid for a share in the Company on the NASDAQ OMX Stockholm during ten trading days following the 2014 Annual General Meeting, however never less than the share quotient value. The employee stock options can be used for subscription of new shares from June 30, 2017 until December 31, 2018. The employee stock options are linked to employment in the Company. The employee stock options will be cancelled if the employment in the Company is terminated and the employee at that time had not earned them. The employee stock options earned by the employee before the time of termination shall be used for subscription no later than six months thereafter. The employee stock options are non-transferable. In view of the above proposed terms, the size of the allotment and other circumstances, the Board of Directors assesses that the proposed employee stock option plan is well-balanced and that it will be beneficial for the Company and its shareholders. (ii) Issue of warrants to IncentivesIn order to secure the Company’s commitments under Employee Stock Option Plan 2014 the Board of Directors proposes that the Annual General Meeting resolves on an issue of a maximum of 258,692 warrants, whereof a maximum of 45,192 warrants are intended to hedge the costs (mainly social security contributions or corresponding taxes) that may arise from the employee stock option plan, on principally the following terms: The warrants shall be issued free of charge and the right to subscription shall, with a deviation from the preferential right of the shareholders, be assigned to Incentives. Subscription of warrants shall take place at the latest on May 20, 2014, with the right for the Board of Directors to extend the subscription period. Each warrant shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price equivalent to 110 per cent of the volume-weighted average price paid for a share in the Company on the NASDAQ OMX Stockholm during ten trading days following the 2014 Annual General Meeting, however never less than the share quotient value. Subscription for new shares in the Company with the support of the warrants shall take place no later than December 31, 2018. The new shares will entitle to dividend for the first time on the record date that occurs after the new shares has been registered at the Swedish Companies Registration Office (Sw: Bolagsverket) and after the shares have been recorded in the share register maintained by Euroclear Sweden AB. In the event that all warrants issued in respect of Employee Stock Option Plan 2014 are used to subscribe for new shares, the Company’s share capital will increase by SEK 25,869.20 from SEK 1,189,357.20 to SEK 1,215,226.40. This is equivalent to a dilution of approximately 2 per cent of the shares and votes in the Company. The reasons for deviating from the shareholders’ preferential rights are that the issue constitutes part of the implementation of Employee Stock Option Plan 2014. The Board of Directors assesses that a long-term personal ownership commitment among the employees will lead to an increased interest in the business and the result, and therefore improves the motivation of the employees. It is advantageous for the Company to be able to offer employees an opportunity to participate in the Company's development. The Board of Directors therefore assesses that the proposal, with regard to the terms, appears to be reasonable. (iii) Approval of transfer of warrants or shares in the Company to employees in the Company, etc.The Board of Directors proposes that the Annual General Meeting resolves to approve that Incentives is entitled to transfer warrants or shares in the Company to personnel in the Company and Moberg North America, who have received employee stock options under the Employee Stock Option Plan 2014, or otherwise dispose of the warrants, in order to secure the Company’s commitments and costs in connection with Employee Stock Option Plan 2014. Costs for Employee Stock Option Plan 2014The Board of Directors assesses that Employee Stock Option Plan 2014 will lead to costs partly in the form of accounting salary costs, partly in the form of social security contributions. These latter costs are hedged by the warrants issued with the purpose of covering these costs. Preparation of the proposal of Employee Stock Option Plan 2014The proposal regarding Employee Stock Option Plan 2014 has been prepared by the Company's Remuneration Committee and has been presented to the Board of Directors. Previous incentive programs in the CompanyFor a description of the Company’s other share-related incentive programs, reference is made to the Company’s 2013 annual report, and the Company’s website www.mobergpharma.com. In addition to the programs described, there are no other share-related incentive programs in the Company. Majority requirementThe Annual General Meeting´s resolution on the above items (i) – (iii) shall be adopted together as one resolution. A resolution in accordance with the Board of Director’s proposal requires the approval of shareholders representing at least nine tenths of the votes cast and the shares represented at the Meeting. Proposal for resolution regarding authorization for the Board of Directors to issue new shares (Item 16)The Board of Directors proposes that the Annual General Meeting authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders’ preferential right, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company’s share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorization may be equivalent to a maximum of 20 per cent of the shares in the Company at the time of the 2014 Annual General Meeting. The issues shall be made with issue rates at market rate, and where applicable be subject to issue discount at market rate, and payment shall, apart from payment in cash, be made in kind or by set-off or otherwise with conditions. The purpose of the authorization and the reasons for any deviation from the shareholders’ preferential right is that the Company shall be able to carry out issues in order to finance the Company’s business, commercialization and development of the Company’s products and/or the acquisition of products, project portfolios, businesses, companies or parts of companies. The Board of Directors, CEO or such person as the Board of Directors authorize, shall be authorized to carry out amendments and clarifications of the Annual General Meeting’s decisions that are required in connection with the filing with the Companies Registration Office. A resolution in accordance with this proposal requires the approval of shareholders representing at least two thirds of the votes cast and the shares represented at the Meeting. Information at the Annual General MeetingShareholders may request that the Board of Directors and the Chief Executive Officer provide information regarding circumstances that may affect the assessment of an item on the agenda for the Annual General Meeting, and circumstances that can affect the assessment of the Company’s financial position. The Board of Directors and the Chief Executive Officer shall provide such information at the Annual General Meeting if they believe that it can be done without material harm to the Company. Shareholders wishing to submit questions in advance may send them to Moberg Pharma AB (publ), att. Anna Ljung, Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden, or by e-mail to anna.ljung@mobergpharma.se. DocumentsCopies of accounting documents and the audit report as well as forms of power of attorney will be available for shareholders at the Company and on the Company´s website www.moberpharma.com, as from Wednesday, April 16, 2014. Complete proposals as well as other documents according to the Swedish Companies Act will be available for shareholders at the Company and on the Company´s website as above, no later than Tuesday, April 22, 2014. All of these documents will also, without charge, be sent to shareholders who so request and state their address. _______________________________________ Stockholm in April 2014 Moberg Pharma AB (publ) The Board of Directors About this informationMoberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:30 am (CET) on April 14th, 2014.

Moberg Pharma acquires global rights to novel topical formulation for treatment of oral pain

Oracain has generated promising clinical data supporting safety and efficacy in several pilot studies – most importantly that the novel lozenge formulation provides significantly longer and better pain relief than currently available non-opioid treatment alternatives for patients with oral mucositis. Moberg Pharma plans to gain additional efficacy data through a phase II study during this year, to be followed by pivotal studies and registration. Under the terms of the agreement, Oracain is entitled to an upfront payment of 1 MSEK, additional 5 MSEK after successful phase II data have been generated and a share of future revenues after such revenues have exceeded Moberg’s accumulated development costs incurred prior to launch. The acquisition and cost for the phase II study are financed through available cash resources. Moberg Pharma plans to pursue several routes to generate near term revenues from the product, including through licensing marketing rights to partners in select territories after completion of phase II as well as through sales for compassionate use for individual patients. Since there is a pressing unmet medical need for pain relief in oral mucositis, the product can be supplied for such compassionate use in certain markets prior to regulatory approval. Moberg Pharma will also examine the possibility for orphan drug status, in the U.S. as well as in EU. Furthermore, Moberg Pharma has identified several additional potential indications for the product beyond oral mucositis, both in the acute and chronic setting, such as Sjögren’s Syndrome, Burning Mouth Syndrome, endoscopic procedures, oral intubations and long-term also OTC use. The company estimates the peak sales potential of the product to 50-100 m$ assuming successful commercialization in oral mucositis and at least one additional indication. “We are excited of the opportunity to create a best in class product for a pressing medical need and to make it available to patients within the next few years. Oral mucositis is a debilitating side effect of cancer therapy. Oracain’s clinical data is highly promising and indicates a potential to provide better and longer pain relief to patients. The acquisition is in line with our strategy of providing niche products that can create significant value based on proven molecules with limited development cost, risk and time to market”, said Peter Wolpert, CEO of Moberg Pharma AB. “Years of clinical practice in oral mucositis – and frustration of inadequate treatments for patients suffering of the severe and disabling mouth pain – were the driving forces behind our innovation. We are excited to partner with Moberg Pharma who has the capabilities to bring this important medical innovation to practical use and benefit for patients. The scientific team of Oracain is fully dedicated to support the continued development”, said Ove Andersen, Chairman of Oracain and inventor. About oral mucositis and the acquired technologyOral mucositis (“OM)” is a painful inflammation and ulceration of the mucous membranes lining the mouth. OM is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy, almost all patients undergoing bone marrow transplantation, and a wide range of patients receiving chemotherapy. OM makes the patient less likely to comply with their cancer treatment, increases mortality and morbidity and contributes to rising health care costs. In the U.S., every year approximately 400 000 patients suffer from OM during cancer therapy.  The technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. The original innovation came out of work by clinicians at Hvidovre Hospital, Copenhagen, Denmark facilitated by XOventure GmbH and SEED Capital Denmark.   About this informationMoberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on April 14, 2014.

NOTICE OF ANNUAL GENERAL MEETING IN BONG AB (publ)

The shareholders of Bong AB (publ) are hereby invited to attend the Annual General Meeting to be held on Wednesday 21 May 2014 at 4.00 p.m. CET in Bong’s premises at Uddevägen 3 in Kristianstad. The registration desk will be open from 2.30 p.m. CET. A tour in the factory will be arranged at 3.00 p.m. – 3.45 p.m. CET. A. Right to attend Shareholders who wish to attend the Annual General Meeting (“AGM”) must –  be recorded in the share register kept by Euroclear Sweden AB made as of Thursday 15 May 2014, and –  notify the company of their intention to attend the AGM no later than Thursday 15 May 2014, by any of the following alternatives: · By post to the address:Bong AB (publ)Att: Katarina SjöströmHans Michelsensgatan 9SE-211 20 Malmö, Sweden · By telephone +46 40-17 60 41 · By telefax +46 40-17 60 39 · By e-mail to anmalan.arsstamma@bong.com · On-line at the company’s website www.bong.com (http://www.bong.com/en/corporate-governance/registration-annual-general-meeting-1.0.605.1) On giving notice of attendance, the shareholder shall state name, personal identity number or corporate identification number, address and telephone number, shareholding and the number of advisors that the shareholder wishes to bring to the General Meeting (maximum two advisors). Shareholders represented by proxy must issue a document authorising the proxy to act on the shareholder’s behalf. A proxy form is available on the company’s website www.bong.com (http://www.bong.com/en/corporate-governance/annual-general-meeting-2014) and will be provided to shareholders who contact the company and state their address. Representatives of a legal entity shall present a copy of the certificate of registration or similar document of authorisation showing the persons authorised to act on behalf of the company. The original of the proxy and the document of authorisation should be sent to the company together with the notice of attendance. In order to participate in the proceedings of the General Meeting, owners with nominee-registered shares must request their bank or broker to have their shares owner-registered with Euroclear Sweden AB. Such registration must be made as of Thursday 15 May 2014 and the banker or broker should therefore be notified in due time before said date. B. Agenda Proposal for Agenda 1. Opening of the Meeting. 2. Election of Chairman of the Meeting. 3. Preparation and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two person(s) to approve the minutes. 6. Determination of compliance with the rules of convocation. 7. Report by the President and CEO. 8. Presentation ofa.      the Annual Report and the Auditor’s Report and the Consolidated Financial Statements and the Group Auditor’s Report,b.      the Board of Directors’ proposal for disposition of the company’s result, andc.      the statement by the auditor on the compliance with the guidelines for remuneration to management applicable since the last AGM, and 9. Resolution regardinga.      adoption of the Statement of Income and the Balance Sheet and the Consolidated Statement of Income and the Consolidated Balance Sheet,b.      appropriation of the company’s profit according to the adopted Balance Sheet, andc.      discharge from liability of the Board of Directors and the President and CEO. 10. Determination of the number of board members and deputies.11. Establishment of fees to the Board of Directors and the auditors.12. Election of the members of the Board of Directors and auditors.13. Election of members of the Nomination Committee.14. Guidelines for remuneration of senior executives.15. Closing of the Meeting. Proposals for Resolutions Appropriation of profit (9b)The Board of Directors has proposed that no dividend is to be distributed for the financial year 2013 and that the results of the company of totally SEK 739,522,181, including this year’s result of SEK -21,375,329 should be carried forward. Proposal of the Nomination Committee (item 2 and items 10-12)The Nomination Committee, consisting of Stéphane Hamelin (Holdham S.A.), Christian Paulsson (Paulsson Advisory AB) and Ulf Hedlundh (Svolder Aktiebolag), has made the following proposals: that   Mikael Ekdahl shall be elected Chairman of the AGM;that   the Board of Directors shall consist of six board members without any deputies;that   Stéphane Hamelin, Mikael Ekdahl, Anders Davidsson, Ulrika Eriksson and Eric Joan shall be re-elected as board members and that Christian Paulsson shall be elected as a new board member for the period up to and including the AGM 2015, whereby it was noted that Christian W. Jansson has declined re-election;that   re-election shall be made of Stéphane Hamelin as Chairman of the Board;that   fees to the board members shall be paid by totally SEK 900,000 (committee work excluded) to be distributed among the board members as follows: SEK 300,000 to the Chairman and SEK 150,000 to each of the other board members elected at General Meetings and not employed with the company, and fees for work in the Audit Committee shall be SEK 100,000 to the Chairman of the Audit Committee and SEK 50,000 to each of the members;that   the accounting company PricewaterhouseCoopers AB shall be elected auditor of the company for a one year period of mandate, consequently, up to and including the AGM 2015, whereby the accounting company has informed that the authorised public accountant Eric Salander will be appointed as auditor in charge, andthat   the auditor’s fees shall be paid as per agreement. Christian Paulsson (born 1975) has a Bachelor of Business Administration from European University Bruxelles and works in his own business as an active investor in smaller and medium-sized companies. Previous operational experiences includes inter alia deputy managing director and CEO of the business software company IBS AB and CEO of the securities brokerage company Lage Jonason AB. Prior to this, Christian Paulsson has extensive experience in Corporate Finance at inter alia Mangold Fondkommission, Alfred Berg/ABN Amro Fondkommission and Booz & Co. Christian Paulsson is a Board member of IBS AB (publ) and Apper Systems AB. Nomination Committee (item 13)Shareholders representing approximately 50 per cent of all shares and votes in the company have proposed that a Nomination Committee shall be appointed also for the AGM 2015 and: that   the Nomination Committee shall have three members;that   Stéphane Hamelin (Holdham S.A.), Christian Paulsson (Paulsson Advisory AB) and Ulf Hedlundh (Svolder Aktiebolag) shall be re‑elected as members of the Nomination Committee;that   Stéphane Hamelin shall be elected as Chairman of the Nomination Committee;that   if a shareholder represented by any of the members of the Nomination Committee should substantially reduce its shareholding in the company or in the event a member no longer is employed with such shareholder or for any other reason should leave the Nomination Committee before the AGM 2015, the Nomination Committee shall be entitled to appoint another representative of the major shareholders to replace such member; andthat   the tasks of the Nomination Committee shall be to prepare election of Chairman and other board members, election of auditor, election of Chairman of the AGM, fee issues and relating issues before the AGM 2015. Guidelines for remuneration of senior executives (item 14)The Board of Directors proposes that the AGM shall resolve for remuneration to the CEO and other senior executives as follows. By senior executives is meant officers of the management, at present consisting of the company’s CEO, Chief Financial Officer (CFO), Business Manager Nordic, Business Manager Central Europe, Business Manager United Kingdom and Business Manager France and Spain. Remuneration shall consist of fixed salary, variable remuneration, other benefits and pension. The aggregate remuneration shall be in accordance with market conditions and competitive in order to ensure that the Bong Group can attract and retain competent senior executives. In addition to the above variable remuneration, long term incentive programs may be resolved upon from time to time. The variable part of the salary shall have a pre-determined cap and may as a fundamental principle never exceed 60 per cent of the fixed annual salary. The variable part is based on earnings and cash flow as well as individual qualitative goals. The basic principle is that the variable remuneration is paid in accordance with the agreed-upon weighting between the interim goals if the interim goal has been achieved. The variable component is based on a vesting period of one year. The goals for senior executives are established by the Board of Directors. Pension benefits shall primarily be fee based, but can also for legal reasons be income based, although not at the Group Management level. Variable remuneration shall not qualify for pension. The Group Management is entitled to pensions under the ITP system or the equivalent. The retirement age is 65 years. In addition to the ITP plan, some members of Group Management are also entitled to an increased occupational pension premium so that the total equals 30 per cent of their fixed salary. The Group Management’s employment contracts include provisions governing remuneration and termination of employment. According to these agreements, employment can ordinarily cease on notice of termination by the employee within a period of notice of 4–12 months and on dismissal by the company within a period of notice of 6–18 months. On dismissal by the company, the period of notice and the period during which compensation is payable shall not together exceed 24 months. Remuneration to the CEO and other senior executives is prepared by the Board of Directors’ remuneration committee and resolved by the Board of Directors based on the remuneration committee’s proposal. These guidelines shall apply to those persons who are included in the Group Management during the period the guidelines are in force. The guidelines shall apply to the employment contracts entered into after the Annual General Meeting’s resolution, and to any changes in existing contracts. The Board of Directors shall have the right to deviate from the above guidelines if motivated by particular reasons on an individual basis. C. Available Documentation The accounting documents and the Auditor’s Report, the complete proposal of the Board of Directors for resolution according to item 14, as well as the statement by the auditor regarding whether the guidelines for remuneration to the management have been observed, are available to the shareholders at the company as from Wednesday 30 April 2014. Copies will also be sent to shareholders on request and be available at the General Meeting. The above documents and the Annual Report will as from said date also be available on the company’s website www.bong.com (http://www.bong.com/en/investors/annual-reports). D. Number of Shares and Votes in the Company At the issue of this notice, the total number of shares and votes in the company amounts to 156,659,604. E. Information at the AGM The Board of Directors and the CEO shall at the AGM, if any shareholder so requests and the Board of Directors believes that it can be done without significant harm to the company, provide information regarding circumstances that (i) may affect the assessment of an item on the agenda, (ii) circumstances that may affect the assessment of the company’s or its subsidiaries’ financial position and (iii) the company’s relation to other companies within the group. Kristianstad in April 2014 The Board of Directors BONG AB (publ) For further information please contact:Anders Davidsson, President and CEOPhone: +46 44 20 70 80 Håkan Gunnarsson, CFOPhone: +46 44 20 70 82 This information is of the kind that Bong AB (publ) are obliged to publish pursuant to the securities market act and/or the act on trade with financial instruments. The information was given for publication at 9.30 am on 14 April 2014. Bong is a leading provider of specialised packaging and envelope products in Europe, offering solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are the Propac packaging concept and Russia. The Group has annual sales of approximately SEK 2.5 billion and about 2,000 employees in 15 countries. Bong has strong market positions in the majo­rity of key markets in Europe, and the Group sees interesting possibilities for continued expansion and development. Bong is a public limited company and its shares are listed on NASDAQ OMX Stockholm Small Cap.

Growth in Brazilian property market funded by World Cup feel good

It’s rare that football makes property markets flutter but that’s exactly what’s happening on the streets of Brazil. This year’s highly anticipated World Cup tournament is proving a boon for those invested in South American property. Buy to let investors are filling their boots before a ball has even been kicked. The Brazilian economy has grown rapidly and looks set to continue offering investors high emerging market returns at low risk. This has created a unique opportunity for those looking to get into the buy to let market. Rental yields of 8% to 11% per annum and an increase in the price of property of between 10% and 15% per annum are widely expected. Putting your money into South America If you’re looking to invest in South America Paul Smith, SWIM Worldwide Investment Management (http://www.swimworldwide.br.com/) feels it would be wise to speak to a local expert: “As a company, we don’t feel that we need to be spending a lot of effort, time and money to go global, when there is so much we can do to help our client’s in this particular region.” Notes to editors: * International Advisor Profile of SWIM Worldwide Investment Management Paul Scott http://www.international-adviser.com/profiles-and-analysis/profiles/living-in-the-fast-lane?page=1 **Brazil hailed as an exciting opportunity for buy to let investors http://www.propertywire.com/news/latin-america/brazil-buy-let-property-201403258933.html *** http://www.swimworldwide.com

Bernarda Pera wins Aegon GB Pro-Series Gloucester

For Saturday’s singles final of the women’s $10,000 event, Oxstalls Sports Park welcomed The Right Worshipful Mayor of Gloucester Chris Chatterton and the Sheriff and Deputy Mayor of Gloucester Said Hansdot alongside other dignitaries and a large crowd of spectators. A number of Oxstalls Be Inpsired girls’ competitions had been organised throughout the week to promote girls’ tennis and compliment the women’s international ITF Pro Circuit tournament. The girls have had the opportunity to meet the professional players, and Bernarda Pera even presented the prizes for the mini orange and green competition on Friday. One lucky girl from Saturday’s mini red competition was selected to do the coin toss for the women’s final. The singles finalists, Bernarda Pera (USA) & Klaartje Liebens (BEL), both 19 years old, are no strangers to ITF Pro Circuit finals, having amassed 17 appearances between them during their relatively young professional careers. The Belgian made the first break through in the second game to take a 2-0 lead, however, it was short lived as Pera fought back to level the score. Settling into the final each player then managed to hold serve, wowing the crowd with their array of shots. Pera took a strong hold on the match when breaking Liebens again in the seventh game and dropped only three points in next three games to establish a one set lead. After an early exchange of breaks in the second set, the young American powered her way from the back of the court, using her leftie serve to great effect. With the momentum firmly back with her, Pera reeled off four consecutive games to seal victory with a clenched fist, winning 63 61. The title at Gloucester is Pera’s first of 2014, adding to the three titles she won in 2013, and helping her move toward her career high ranking of 354 that she achieved in October last year. After the match Pera said “It always feels good to win of course, especially as it was a tough draw this week. I didn’t start so well, I dropped my serve in the second game, but I came back and I am happy. When asked about her best memory of the week, Pera said “I think it would be the final as there were a lot of people watching, there was great support.”

Pricer is revolutionizing the shopping experience in Carrefour

Pricer, the world leader in providing Electronic Shelf Label solutions, has announced that Carrefour, the world’s second largest retailer, will use Pricer’s latest retail technology for a fully-connected store that significantly improves the customer experience. Carrefour Villeneuve la Garenne is the first store worldwide that allows customers to benefit from Pricer’s integrated solution using indoor navigation, mobile shopping and SmartTAG graphic labels. “Carrefour came to us 6 months ago searching for ideas to modernize the shopping experience in their stores,” says Arnaud Lecat, VP Store Solutions at Pricer, “Pricer delivered a solution enabling Carrefour to interact with their customers through their smartphones and the ESLs.” The mobile App created for Carrefour called "C-où", which is available on Android and iOS, allows customers to create shopping lists, search products, get promotions, find recipe ideas. The solution also includes geolocalisation – once inside the store, it helps you find any product, and optimises your shopping route through indoor navigation. The store has been equipped throughout with over 55 000 Pricer NFC-enabled ESLs. Not only do these bring all the benefits of ESLs – including centralized price automation – but customers can even ‘like’ a product with their phone and the label will display the total number of ‘likes’. “We are proud to play a role in this prestigious project,” concluded Lecat. “For Carrefour, customer service is paramount – it is a retailer that understands that innovative new technologies can enrich this experience, and therefore boost customer loyalty.” Press contact:Milla NurmikkoMulberry Marketing Communications/+44 (0) 207 928 7676/ mnurmikko@mulberrymc.com Niclas QvistPricer/+33 (0)1 61 08 40 20/ niclas.qvist@pricer.com   In its capacity as issuer, Pricer AB is releasing the information in this press release in accordance with the Swedish Securities Exchange Act (2007:528). The information was distributed to the media for publication at 14:45 hrs CET on Monday, April 14th, 2014. Pricer provides the retail industry’s leading electronic display and Electronic Shelf Label (ESL) platform, solutions, and services for intelligently communicating, managing, and optimizing price and product information on the retail floor. The platform is based on a two-way communication protocol to ensure a complete traceability and effective management of resources. The Pricer system significantly improves consumer benefit and store productivity by simplifying work in the store. Pricer, founded in 1991 in Uppsala, Sweden, offers the most complete and scalable ESL solution. Pricer has installations in over 50 countries with the largest ESL world market share. Customers include many of the world’s top retailers and some of the foremost retail chains in Europe, Japan and the USA. Pricer, in co-operation with qualified partners, offers a totally integrated solution together with supplementary products, applications and services. Pricer AB (publ.) is quoted on the Nordic Small Cap list of OMX. For further information, please visit www.pricer.com

Proposal to the 2014 AGM from the Nomination Committee of Oriflame Cosmetics S.A.

The Nomination Committee today announces its proposal to the Annual General Meeting on 19 May 2014. The proposal will also be presented in the notice to attend the Meeting. – We regret that as a consequence of the new EU directives, Oriflame can no longer benefit from Marie Ehrling's competence and experience, which have been important to the company's performance during the seven years she served as a director. Meanwhile, we are pleased to welcome Anna Malmhake with the experience she brings in fast moving consumer goods, marketing and international operations. The proposal of Alexander af Jochnick as chairman is natural when the af Jochnick family is, and aim to continue to be, the company's majority owner. Alexander knows Oriflame well from over fifteen years within the company, having first worked in the operations and then served on the Board, says Chairman of the Nomination Committee Per Hesselmark. Election of Board members and the Chairman of the BoardThe Nomination Committee proposes re-election until the end of the next Annual General Meeting of Alexander af Jochnick, Robert af Jochnick, Jonas af Jochnick, Anders Dahlvig, Lilian Fossum Biner, Helle Kruse-Nielsen, Christian Salamon and Magnus Brännström and also that Anna Malmhake be elected as new Board member for the same period. The Nomination Committee proposes Alexander af Jochnick to be elected Chairman of the Board. Short facts on the proposed changes of the BoardMarie Ehrling has, following new EU regulations, limited the number of Board representations and therefore declined re-election to the Board. Robert af Jochnick, one of the company’s founders, has declined re-election as the Chairman of the Board but remains a member of the Board. Alexander af Jochnick has been a member of the Board since 2007. He was an employee of the company during 1999-2007. He is member of the Remuneration Committee and of the Audit Committee. Alexander af Jochnick was born 1971 and holds a MSc in Business Administration from Stockholm School of Economics and started his career at Boston Consulting Group. He is Chairman of Oriflame Foundation, and board member of CL Intressenter AB, Credus Management AB, Postkodstiftelsen and NC Holding AB. Alexander af Jochnick is the founder and board member of Serious Nature. Alexander af Jochnick owns 418,884 shares in Oriflame. Anna Malmhake was born 1966. She holds a BSc from University of Stockholm. Anna Malmhake is Chairman and CEO of Irish Distillers Pernod Ricard since 2011. Her previous career includes executive positions with Absolut Vodka, Coca-Cola Sverige, Temo AB, Motorola and Procter & Gamble. Anna Malmhake owns no shares in Oriflame. Independence according to Swedish Code for Corporate GovernanceAll of the proposed Board members are according to the Nomination Committee to be considered as independent in relation to the company's major shareholders except for Alexander af Jochnick, Robert af Jochnick and Jonas af Jochnick. Magnus Brännström is the CEO of Oriflame. For additional information, please contact:Per Hesselmark, Chairman Chairman of the Nomination Committee: +46 8 622 36 00 Appendix: Photo of Alexander af Jochnick and Anna Malmhake.

JMC Steel Group Announces Plant Modernization Project for Wheatland Tube Location

Chicago, IL (April 14, 2014) – Wheatland Tube, a JMC Steel Group operating company, has launched a revitalization program for its Council Avenue location in Wheatland, Pennsylvania. The company is adding new equipment, realigning the manufacturing footprint and automating many processes in the facility.  Over the next two years, the thirty five million dollar ($35,000,000.00) investment will create a safer, cleaner workplace, eliminate production bottlenecks, reduce work in process inventory levels, enhance production efficiencies, improve product quality and improve customer service. At a recent meeting with Wheatland Tube employees, Barry Zekelman, Chairman and Chief Executive Officer of JMC Steel Group commented, “We know that the products this facility produces are both unique to the industry and second to none in their quality. For years we have discussed the need to update the equipment and production environment of this facility in order to continue to successfully compete at a global level. We are proud to take this step with the employees of Council Avenue and the Wheatland Tube community. We believe in the products that this facility produces and the people that produce them.  The result will be a revitalized and modernized facility which will be poised to aggressively grow the standard pipe market and compete long into the future.” Mark Magno, President of Wheatland Tube, stated “This project represents an incredible investment in Wheatland Tube by JMC Steel Group and the Zekelman family for our customers and employees.  For years, this facility has been negatively affected by high levels of  unfairly traded imports.  The new equipment and revitalized facility will allow us to provide our customers with unmatched quality and service.” According to Wheatland Tube General Manager Tim Feeney, “We are extremely excited by this announcement.  This investment solidifies the future of Wheatland Tube as the world’s premier continuous weld pipe manufacturer.”  

NOTIFICATION OF THE ANNUAL GENERAL MEETING

Kongsberg, April 10 201 The shareholders are hereby notified of the ordinary Annual General Meeting of Kongsberg Automotive Holding ASA on 7th May 2014 at 10 AM. Venue: Thon Conference Vika Atrium Munkedamsveien 45 0121 Oslo. The following items are on the agenda: 1.         Opening of the Annual General Meeting by the Chairman of the Board 2.       Presentation of the list of shareholders and proxies in attendance 3.         Election of a chairman of the meeting and a co-signer for the minutes 4.       Approval of the notification and agenda 5.      Adoption of the consolidated and parent company financial statements, including the allocation of the profit for the year Reference is made to the annual report available at the company’s web pages (www.kongsbergautomotive.com) and the Board of Directors’ proposed resolutions (attached). 6               The Company’s statement of remuneration to leading employees. The statement is attached, an advisory vote will be held. 7.      Election of directors of the Board and stipulation of remunerations to the Board of Directors The Nomination Committee’s recommendation is attached. 8        Election of members of the Nomination Committee, and stipulation of the remuneration to the Nomination Committee, Audit Committee and Compensation committee. The Nomination Committee’s recommendation is attached. 9       Stipulation of the Auditor’s fee.           The Board of Directors’ recommendation is attached 10      Amendment to the Articles of association           Proposal to amend the company name to ”Kongsberg Automotive ASA” 11.     Share option program           The Board of Directors’ recommendation is attached. 12.     Authorization for the purchase of own shares The Board of Directors’ recommendation is attached. 13.     Authorization to increase the company's share capital The Board of Directors’ recommendation is attached. Shareholders who are unable to attend the Annual General Meeting personally are entitled to be represented by a proxy. This will require a written and dated power of attorney. The enclosed proxy slip may be used. A company certificate should be enclosed with the proxy in the event that the principal is a corporate entity. Shareholders who wish to attend the Annual General Meeting themselves, or by proxy are required to register as soon as possible and no later than 2nd May 1200 CET to Nordea Bank Norge ASA, Issuer Services, Postbox 1166 Sentrum, 0107 Oslo, Fax (+47) 22 48 63 49 or issuerservices.No@nordea.com. Please use the enclosed attendance slip/proxy form. The Company’s annual report and annual accounts are available at the Company’s web pages www.kongsbergautomotive.com. Other documents that will be presented at the general meeting and proposals for resolutions are accessible at the same web site. The annual report will also be sent by mail upon request to the company, phone +47 32 77 05 00. The company has issued 406,768,131 shares each carrying one vote. All shares enjoy equal rights. At the date of this notification, the company owned 6,572,268 treasury shares for which voting rights may not be exercised. The shareholders may require board directors and the CEO to furnish in the general meeting available information about matters that may affect the consideration of a) the approval of the annual accounts and the annual report, b) any matters submitted to the shareholders for decision and c) the company’s financial position, and the business of other companies in which the company participates and any matter which the general meeting is to deal with unless the information required cannot be given without disproportionately harming the company. Representatives of the management and the board of directors will be present also after the general meeting to answer any other question that the present shareholders may have Kongsberg, 10th April 2014 For the Board of Directors of Kongsberg Automotive Holding ASA Ulla-Britt Fräjdin-Hellqvist Chairman of the Board See attached document for complete invitation and attendance slip

IFPA, ILDS and IPC form partnership to develop Global Psoriasis Atlas

(April 15, Stockholm)   While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization (WHO), reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6%[1] (http://file:///O:/IFPA/2014/Psoriasis%20Atlas/IFPA,%20ILDS%20and%20IPC%20form%20partnership%20to%20develop%20Global%20Psoriasis%20Atlas%20-%20press%20release%20April%2015.docx#_ftn1). The project’s initial task therefore will be to establish a credible and reliable database recording the prevalence of psoriasis worldwide and by country. “By gathering data on the prevalence of psoriasis from as many countries as possible we will be able to form a clear picture of the burden of psoriasis worldwide and in so doing inform better decision making on the use of resources,” says Professor Wolfram Sterry, president of the ILDS. While gathering detailed information on prevalence, the initiative will undertake to build a framework for improved collection of data on the burden of psoriasis. In the long-term, the aim is to look at incidence over time and the burden associated with comorbidities as well as the economic impact of psoriasis. “The atlas project is about driving constant improvement in the understanding of psoriasis and encouraging the ongoing collection of data and research,” according to Professor Christopher Griffiths, president of the IPC. The development of a Global Psoriasis Atlas is a long-term project that seeks both to drive continuous improvement in the understanding of psoriasis and uncover how it affects both the individual and society at large. Due to lack of evidence, among other factors, recognition of psoriasis as a serious, noncommunicable, chronic disease that is widespread and represents a significant public health challenge is poor – at both the local and global level. Lars Ettarp, president of IFPA explains that, “building an evidence base that all stakeholders can use to advocate for improved treatment, access to care and recognition of psoriasis is a priority. Only once we truly understand the burden will we be able to command the recognition that people living with psoriasis deserve.” About the Global Psoriasis Atlas Project The objectives of this joint project are to: · Build an evidence base that stakeholders can use to advocate for improved treatment, access to care and recognition of psoriasis as a priority of public healthcare policy. · Unite all stakeholders on one mutually beneficial agenda that works towards improving the lives of people with psoriasis and psoriatic arthritis. · Encourage collection of data and research into psoriasis that could ultimately lead to better use of resources, as well as improvements in treatment and care. · Enable benchmarking within and between countries by providing all stakeholders with local and regional evidence that is consistent and comparable. About the partners The International Federation of Psoriasis Associations (IFPA) The International Federation of Psoriasis Associations (IFPA) is a nonprofit organisation made up of psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis.  Through cost effective, successful and high quality programmes such as World Psoriasis Day and the World Psoriasis & Psoriatic Arthritis Conferences, IFPA brings together psoriasis associations, healthcare professionals and the healthcare industry to actively pursue the vision of a world without human suffering from psoriasis. To learn more about IFPA please visit www.ifpa-pso.org. The International League of Dermatological Societies (ILDS) The International League of Dermatological Societies (ILDS) is a non-governmental organisation in official relations with the World Health Organization. It was formed to: · Stimulate the cooperation of societies of dermatology and societies interested in all fields of cutaneous medicine and biology throughout the world · Encourage the worldwide advancement of dermatological education, care and sciences · Promote personal and professional relations among the dermatologists of the world · Represent dermatology in commissions and international health organisations · Organise a World Congress of Dermatology every four (4) years To learn more about ILDS please visit http://web.ilds.org. The International Psoriasis Council (IPC) Founded in 2004, The International Psoriasis Council (IPC) is a dermatology led, voluntary, global nonprofit organisation dedicated to innovation across the full spectrum of psoriasis through research, education and patient care.  The mission of the IPC is to empower our network of global key opinion leaders to advance the knowledge of psoriasis and its associated comorbidities, thereby enhancing the care of patients worldwide. To learn more about IPC visit www.psoriasiscouncil.org. ---------------------------------------------------------------------- [1] (http://file:///O:/IFPA/2014/Psoriasis%20Atlas/IFPA,%20ILDS%20and%20IPC%20form%20partnership%20to%20develop%20Global%20Psoriasis%20Atlas%20-%20press%20release%20April%2015.docx#_ftnref1) World Health Organisation. Psoriasis report by the Secretariat. Executive board, 133 session, provisional agenda item 6.2. 5 April 2013. ----------------------------------------------------------------------

Changes in management

The following changes have been made in the Group’s Russian business: - Eduard Gaidar appointed Russia Managing Director. Mr Gaidar was previously Head of Logistics for Russia. - Torbjorn Karlsson appointed Russia COO. Mr Karlsson was previously Head of Agronomy Russia. Eduard Gaidar (age 46) has worked with Agrokultura the since 2010. Prior to this he worked as a project manager in a food and dairy business. He also worked for PepsiCo and Gallina Blanca companies involved in starting up their new branch offices in Russia. He holds a university degree in crisis management from Moscow State University of Economics, Statistics and Informatics. He will focus on running the non-farming aspects of the business in Russia. Mr Gaidar lives and works in Voronezh, Russia. Torbjorn Karlsson (age 38) joined Agrokultura’s Russian business in February 2010 following two years as a production director at Black Earth Farming. Mr Karlsson has MSc in Agronomy from Swedish University of Agricultural Sciences. Prior to moving to Russia, Mr Karlsson worked from 2002 to 2008 as a crop consultant in Farmers’ Cooperative Lantmännen in Sweden. Mr Karlsson is responsible for Russian farming related operations and lives and works in Voronezh, Russia. Following the resignation of the Deputy Managing Director in December 2013 and following the promotion of Kristian Shaw to Group CFO, both the posts of Deputy Managing Director and Deputy CFO have remained and will remain unfilled. In addition the former roles of the new Russian Managing Director and COO will not be filled. Stephen Pickup, Managing Director commented: “I am delighted to welcome Eduard and Torbjorn into their new roles. Both have considerable experience with the company and their appointment will streamline the Russian management team whilst clarifying reporting structures. The ambitious targets we have set for cost cutting require all staff to take on responsibility and I am pleased there is enthusiasm within the business to do this. I would like to thank Jens Peter Aabyen and Igor Suvorov respectively former Russia Managing Director and Russia COO for their contributions over the past years.”Stockholm, 15 April 2014Stephen Pickup, Group Managing Director, tel. +44 782 529 4352Kristian Shaw, Group CFO, tel. +44 782 529 4356

SKF First-quarter report 2014

Tom Johnstone, President and CEO:“Sales developed well in the first quarter compared to the low first quarter last year and were relatively unchanged compared to the fourth quarter. We continued to have a negative mix in our sales with a stronger development of our automotive business and our industrial OEM sales in Asia. The possible pre-buy ahead of the price increase in the aftermarket in Europe and North America was not as anticipated.   During the quarter we received a number of awards and continued to strengthen SKF by gaining new business, launching a number of new products and making good progress with our cost reduction programme.   Kaydon is developing well and had a first good quarter. The integration is proceeding according to plan with a strong focus on both sales and cost synergies.   Agreement was reached in the quarter with the European Commission regarding theirinvestigation and is within the amount taken as a provision in the fourth quarter last year.This will be paid in June and will impact cash flow in the second quarter.      Going forward we expect demand to develop positively both sequentially and comparedto the second quarter last year. Manufacturing will be higher year on year and slightlyhigher compared to the first quarter.” Key figures Q1 2014 Q1 2013Net sales, SEKm 16,734 15,152Operating profit, SEKm 2,024 1,480Operating margin, % 12.1 9.8Operating margin excl. one-time costs, % 11.4 11.4Profit before taxes, SEKm 1,787 1,237Net profit, SEKm 1,275 818Basic earnings per share, SEK 2.72 1.74 Operating profit for Q1 includes the net positive effect of one-time items totalling around SEK 120 million. As a result of the settlement with the European Commission a reversal of SEK 150 million was made related to the provision taken in Q4 2013. The quarter also contained one-time items of around SEK 30 million related to restructuring as well as a negative revaluation effect due to the devaluation of the Argentine peso. Net sales change y-o-y, Volume Price/ Structure Currency Totalin SEK,attributable to: mix effectQ1 2014 6.2% -0.4% 4.7% -0.1% 10.4% Sales in the first quarter in local currencies and excluding structure increased by 4.4% in Europe, by 2.9% in North America, by 4.1% in Latin America, by 10.6% in Asia and by 21.4% in Middle East and Africa.Manufacturing in the first quarter was higher compared to last year. Outlook for the second quarter of 2014 Demand compared to the second quarter 2013The demand for SKF’s products and services is expected to be slightly higher for the Group, North America and Asia. It is expected to be relatively unchanged for Europe and slightly lower for Latin America. For Strategic Industries and Automotive it is expected to be slightly higher and for Regional Sales and Service relatively unchanged. Demand compared to the first quarter 2014The demand for SKF’s products and services is expected to be slightly higher for the Group, for North America and Asia. It is expected to be relatively unchanged for Latin America. For Strategic Industries and Automotive it is expected to be slightly higher and for Regional Sales and Service relatively unchanged. ManufacturingManufacturing is expected to be higher year over year and slightly higher compared to the first quarter. Gothenburg, 15 April 2014 Aktiebolaget SKF       (publ) A teleconference will be held on 15 April at 09.00 CEST, 08.00 (UK):SE: +46 (0)8 505 564 74UK: +44 (0)203 364 5374 You will find all information regarding SKF First-quarter results 2014on the IR website.investors.skf.com/quarterlyreporting AB SKF is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at around 08.00 on 15 April 2014.

NMG: NOTICE of Extraordinary General Shareholders’ Meeting in Nickel Mountain Group AB (publ) on May 8, 2014

Notice is hereby given of an Extraordinary General Meeting (EGM) with the shareholders of Nickel Mountain Group AB (publ), 556227-8043, on Thursday, May 8, 2014 beginning at 10.00 in the office of the Company at the address Kungsgatan 44, 7th floor in Stockholm. Right to participate at the Extra General Meeting Shareholders who wish to participate in the EGM must, -      firstly be recorded in the share register maintained by Euroclear Sweden AB on Friday, May 2, 2014 (see also under the headline Nominee-registered shares below), and -      secondly notify the Company at the address Kungsgatan 44, 7thfloor, 111 35 STOCKHOLM about their intention to attend the EGM not later than 16.00 on Friday, May 2, 2014 by phone +46 8 402 28 00, by fax +46 8 402 28 01 or by mail to torbjorn.ranta@nickelmountain.se . When notifying the company, please state your name, personal identity/registration number, address, shareholding and details about any assistants (not more than two). Nominee-registered shares Shareholders whose shares are nominee-registered must also request a temporary entry in the register of shareholders kept by Euroclear Sweden AB in order to be entitled to participate at the EGM. Shareholders must notify the nominee about this well in advance of Friday May 2, 2014, which is the day when such entry must have been executed in order to be considered in the excerpt of the share register, made by Euroclear Sweden AB. Shareholders registered in the Norwegian Verdipapirsentralen (VPS) must request temporary entry as shareholders in the register of shareholders kept by Euroclear Sweden AB in order to be entitled to participate at the EGM. In connection thereto, shareholders must notify DNB Bank ASA about this at the addressVerdipapirservice, Postboks 1600 Sentrum, 0021 Oslo or by fax: +47 24 05 02 56, or by email: vote@dnb.no no later than 12.00 noon CET on Monday, April 28, 2014, in order for DNB Bank to be able to ensure that entry is made in the register of shareholders kept by Euroclear Sweden AB by Friday the 2nd of May, 2014, which is the day when such entry must have been executed. Following the EGM, DNB Bank will arrange for shareholders to be re-registered in the Norwegian Verdipapirsentralen. Proxy etc. The rights of shareholders during the EGM may be exercised by an authorized representative (proxy). Any proxies must be presented in original. Proxies in original can be sent to the company at the following address: Nickel Mountain Group AB, Kungsgatan 44, 7 trp, 111 35 Stockholm, Sweden. A proxy form will be available at the company’s website www.nickelmountain.se .  (http://www.ige.se/)Representatives of legal entities must present registration documents in original or certified copy of the same or equivalent proof of authorization. Proposed agenda 1. Opening of the EGM. 2. Election of Chairman of the EGM. 3. Drafting and approval of voting list. 4. Approval of agenda. 5. Appointment of persons to keep and approve the minutes. 6. Determination whether the EGM has been duly convened. 7. Approval of the Board’s proposal to conduct a set-off issue 8. Approval of the Board’s proposal to decide on a divided 1:1 of all the shares in the subsidiary African Diamond AB 9. Other items10. Closing of the EGM The Board of directors’ proposal for decisions §7 The Board’s proposal for a set-off issue The Board of Directors propose that the EGM decides on an increase of the Company’s share capital by SEK 737,309.50 by issuing 1,474,619 new shares with a subscription price of SEK 3.80 per share. The other conditions are proposed to be the following: · The new shares are only supposed to be subscribed to as described below: Subscriber           Number of shares     Loan amount to be set-off (SEK)Altro Invest AB      1.179.580                    4.482.404Renud Invest AS      114.997                      436.988,60Svein Breivik          153.132                      581.901,60     Ole Weiss               26.910                     102.258                      1.474.619             5.603.552,20 · Subscription of and payment for the new ordinary shares must take place latest on May 30, 2014. The Board of Directors of the Company shall be authorized, in case need arises, to decide on a prolongation of the subscription- and payment period. · Payment shall be executed via set-off of claims in an amount corresponding to SEK 5,603,552.20. The set-off shall be considered executed when the subscription list has been signed. · The new shares shall be entitled to receiving dividends, if such ones get declared, for the first time on the record date that occurs after the date when the set-off issue      has been registered by the Swedish Companies Registrar (“Bolagsverket”). · After the registration of the set-off issue amounting to 1,474,619 new shares by the Swedish Companies Registrar, the total share capital of the Company will amount to SEK 11,351,170 and the new number of shares outstanding will be 22,702,340. · The parties entitled to subscribe for new shares according to above, and who are either directly or indirectly via representatives, Board members of the Company, have  committed to set off claims on the company as described above. The set off issue is conducted as a means of strengthening the balance sheet of the Company by reducing debt. The subscription price, SEK 3.80 per share, has been agreed between the subscribers and the Company, and represents a premium of some 50% to the current market price on the stock exchange (as per closing price on April 10, 2014). As a consequence of the subscribers being either directly or indirectly Board members of the Company, it is necessary according to the Chapter 16 provisions of the Swedish Companies Act (also called “Lex Leo”), that the decision at the Extraordinary General Meeting is taken by a quorum representing at least 90% of the votes present and of the shares actively voting at the EGM. §8 The Board’s proposal to give a dividend 1:1 of all the shares in wholly-owned subsidiary African Diamond AB The Board of Directors propose that the Extraordinary General Meeting decide on distributing as a dividend all the shares of wholly-owned subsidiary African Diamond AB pro rata to the shareholders of Nickel Mountain Group AB. In this context, it is proposed that 1 existing share of Nickel Mountain Group AB gives the right to receive 1 share of African Diamond AB. The total dividend, according to the book value of African Diamond AB, corresponds to SEK 556,558.50 as per March 31, 2014, which corresponds to SEK 0.025 per Nickel Mountain Group share after the above set-off issue. The Board of Directors shall be authorized to decide on a record date for the dividend, which however shall occur after the registration of the set-off issue above according to §7 by the Swedish Companies Registrar, but before the 2014 Annual General Meeting. Miscellaneous Required documentation covering §§ 7 and 8 above, as well as other information required according to the Swedish Companies Act will, at the latest two weeks before the EGM, be available in the office of the Company and on the Company’s website, www.nickelmountain.se ,  (http://www.ige.se/)and will be sent free of charge by mail to shareholders who so request and state their address. The shareholders are reminded of their right to request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. The number of shares outstanding in the Company at the time of this EGM-notice is 21,227,721. *** Stockholm, April 15, 2014 Nickel Mountain Group AB (publ) The Board of Directors

Sanofi launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare divison of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis®starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters. Sanofi is a leading Healthcare company with more than 100.000 employees worldwide and plays an important role in the global probiotic consumer market. Sanofi’s Consumer Healthcare division in Korea offers diverse vitamins, minerals, and health supplements under the well-established Cenovis brand. Sanofi Korea is one of the major players in dietary supplements in the mass retail channel in Korea. “Probiotics is the next major growth category in Korea and the launch of Probi Digestis®will be our focus for the Cenovis brand in 2014 and 2015. In Probi Digestis® we found a high quality probiotic product with good clinical documentation and we plan to extend the Probi range further, so it will play an important role in the Cenovis probiotic strategy going forward” says DongWoo Shin, head of Consumer Healthcare Sanofi Korea. Probi Digestis® will be launched in all channels Sanofi Korea is currently operating in, mass retail, department stores, drugstore/pharmacy, internet and TV home shopping. The product will be sold with Probi Digestis® predominantly displayed on front of the pack and Sanofi will make substantial consumer marketing investment during the launch. “Probi is looking forward to further strengthen our presence in the fast growing Asian markets together with Sanofi Korea and the strong Cenovis brand” says Peter Nählstedt, CEO of Probi. Peter Nählstedt adds, “Sanofi is a strong global player and has potential of quickly becoming one of our largest customers.” The South Korean market for probiotic supplements is estimated to have a value of USD 54 million. The annual growth rate over the past five years has been on avarage 15 percent however the growth rate is expected to be even higher in the coming years. The increasing health awareness and disposable income are positive factors driving the market growth in Korea. Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS – Irritable Bowel Syndrome. The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. FOR FURTHER INFORMATION, CONTACT:Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.seNiklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se ABOUT PROBIProbi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 30 countries worldwide.  The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm, Small-cap. Probi has approximately 3,500 shareholders. Read more on www.probi.se. ABOUT SANOFISanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY). In Korea, Sanofi has four legal entities in the fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea), vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health (Merial Korea).

Assar Gabrielsson Award for research that may provide better treatment of glandular cancer

Cancer is a condition caused by various types of damage to the genetic material (DNA). One such change is the emergence of fusion oncogenes, which can occur when damage is repaired incorrectly so that the genetic material from two chromosomes joins together. Increased knowledge about the links between fusion oncogenes and cancer is therefore important in order to understand how cancer occurs, which in turn can promote new and better treatment methods. “Marta Persson has in particular studied the molecular and clinical significance of the existence of fusion oncogenes. She has obtained results that may be significant in the treatment of the most common form of cancer in the salivary gland,” says Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation. In her doctoral thesis at University of Gothenburg, Marta Persson successfully linked together clinical information about patients with laboratory-based analyses. She currently holds a post-doctoral position in Professor Göran Stenman’s research team at the Sahlgrenska Cancer Center and is working on a project that is a direct continuation of her thesis speciality – adenoid cystic carcinoma (a malignant salivary gland tumour). Assar Gabrielsson was one of the founders of Volvo, together with Gustaf Larson. In accordance with Assar Gabrielsson’s wishes, a foundation to provide funding for clinical research into cancer diseases was created in 1962. The foundation aims particularly at furthering cancer research together with Gothenburg University. The Assar Gabrielsson Award also offers a research grant of SEK 100,000. AB Volvo has contributed to the fund’s capital and the fund is now able to contribute about five million kronor annually in research grants to young cancer researchers. April 15, 2014 Journalists, who would like further information, please contact: Professor Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation, mobile +46 703 72 26 26. Read more about the Assar Gabrielsson Foundation at www.agfond.se

TeliaSonera’s Interim Report January-March 2014

Wednesday April 23, 2014 Press and Analyst ConferenceTime: 10:30 (CET)Place: TeliaSonera’s Head Office, Stureplan 8, Stockholm Mr Johan Dennelind, President and Chief Executive Officer of TeliaSonera and Mr Christian Luiga, Senior Vice President and Chief Financial Officer of TeliaSonera will present the Interim report January-March, 2014. Press identification card or similar is required to attend. The press and analyst conference will be held in English and will be webcasted at www.teliasonera.com (http://www.teliasonera.com/en/). Telephone conference in connection to the press and analyst conferenceYou can also listen to the conference live over the phone and attend the Q&A session via a conference call. To ensure that you are connected to the conference call, please dial in a few minutes before the start of the press and analyst conference to register your attendance. Dial-in numbers:+44 (0) 1452 588 613, 0800 694 57 28 Access code:29653940 Please note that there might be a time lag of up to 30 seconds between the webcast and the conference call if you are simultaneously watching and calling in to the press and analyst conference. You can also listen to the conference call afterwards until April 29, 2014. Replay number:+44 (0) 1452 55 00 00Access code:29653940   For more information, please contact the TeliaSonera press office +46 771 77 58 30, press@teliasonera.com, visit our Newsroom (http://www.teliasonera.com/en/newsroom/) or follow us on Twitter @TLSN_Media (https://twitter.com/TLSN_Media). TeliaSonera provides network access and telecommunication services in the Nordic and Baltic countries, the emerging markets of Eurasia, including Russia and Turkey, and in Spain. TeliaSonera helps people and companies communicate in an easy, efficient and environmentally friendly way. Our ambition is to be number one or two in all our markets, providing the best customer experience, high quality networks and cost efficient operations. TeliaSonera is also a leading wholesale provider who owns and operate one of the world’s most extensive fiber backbones. In 2013, net sales amounted to SEK 101.7 billion, EBITDA to SEK 35.6 billion and earnings per share to SEK 3.46. The TeliaSonera share is listed on NASDAQ OMX Stockholm and NASDAQ OMX Helsinki. Read more at www.teliasonera.com.     

Scania to deliver 200 refuse trucks to Italy

The trucks will be supplied to Amsa S.p.A., a provider of street cleaning and waste management services, which operates in both centralMilanand surrounding municipalities. The company issued the tender with the aim of strengthening the fleet of vehicles used by its urban refuse collection service. Scania and its bodybuilding partner Farid Industrie worked together on the tender application to produce a framework agreement for rear-loader trucks. The agreement will mean delivery of up to 100 diesel trucks and up to 100 compressed natural gas (CNG) trucks over a period of 24 months from the signing of the contract. The vehicles will be 3-axle Scania P-series trucks and will be powered by a 9-litre 250 or 280 hp engine. “This order is extremely important as it represents further advancement of our relationship with both AMSA and Farid Industrie,” says Franco Fenoglio, Managing Director at Italscania S.p.A. “We will supply the client with a high-quality product, tailor-made for this specific application. The Euro 6 engine range, which includes diesel and gas versions, is the perfect choice for operators with strict environmental sustainability demands.” The vehicles are covered by service contracts through Scania’s workshop network. The close collaboration with Farid Industrie has allowed Scania to significantly increase its market share in the public and special-purpose segments in Italy over the past 18 months. For more information, please contact Hans-Åke Danielsson, Press Manager, tel +46 8 553 856 62.

Good market uptake for Simeprevir during the first quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first quarter 2014. In light of this, Johnson & Johnson and Medivir are now disclosing the simeprevir sales in conjunction with Johnson & Johnson’s first quarter report 2014. The global first quarter sales (Net sales) of simeprevir amounted to 354 MUSD, of which 291 MUSD were sales in the USA. Medivir’s royalties based on these sales amounted to 162 MSEK (18 MEUR) for the first quarter. “We are looking forward with confidence to a continued good sales development for simeprevir and the increasing royalty revenue according to our license agreement“, said Maris Hartmanis, Medivir’s CEO. Medivir will publish its first quarter report on May 8, 2014. Medivir will host a short telephone conference today. Conference call Date: 15 April 2014Time: 14.45 (CET) Phone numbers for participants from: England +44 (0)20 707 532 17US +1 866 565 2905Sweden +46 (0)8 619 75 30Code 946208# For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 15 April 2014.   About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Arise successfully issues a five year green bond of SEK 1.1 billion

Arise AB has today successfully issued a five year senior secured green bond of SEK 1.1 billion with a floating rate of 3 months STIBOR + 3 percent p.a. The bond matures in April 2019. Arise AB will apply for a listing of the bonds on NASDAQ OMX Stockholm. In connection with the transaction the company’s debt is reduced with about SEK 90 million and negative interest rate hedges of another ca SEK 70 million are terminated. Together with a slightly improved amortization profile of the bond it means that the company’s cash flow will improve by just over SEK 30 million per year, on average, during the next five years. This is the first senior secured bond issue in Sweden in the wind power sector. The security of the bond consists of a number of wind farms in the southern part of Sweden, all with good production and operating history. The bond replaces the current bank debt financing of the secured wind farms and allows the company to diversify its financing on favorable terms in the credit market. “The interest for Arise and the bond has been strong. The fact that the bond also has an environmental quality stamp has been important for many investors”, comments Arise AB’s Head of Corporate Finance Linus Hägg. Regarding green bond and DNV GL’s opinion Arise AB has today issued a senior secured “green bond” to re-finance 10 of its wind energy assets. DNV GL has given an opinion stating that the bond meets the criteria for the Green Bond Principles. The Green Bond Principles were established in January 2014 by a number of international banks to, inter alia, standardize the green bond market. By this opinion the green integrity of the bond is verified. DNB Markets has acted as financial advisor to Arise and Sole Bookrunner for the issue, while Setterwalls has acted as legal advisor to Arise and Mannheimer Swartling has acted as legal advisor to the Sole Bookrunner. Halmstad, 15 April 2014 ARISE AB (publ) For further information, please contact Linus Hägg, Head of Corporate Finance, Arise AB, +46 702 448 916 The information contained herein constitutes information which Arise AB is legally required to publish under the Swedish Securities Market Act (2007:528) and/or the Swedish Financial Instruments Trading Act (1991:980). The information was released for publication at 15.15 p.m. on 15 April 2014.

Notice of Nexam’s Annual General Meeting 2014

NotificationA complete notice follows below and is also available at Nexam’s website www.nexam.se (http://www.nexam.se/agm2014). Complete notice will also be inserted in Post- och Inrikes Tidningar on 16 April 2014. The fact that notice to attend a shareholders’ meeting has been published will be announced on the same day in the Swedish newspaper Svenska Dagbladet. The notice is also available at Nexam’s head office and is sent free of charge upon shareholder's request. Notice to attendShareholders wishing to attend the AGM must, first, be listed in the share register kept by Euroclear Sweden AB on Thursday May 8, 2014 and secondly, on Thursday May 8, 2014, they must have informed Nexam of their attendance and number of assistances, if any, by email to till Ann-Gerd Salmonson, ann-gerd.salmonson@nexam.se. Such notification can also be given by telephone +46 76-108 18 00, or mail to Nexam  Chemical Holding AB (publ), Bolagsstämma, Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden. Notification ought to include the shareholder’s name, address, telephone number, personal or corporate identity number, registered shareholding and information on number of assistances, if any. Notification and particulars of any proxy and assistances will be registered with Nexam to provide the basis for the voting list. Shareholders represented by proxy must issue a signed and dated power of attorney for the proxy. If the power of attorney is issued by a legal entity, a certified copy of registration certificate or equivalent document for the legal entity shall be presented. Any powers of attorney shall be in writing and submitted no later than at the AGM, but preferably by sending a copy thereof before that. The validity period of any power of attorney may be no longer than five years if set out specifically. If no validity period is specified, the power of attorney is valid for no more than one year. Forms for power of attorney can be found at the company’s website www.nexam.se and at the head office in Lund, (Medicon Village, Scheelevägen 2) and will be sent to shareholders who so request and state their address. Shareholders who have their holdings nominee-registered must temporarily register the shares in their own name to be entitled to participate in the AGM. Such temporary re-registration of ownership must be implemented no later than Thursday May 8, 2014. Accordingly, shareholders must inform their nominees or banks well in advance of that date of their wish to obtain temporary owner registration (so called voting-rights registration). Accounting documents and complete proposalsAccounting documents and complete proposals according to item 13-16 are available at the company’s head office in Lund and at the company’s website www.nexam.se no later than Wednesday April 23, 2014. Copies of the documents will upon request be sent to shareholders who state their address. Copies of the documents will also be available at the AGM. Duty of disclosure at the AGMShareholders are reminded of their right to request that the board and the CEO provide information pursuant to chapter 7, section 32 of the Swedish Companies Act. Agenda 1. Opening of the meeting 2. Election of Chairman of the meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to verify the minutes 6. Consideration of whether the meeting has been duly convened 7. Address by the CEO 8. Presentation of the Annual Report and Audit Report for 2013 and the Consolidated Annual Report and Consolidated Audit Report for 2013 9. Resolution ona) adoption on the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and consolidated balance sheetb) distribution of the company’s resultsc) discharge from liability for the Board members and CEO10. Determination of the number of Board members as well as the auditor and deputy auditor11. Determination of remuneration for the Board members and auditors12. Election of Board members as well as the auditor and deputy auditor13. Instruction for the Nomination Committee14. Adoption of Remuneration Policy15. Resolution on proposal for issuance of warrants and approval of transfer of warrants16. Authorization for issuing new shares17. Closing of the meeting Proposed resolutionsItem 2The Nomination Committee proposes that the Chairman of the Board, Lennart Holm, is appointed Chairman of the meeting. Item 9bThe Board proposes that no dividends are paid and that unappropriated earnings of SEK 243,112,000 are carried forward to a new account. Item 10The Nomination Committee proposes that four ordinary Board members without deputies are elected. The members are to be appointed until the next AGM. Further, the Nomination Committee proposes that a registered public accounting firm is appointed as auditor. The Nomination Committee proposes that the registered public accounting firm is elected until the next AGM. Item 11The Nomination Committee proposes that the remuneration paid to the Board is SEK 300,000, of which SEK 150,000 is remuneration to the Chairman and SEK 75,000 is remuneration to every other Board member who is not employed by the company. It is proposed that the remuneration for the auditor should be paid according to customary norms and approved invoice. Item 12The Nomination Committee proposes re-election of Lennart Holm, Michael Karlsson and Daniel Röme as ordinary board members. Further, the Nomination Committee proposes new election of Cecilia Jinert Johansson as ordinary board member. The Nomination Committee proposes re-election of Lennart Holm as Chairman of the Board. Per Palmqvist Morin has declined re-election. Information on the Board members proposed for re-election may be found in the Annual Report and at www.nexam.se.  Cecilia Jinert Johansson, born 1963, was until March 2014 head of production and head of EHSQ at Lantmännen division Lantbruk and has former i.e worked as Senior Vice President Operations at Ruukki Construction, in SVP Supply Chain Management for Rautaruukki Oyj and as Vice President Operations at Crawford Group. The Nomination Committee further proposes that Öhrlings PricewaterhouseCoopers AB is re-elected as accounting firm until the next AGM. Item 13Appointment of the Nomination Committee will take place before coming elections and payment of remuneration. It is proposed that the Nomination Committee should consist of three members, representing the two largest shareholders at the end of September together with the Chairman of the Board. Remuneration will not be paid to the members of the Nomination Committee. It is further proposed that instruction and charter for the Nomination Committee is adopted. Item 14The Board proposes that the AGM resolves to adopt guidelines regarding remuneration for the CEO and other senior executives in Nexam. The remuneration for the CEO and other senior executives may be fixed salary, pension, other benefits and share-based incentive programs. The guidelines means i.e that the CEO and other senior executives will be offered a fixed salary that is marketable. The remuneration of the CEO and other senior executives is based on factors such as work tasks, expertise, experience, position and performance. The CEO and other senior executives are entitled to annual pension contributions equivalent to 12 percent of the pensionable salary. A mutual notice period of six months for Nexam, the CEO and other senior executives and severance pay, in addition to salary, during the notice period may be up to a maximum of nine months' salary for the CEO and a maximum of 6 months for other senior executives. Item 15The Board proposes that the AGM resolves to implement an incentive program with warrants for senior executives and key persons in the company in accordance with the following: · A maximum of 1,083,849 warrants shall be issued. · With deviation from the shareholders’ preferential rights, the warrants may only be subscribed for by Nexam’s wholly owned subsidiary Nexam Chemical AB. Over subscription cannot occur. · Subscription shall be made at the latest on 31 October 2014, provided that the Board shall be entitled to prolong the subscription period. · The warrants shall be issued without consideration. The reason for issuing the warrants without consideration is that the warrants shall be utilized for implementation of Incentive Program 2014/2017. · Nexam Chemical AB shall have the right to, at one or several occasions, transfer warrants to senior executives and key persons in the Nexam group and to otherwise handle the warrants to fulfil the obligations under Incentive Program 2014/2017. Transfers to participants in Incentive Program 2014/2017 shall be made against cash consideration corresponding to the market value of the warrants calculated in accordance with the “Black Scholes” formula and accepted assumptions regarding among others volatility and risk free interest, which assumptions shall be based on measurements during the period 1 September 2014 – 12 September 2014 (the “Measurement Period”). · Each warrant confers right to subscribe for one new share in Nexam against cash payment at a subscription price corresponding to 150 per cent of the volume weighted average last closing price for Nexam’s share on Nasdaq OMX First North during the Measurement Period. The subscription price shall be rounded off to the nearest whole 10 öre, where 5 öre shall be rounded upwards. The subscription price and the number of shares that each warrant confers right to subscribe for shall be subject to customary recalculation formulas in connection with i.a. split, consolidation and rights issues. · The subscription right may be utilized during the period from and including 25 September 2017 to and including 9 October 2017. · The shares issued upon utilization of a warrant shall confer right to dividends as from the first AGM occurring after effectuation of the subscription. · The Board shall be entitled to resolve on transfer of warrants to senior executives and key persons in the Nexam group in accordance with the following guidelines:a) Key executives       at maximum 160,000 warrants per individual(apprx. 5)b) Key persons           at maximum 40,000 warrants per individual(apprx. 12) · Key executive who is also a member of the Board, shall not be entitled to participate in Incentive Program 2014/2017. · Notice of participation from key executives and key persons to participate in Incentive Program 2014/2017 shall have been received by Nexam at the latest on 30 September 2014, provided that the Board shall be entitled to prolong this time period and to apply a different notification period for participants that are subsequently employed in the Nexam group. · In case all warrants are exercised for subscription of new shares, the share capital will increase with SEK 20,843.250001. The reasons for the implementation of the warrant program with deviation from the shareholders’ preferential rights are to be able to create possibilities for Nexam to retain competent key persons through the offering of a long term ownership engagement for the key persons. Such ownership engagement is expected to stimulate the key persons to an increased interest in the business and profit development and increase the feeling of connectedness with Nexam. Nexam’s subsidiary Nexam Chemical AB has previously issued 7,280 warrants to employees. Each warrant confers right to subscription of one new share in the subsidiary at a subscription price of SEK 1,000 per share (4,340 warrants) and the subscription price of SEK 2,000 per share (2,940 warrants), respectively. The warrants can be utilized during the periods 15 September 2016 – 15 December 2016 (2,040 warrants), 15 September 2017 – 15 December 2017 (2,300 warrants) and 1 October 2018 – 31 December 2018 (2,940 warrants). Nexam has entered into agreements with the holder of the warrants pursuant to which Nexam has the right to acquire the shares potentially subscribed for against payment in the form of 182.5034 shares in Nexam for each new issued share in the subsidiary. In case all warrants are exercised for subscription of shares in the subsidiary, Nexam will issue 1,328,625 shares as consideration. The now proposed Incentive Program 2014/2017 and thereby associated issue of at maximum 1,083,849 warrants in accordance with the proposal above, may cause a dilution of approximately 2.0 per cent of Nexam’s share capital and votes after full dilution, calculated as the number of shares that will be added upon full exercise of Incentive Program 2014/2017 in relation to the number of existing shares with the addition of the shares that will be added upon full exercise of all warrants outstanding in the group. In case all warrants (existing as well as the now proposed) are exercised, the aggregate dilution, calculated in the same manner, will amount to approximately 4.45 per cent. Since the warrants in Incentive Program 2014/2017 will be transferred at market value, it is Nexam’s opinion that no social charges will be triggered for Nexam due to Incentive Program 2014/2017. The costs for Incentive Program 2014/2017 will hence only consist of limited costs related to implementation and administration of the program.Item 16The Board proposes that the AGM authorizes the Board, on one or several occasions until the next AGM, with or without deviation from the shareholders’ preferential rights, to resolve on new issues of shares. Issues may be made with or without the provisions regarding contribution in kind, set-off or other conditions. The number of shares that may be issued may not exceed a total of 5,753,333 shares (provided that such number of shares may be issued without amendment of the Articles of Association). The dilution may, upon full exercise of the authorization, amount to at the highest approximately 10 per cent. The purpose of the authorization is to enable to raise working capital, to enable to execute and finance acquisitions and to enable new issues to industrial partners within the framework of partnerships and alliances. To the extent the authorization is used for new issues with cash payment with deviation from the shareholders’ preferential rights, the issue price shall be on market terms. Particular majority decisionsValid resolution under item 15 requires that the proposals are supported by shareholders representing at least nine tenths of the votes submitted and represented at the AGM. Valid resolution under item 16 requires that the proposals are supported by shareholders representing at least two thirds of the votes submitted and represented at the AGM. Number of shares and votesAs of the date of issuing of this notice to attend, the total number of registered shares and votes in the company amounts to 51,780,000. The company holds no own shares.Lund, April 2014 Nexam Chemical Holding AB (publ)The Board of Directors Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Researchers transplant regenerated oesophagus

The new method has been developed by researchers at Karolinska Institutet in Sweden, within an international collaboration lead by Professor Paolo Macchiarini. The technique to grow human tissues and organs, so called tissue engineering, has been employed so far to produce urinary bladder, trachea and blood vessels, which have also been used clinically. However, despite several attempts, it has been proven difficult to grow tissue to replace a damaged oesophagus. In this new study, the researchers created the bioengineered organs by using oesophagi from rats and removing all the cells. With the cells gone, a scaffold remains in which the structure as well as mechanical and chemical properties of the organ are preserved. The produced scaffolds were then reseeded with cells from the bone marrow. The adhering cells have low immunogenicity which minimizes the risk of immune reaction and graft rejection and also eliminates the need for immunosuppressive drugs. The cells adhered to the biological scaffold and started to show organ-specific characteristics within three weeks. The cultured tissues were used to replace segments of the oesophagus in rats. All rats survived and after two weeks the researchers found indications of the major components in the regenerated graft: epithelium, muscle cells, blood vessels and nerves. “We believe that these very promising findings represent major advances towards the clinical translation of tissue engineered esophagi”, says Paolo Macchiarini, Director of Advanced center for translational regenerative medicine (ACTREM) at Karolinska Institutet. Tissue engineered organs could improve survival and quality of life for the hundreds of thousands of patients yearly diagnosed with oesophageal disorders such as cancer, congenital anomalies or trauma. Today the patients’ own intestine or stomach is used for esophageal replacements, but satisfactory function rarely achieved. Cultured tissue might eliminate this current need and likely improve surgery-related mortality, morbidity and functional outcome. The current study was conducted in collaboration with the Texas Heart Institute in the U.S., as well as universities in Italy, Russia, and Germany. It was supported financially by, among others, the Swedish Research Council, the Stockholm County Council through the ALF agreement, and the European Union’s Seventh Framework Programme. The equipment used in the study was developed by the company Harvard Apparatus Regenerative Technology. Publication: ‘Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats’, Sebastian Sjöqvist, Philipp Jungebluth, Mei Ling Lim, Johannes C. Haag, Ylva Gustafsson, Greg Lemon, Silvia Baiguera, Miguel Angel Burguillos, Costantino Del Gaudio, Alexander Sotnichenko, Karolina Kublickiene, Henrik Ullman, Heike Kielstein, Peter Damberg, Alessandra Bianco, Rainer Heuchel, Ying Zhao, Domenico Ribatti, Cristián Ibarra, Bertrand Joseph, Doris A. Taylor & Paolo Macchiarini, Nature Communications (http://www.nature.com/ncomms/index.html), online 15 April 2014, doi:10.1038/ncomms4562.

PA Resources' Interim Report 1 January – 31 March 2014

FIRST QUARTER · Group revenue totalled SEK 178 million (359) · EBITDA was SEK 114 million (211) · Profit after tax was SEK -48 million (34) · Earnings per share were SEK -0.43 (1.57) KEY EVENTS · Successful long term drilling test carried out on Diega – pilot well encountered oil · The Mer Profonde Sud farm-out received governmental approval · Working capital facility of USD 50 million signed with Gunvor SUBSEQUENT EVENTS · Nomination committee proposes new Chairman and new board member · Uncertainty and delays in the farm-out process in Tunisia FINANCIAL KEY RATIOS   January - March Full year 2014 2013 2013Average production, barrels/day 3,400 6,800 4,600Revenue, SEK million 178 359 1,049EBITDA, SEK million 114 211 -494EBITDA margin, % 64% 59% negOperating profit, SEK million 71 117 -1,234Profit for the period, SEK million -48 34 -1,219Earnings per share after dilution, SEK -0.43 1.57 -21.54 For the complete Interim Report, see attached file. WEBCAST PA Resources' results for the first quarter of 2014 will be presented on 16 April 2014 at the Annual General Meeting. An on-demand webcast will be available on PA Resources’ website www.paresources.se after the AGM. CONTACT Queries concerning this report can be directed to: Tomas Hedström, CFO +46 8 545 211 50 ir@paresources.se Mark McAllister, President and CEO +46 8 545 211 50 ir@paresources.se Disclosure The information in this interim report is such that PA Resources AB is required to disclose pursuant to the Securities Market Act and Financial Instruments Trading Act. Submitted for publication at 07:30 a.m. (CET) on 16 April 2013. PA Resources in brief PA Resources AB (publ) is an international oil and gas group that conducts exploration, development and production of oil and gas assets. The Group operates in Tunisia, the Republic of Congo (Brazzaville), Equatorial Guinea, the United Knigdom, Denmark, the Netherlands and Germany. PA Resources is producing oil in West Africa and North Africa. The parent company is located in Stockholm, Sweden. PA Resources’ shares are listed on NASDAQ OMX in Stockholm, Sweden. For further information, please visit www.paresources.se.

ICA Gruppen sells Kjell & Company, capital gain c. SEK 440 million

ICA Gruppen has signed an agreement with FSN Capital to sell its 50% holding in Kjell & Company for a cash consideration of SEK 630 million. The capital gain is expected to amount to approximately SEK 440 million after deduction for costs and will be recognised in the second quarter of 2014. ICA Gruppen’s CEO, Per Strömberg, comments: “The divestment of Kjell & Company is in line with the plan we presented in November last year which means that we are focusing our non-food offering. This is a good moment for a change of ownership in Kjell & Company.” Last year, ICA Gruppen performed an evaluation of the portfolio companies in parallel with the formulation of a new non-food strategy for the Group. As a result of this evaluation it was decided to initiate a divestment process for Kjell & Company. In the year-end report for 2013 the holding in Kjell & Company was recognised among assets held for sale. ICA Gruppen, formerly Hakon Invest, has been an owner of Kjell & Company since 2006, when 50% of the company was acquired from the founders. Since this investment was made, Kjell & Company has grown from 15 stores with annual sales of SEK 255 million to 74 stores with annual sales of SEK 931 million in 2013. In conjunction with this transaction, the other shareholders will sell shares in Kjell & Company on the same terms as ICA Gruppen. The founders will remain as significant owners of the company. The sale, which is subject to approval from the Swedish Competition Authority, is expected to be completed in the second quarter of 2014. For more informationICA Gruppen’s press service, telephone: +46 10 422 5252 ICA Gruppen AB discloses the information provided herein pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on Wednesday, 16 April 2014.

Pandox sells 14 hotel properties

Pandox has sold a portfolio which comprises 14 Swedish hotel properties with a total of 2 400 rooms to Fastighets AB Balder. The total purchase price is SEK 2.2 billion. The buyer will assume ownership of the properties during the second quarter of 2014. The hotels included in the portfolio are: · Best Western Royal Corner Växjö, 159 rooms · Clarion Hotel Plaza Karlstad, 131 rooms · Park Inn by Radisson Solna, 247 rooms · Quality Hotel Grand Kristianstad, 137 rooms · Quality Hotel Nacka, 164 rooms · Scandic Gävle Väst, 200 rooms · Scandic Skogshöjd Södertälje, 225 rooms · Scandic Star Lund, 196 rooms · Scandic Swania Trollhättan, 201 rooms · Scandic Uplandia Uppsala, 133 rooms · Scandic Upplands Väsby, 156 rooms · Scandic Uppsala Nord, 184 rooms · Scandic Västerås, 174 rooms · Scandic Växjö, 123 rooms Pandox is one of the leading players in the European hotel property market as regards geographical spread, number of hotels, brand names and size. After the divestment, the Pandox portfolio will comprise 105 hotel properties, one congress centre and 16 hotel operations with a total of 22 000 rooms in nine countries. The hotels are run under various types of leases, either under well-known brands such as Scandic, Hilton, InterContinental, Hyatt, Radisson Blu, Crowne Plaza, Holiday Inn, Clarion, Comfort, Quality, Elite, First, Rica, Best Western, Rantasipi and Omena or through independent distribution channels. Pandox AB (publ) is owned by Eiendomsspar AS, CGS Holding AS and Helene Sundt AS. For further information, please contact:   Anders Nissen                    CEO Pandox AB (publ)        +46 (0)8 506 205 50+46 (0)708 46 02 02anders.nissen@pandox.se Liia Nõu CFO Pandox AB (publ) +46 (0)8 506 205 80+46 (0)70 237 44 04 liia.nou@pandox.se

Getinge Group Interim Report January - March 2014

Reporting period January – March · Order intake increased 0.2% to SEK 5,977 M (5,968), and grew 0.3% organically. · Net sales declined 0.6% to SEK 5,632 M (5,664), and fell 0.4% organically. · The result before tax declined to a loss of SEK 452 M (252). Adjusted for the provision of SEK 799 M for consulting efforts to strengthen the quality management system within Medical Systems, profit before tax rose 37.7% to SEK 347 M. · The net profit declined to a loss of SEK 330 M (148). Adjusted for the provision of SEK 799 M for consulting efforts to strengthen the quality management system within Medical Systems, net profit increased 70.9 % to SEK 253 M. · Earnings per share were a negative SEK 1.39 (0.76). · EBITA before restructuring costs declined 15.4% to SEK 670 M (792). First quarter of 2014 Order intake The Group’s order intake grew 0.3% organically during the first quarter of the year. The order intake for Medical Systems, which reported a highly satisfactory order intake in the year-earlier period, declined organically by 3.4%. Adjusted for delivery disruptions that impacted the Cardiovascular division during the quarter and were previously announced, the order intake for Medical Systems increased marginally. The order intake for Extended Care increased 0.9% organically compared with a weak year-earlier period and the order intake for Infection Control amounted to 8.9% organically. The increase in demand in Western Europe noted during the latter part of last year was confirmed by the order intake for the first quarter, which rose 5% organically. In the North American market, the organic order intake increased 1.0%. Most of the delivery disruptions that impacted Medical Systems pertained to the North American market. With respect to the order intake for markets outside North America and Western Europe, the trend for the period was weak, particularly in the BRIC countries. Teleconference with CEO Johan Malmquist and CFO Ulf GrunanderApril 16, 2014 at 3:00 p.m. Swedish timeSweden: +46 (0) 8 5033 6538UK: +44 (0) 20 3427 1906US: +1 212 444 0481Code: 53 86 501

Tele2 AB: First Quarter 2014 Result Presentation

Tele2 AB will announce its financial results for Q1 2014 at 07:00 am CEST (06:00 am BST/01:00 am EDT) on Friday, April 25, 2014. Tele2 will host a presentation with the possibility to join through a conference call, for the global financial community at 10:00 am CEST (09:00 am BST/04:00 am EDT) on Friday, April 25, 2014. The presentation will be held in English and also made available as an audiocast on Tele2’s website: www.tele2.com. Dial-in information: To ensure that you are connected to the conference call, please dial in a few minutes before the start of the conference call to register your attendance. Dial-in numbers: Sweden: +46 8 505 564 74 UK: +44 203 364 5374 US: +1 855 753 2230 Contacts Lars Torstensson, EVP Corporate Communication, Telephone: +46 702 73 48 79 Viktor Wallström, Press Inquiries, +46 703 63 53 27 TELE2 IS ONE OF EUROPE'S FASTEST GROWING TELECOM OPERATORS, ALWAYS PROVIDING CUSTOMERS WHAT THEY NEED FOR LESS. We have 15 million customers in 10 countries. Tele2 offers mobile services, fixed broadband and telephony, data network services, cable TV and content services. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2012, we had net sales of SEK 31 billion and reported an operating profit (EBITDA) of SEK 6 billion

Blue Canyon Holdings’ comments on Meltwater’s press release

The offer from Blue Canyon Holdings AB (“Blue Canyon Holdings”), controlled by GTCR Investment X AIV Ltd., to the shareholders of Cision AB (publ) (“Cision”) expires on 22 April 2014 (the “Offer”). Blue Canyon Holdings offers SEK 61 in cash per share in Cision. In relation to Meltwater Drive Sverige AB’s (“Meltwater”) press release dated yesterday, 16 April 2014, Blue Canyon Holdings advises the shareholders of Cision of the following: · The Swedish Securities Council (Sw. Aktiemarknadsnämnden) has in its statement no. 2014:16 (available at www.aktiemarknadsnamnden.se) confirmed that Blue Canyon Holdings has not acted in breach of best market practice on the Swedish stock market; · It is Blue Canyon Holdings’ firm view that it has complied with applicable laws and the provisions of NASDAQ OMX Stockholm’s Rules concerning Takeover Bids on the Stock Market, including the policies and practices established by the Swedish Securities Council, in connection with its offer; · Blue Canyon Holdings furthermore confirms that the Stockholm District Court (Sw. Stockholms Tingsrätt) on 4 April 2014 issued an injunction against Fairford Holdings Finance AB, Cyril Acquisition AB, Lannebo Fonder and Accendo Capital SICAV-SIF, pursuant to their irrevocable undertakings with Blue Canyon Holdings, inter alia, prohibiting them to sell their shares in Cision other than pursuant to Blue Canyon Holdings’ offer; and · Meltwater’s offer is conditioned upon a number of items, including an acceptance level of at least 70 per cent. Blue Canyon Holdings owns shares representing 63.4 per cent of the shares and votes in Cision and will not tender its shares into Meltwater’s offer. As a result hereof, the acceptance level condition for Meltwater’s offer cannot be fulfilled. Blue Canyon Holding’s offer expires on Tuesday 22 April 2014. Duly completed acceptance forms shall be delivered or mailed and be received by SEB Emissioner no later than 17.00 (CET) on 22 April 2014. As Blue Canyon Holding’s offer is unconditional, shareholders do not have the right to withdraw given acceptances. Settlement is expected to begin around 30 April 2014. Information about the OfferFor information about Blue Canyon Holding’s offer, please see www.bluecanyon.se. Further informationFor media questions, please contact:Eileen RochfordPhone: +1 312.953.3305E-mail: eileenr@theharbingergroup.com This press release was submitted for publication on 17 April 2014 at 08:15 (CET). Important noticeThis is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail. Offer restrictionsThe Offer is not being made to persons whose participation in the Offer requires that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law. This press release and any documentation relating to the Offer are not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Any such action will not be permitted or sanctioned by Blue Canyon Holdings. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Blue Canyon Holdings will not deliver any consideration under the Offer into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Blue Canyon Holdings and Cision. Any such forward-looking statements speak only as of the date on which they are made and Blue Canyon Holdings has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United StatesThe Offer described in this announcement is subject to the laws of Sweden. It is important for US securities holders to be aware that this document is subject to disclosure and takeover laws and regulations in Sweden that are different from those in the United States. As applicable, Blue Canyon Holdings will comply with Regulation 14E under the US Securities Exchange Act of 1934, as amended (“Exchange Act”) in connection with the Offer. The Offer is being treated in the United States as one to which the “Tier II” exemption mentioned in Rule 14d-1(d) under the Exchange Act is applicable. Pursuant to an exemption from Rule 14e-5 under the Exchange Act, Blue Canyon Holdings and certain of its Representatives may, from time to time, purchase or make arrangements to purchase shares outside the Offer from the time the Offer was announced until the expiration of the acceptance period of the Offer, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, in each case, outside of the United States and to the extent permitted under the applicable Swedish laws and regulations. Any such purchases will not be made at prices higher than the price of the Offer provided in this announcement unless the price of the Offer is increased accordingly. Any future purchases will be made in accordance with applicable laws, rules and regulations. Any such purchases of shares will be disclosed to the extent required by Swedish law or rules or regulations and, if so disclosed, will also be disclosed in the US. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THIS OFFER, PASSED UPON THE FAIRNESS OR MERITS OF THIS ANNOUNCEMENT OR DETERMINED WHETHER THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE IN THE UNITED STATES.

Interim report January – March 2014

·Net sales increased by 70% to 64.9 (38.1) MSEK ·Net profit after financial items increased to 3.6 (0.1) MSEK(including non-recurring costs associated with the acquisition of AP&C of 6 MSEK) ·Earnings per share amounted to 0.20 (0.01) MSEK ·Cash at the end of the period 368.1 (38.3) MSEK ·Order intake amounted to 6 (6) systems, and 7(4) systems were delivered in the period. ·The order book contained 11 (12) systems by the end of the period ·The acquisition of the metal powder manufacturer AP&C was completed on February 11. Significant events after the end of March: ·Two EBM system orders beginning of April Telephone conference with CEO Magnus René and CFO Johan Brandt April 17, 2014 at 2.00 p.m. (CET) SE: +46 8 505 982 61UK: +44 2 031 940 554US: +1 855 716 158 9 Link to presentation: http://event.onlineseminarsolutions.com/r.htm?e=782857&s=1&k=9B56BCCA7BBBB5AD6F347F6B395EE002 Increased sales and improved earnings For the first quarter we report a 70% increase in sales compared to the first quarter in 2013 and a significantly improved result. Trailing twelve month sales amounts to 226.2 MSEK and earnings amount to 18.9 MSEK. The result includes non-recurring costs in the first quarter 2014 associated with the acquisition of AP&C of 6 MSEK. The order intake during the period amounts to 6 systems and the order book as of today comprises 13 systems. Acquisition of AP&C In February we acquired the powder producer AP&C from Raymor Industries in Canada. AP&C is a leading manufacturer of high quality metal powder and supplier of titanium powder to Arcam since 2006. Titanium powder is an important part of our offering and with this acquisition we have secured access to the best technology for the production of high quality metal powder for our customers. The acquisition is fully in line with our growth strategy and complements our EBM technology and product portfolio. The acquisition was completed on February 11, and is consolidated from this date. AP&C´s share of group sales in the first quarter amounts to 3.5 MSEK after group eliminations. Business status We received 6 new orders during the quarter and we see a continued strong demand, particularly in Asia. The sales of our new large system, Arcam Q20, gains momentum and we have received 4 system orders. Arcam Q20 is planned for delivery to the first customers during the second quarter.  The work to industrialize our technology with the major players within the aerospace and implant industries continue and we can now see good opportunities for volume orders during the year. At the same time, we see that the growing interest and knowledge in Additive Manufacturing and 3D printing creates interest within new segments. This may long term give opportunities for broadening of our product applications. Of the 7 systems that were delivered during the first quarter the majority went to customers within the implant or the aerospace industry. The cooperation with DiSanto is progressing with agreements with customers for which DiSanto is manufacturing products. Growth – organic and through acquisition In addition to the acquisition of AP&C we are in rapid organic growth. We thus continue to recruit qualified employees in order to meet the expectations from our customers. During the quarter we have strengthened our service office in China and the support organization in Sweden. Through the acquisition of AP&C and through recruitment the number of employees has increased from 55 to 109 since March 2013. An order book of 13 systems, increasing aftermarket sales and a positive business situation lays a solid foundation for a continued strong growth in 2014.  Mölndal, April 17, 2014 Magnus René, CEO The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on April 17, 2014 at 08.30 (CET).